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Abstract 
 
Delivery of various drugs and biomolecules into cells is crucial in modern medicine, providing 
promising potential in the treatment of incurable diseases. Most naked therapeutic biomolecules, for 
example, proteins, siRNAs and some free drugs can hardly penetrate into cells, thus various natural 
particulates and synthetic vectors have been used as cellular delivery vehicles. The understanding of 
structure–function relationships of natural particulates provides a useful guide for the design of new 
nanocarriers with better safety and higher delivery efficiency. Currently, many research attempts 
have focused on the synthesis of new drug delivery systems by mimicking the advantages of 
enveloped viruses, which have evolved sophisticated mechanisms that make use of or shield off 
cellular signalling and transport pathways to traffic within host cells and deliver cargos into 
appropriate subcellular compartments. However, there are still some parameters of enveloped 
viruses requiring intensive study, for example, the contribution of viral surface topography (rough 
surface) to intracellular delivery of cargo molecules. 
This thesis focuses on the development of a novel drug delivery system with high performance 
based on the preparation of silica nanoparticles with virus-mimicking rough morphology and gains 
insight into the roles of surface roughness variation and surface functionality (e.g. polyethylenimine 
and octadecyl-group) in biomolecule (e.g. siRNAs and therapeutic proteins) delivery performance. 
The main achievements obtained in this thesis are listed below. 
In the first part, a new and facile approach has been developed to prepare the virus-mimicking silica 
nanoparticle (VMSN) with a rough surface. We show that increases in nanoscale surface roughness 
promote both binding of biomolecules (e.g., genetic molecules) and cellular uptake; thus, the cargo 
delivery efficiency is significantly increased, regardless of surface functionality and cell types. 
Finally, gene delivery efficiency was tested, where the biomimetic nanoparticles shows a better cell 
growth inhibition performance than the smooth silica nanoparticle and a commercial delivery 
reagent. 
In the second part, the novel and facile approach for systematically controlling surface roughness of 
silica nanoparticles has been developed. Based on our "neck-enhancing" approach, rough silica 
nanoparticles (RSNs) with a fixed core particle (211 nm in diameter) and varied shell particles are 
obtained. The increase of shell particle s z s  rom   13 to   98 nm enlarges interspacing distance 
  tw  n n     our n  s  ll p rt  l s  rom   7 to   38 nm, where protein molecules will favourably 
absorb onto one of RSNs without impacting protein binding ability. Moreover, hydrophobically 
modified RSN having the optimized interspacing distance of   38 nm successfully complexes with 
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therapeutic anti-pAkt antibody, and it shows enhanced intracellular delivery efficiency in human 
breast cancer (MCF-7) cells, leading to significant cell growth inhibition by blocking pAkt and the 
downstream anti-apoptotic protein of Bcl-2. 
In the third part, we quantitatively demonstrate both the individual and combined contributions of 
surface roughness and hydrophobic modification for the improvement of protein therapeutics. Both 
surface roughening and hydrophobic modification enhance the protein adsorption capacity, while 
the contribution from surface roughness is more effective. For sustained protein release, 
hydrophobic modification has a stronger effect compared to rough surface. Both structural 
parameters improve cellular uptake performance; however the contribution difference is cell type-
dependent. It is clear that surface roughness has little contribution to endo/lysosomal escape. Only 
surface chemistry, i.e., hydrophobic modification, facilitates the release of nanoparticle/cargo 
molecules from endosome/ lysosome entrapment. Collectively, octadecyl-functionalized rough 
silica nanoparticle (C18-RSN) shows the best performance in therapeutic protein (RNase A) 
delivery, causing significant cell viability inhibition in MCF-7 and SCC-25 cell lines compared to 
RSN and smooth silica nanoparticle with (C18-SSN) and without (SSN) C18-modification. 
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of Cy3-oligoDNA alone is incubated with cells, indicating the inability of genetic molecules 
t  ms lv s to p n tr t   nto   lls. S  l    r: 20 μm. 
Figure 4.S4 FACS analysis showing the peak shifts in the MFI from HeLa cells incubated with the 
complexes of 1-NH2 (blue colour)/ 3-NH2 (yellow colour) +Cy3- oligoDNA. The Cy3-oligoDNA 
in the absence of nano-carriers (red colour) is used as a control. 
Figure 4.S5 Comparison of cellular delivery of cargos among different nanoparticles. a, b, c) Very 
weak signals were observed in the groups of naked Cy3-oligoDNA, Cy3- oligoDNA coupled with d, 
e, f) 2-NH2 (0.9 μ /mL, dosage calculated from ET results) and g, h & i) 1-NH2. j, k & l) Only 3-
NH2 induced evident Cy3 signals across all groups. 
Figure 4.S6 Agarose gel analysis. a) The complex of amino-modified nanocarriers with Cy3-
oligoDNA. Lane 0: 25 pmol Cy3-oligoDNA only. Lane 1: 25 pmol Cy3- oligoDNA coupled with 
50 μ  o  1-NH2. Lane 2: 25 pmol Cy3-ol  oDNA  oupl d w t  50 μ  o  3-NH2. In the case of 1-
NH2, a small amount of released Cy3-oligoDNA was observed. For 3-NH2, nearly no release could 
be seen by naked eyes. b, c) the complexes of PEI-modified nano-carriers with PLK1-siRNA. Lane 
0: 25 pmol PLK1- siRNA only. Lane 1, 2, 3: 100, 50 and 25 pmol PLK1-siRNA are coupled with 
50 μ  o  1-PEI and 3-PEI, respectively. In each lane from 1 to 3, the PLK1-siRNA release was 
evident in the case of 1-NH2, compared to that of 3-NH2. 
Figure 4.S7 Investigation of pure silica nano-carriers in adsorption and cellular uptake. a) 
Cytochrome C adsorption. The adsorption amount is 2.71 nmol/mg on 3, and 0.88 nmol/mg on 1. b) 
cellular uptake into KHOS cells. 128 pg/cell was internalized for 3, while 62 pg/cell for 1. c) 
cellular uptake into HeLa cells. 242 pg/cell was internalized for 3, while 187 pg/cell for 1. Data 
represent mean ± s.e.m of three independent experiments. *p<0.05, ***p<0.001,****p<0.0001 (t-
test). 
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Figure 4.S8 Cytotoxicity of nanoparticles. a, b) sample 1 & 3 in HeLa (left) and KHOS (right) cells. 
c, d) 1-NH2 & 3-NH2 in HeLa (left) and KHOS (right) cells. e) 1-PEI & 3- PEI in KHOS cells. 
Pure and amino-modified silica nanoparticles have relatively mild cytotoxicity to both HeLa and 
KHOS cells, and the ones with rough surface are more toxic due to the improved cellular uptake. 
However, the attachment of PEI caused a high toxicity to cells, so that the concentrations of 1-PEI 
& 3-PEI w ll    d  r  s d to 20 μ /mL in gene silencing experiment. Data represent mean ± s.e.m 
of three independent experiments. 
Figure 4.S9 Gene delivery performance of virus-mimicking nanoparticles in KHOS cells using 
amino-modified nanoparticles. Neither PLK1-siRNA nor S10-siRNA delivered by 1-NH2 and 3-
NH2 induced the decrease of cell viability by gene silencing effect. In the bar chart, data represent 
mean ± s.e.m of three independent experiments, and were analyzed using t-test. 
Figure 4.S10 TGA of PEI-conjugation. In both a) 1–PEI and b) 3-PEI, the TGA curves of (i) 
represent pure silica nanoparticles, (ii) show epoxy-group modified nanoparticles, (iii) are the PEI-
conjugated separately. 
Figure 4.S11 Morphology adjustment of virus-mimicking nanoparticles. After fabricating the virus-
mimicking nanoparticles by mixing shell particles with core particles, morphology changes were 
traced by TEM images. On adjusting the feed volumes of shell particle solutions from a) 0.68 mL to 
b) 1.35 mL, to 2.70 mL (Figure. S1e), to c) 5.40 mL and finally to d) 6.75 mL, the surface 
morphologies changed significantly, with the best sample being obtained when the feed volume was 
2.70 mL. It is noted that a failure to obtain optimized virus-mimicking morphologies can be 
attributed to either insufficient or excessive feed amount of shell particles, where only a proper feed 
amount will lead to successful synthesis. Scale bar: 100 nm. 
Figure 4.S12 The influence of calcination treatment. TEM image a) shows that without calcination, 
shell particles peeled off on ultrasonication. In contrast, b) shows that the calcined sample 3 
maintained its morphology after ultrasonication. Scale bar: 100 nm. 
Figure 5.1 Schematic illustrations of the synthesis of RSNs using a "neck-enhancing" approach (a) 
and a conventional interaction approach (b). Scheme c shows the cellular delivery of therapeutic 
anti-pAkt antibody using C18-RSNs and the cell growth inhibition mechanism. 
Figure 5.2 TEM (a-d) and HRSEM (e-h) images of RSNs with varied shell particle sizes: a&e) 
RSN-211@13, b&f) RSN-211@28, c&g) RSN-211@54, d&h) RSN-211@98 and the red arrows 
indicate the formation of bigger “n  ks”  onn  t n  s  ll  nd  or  p rt  l s. S  l    r: 100nm. 
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Figure 5.3 Protein Adsorption profiles ( IgG-A;  IgG-F; ▲  yto  rom  c). Solid lines represent 
different protein adsorption onto unmodified rough silica nanoparticles. The dash line also 
represents the IgG-A adsorption onto different rough silica nanoparticles, except they are all 
modified with C18-groups. Data represent mean ± SD. Specific surface area variations (×) of 
different unmodified rough silica nanoparticles are displayed to compare with protein adsorption 
trend. 
Figure 5.4 Surface topography studies. AFM images of RSN-211@54 before (a) and after (c) the 
adsorption of IgG-F. A cross-sectional line is drawn to characterize the height changes of shell 
particles on the top region before (b) and after (d) protein adsorption. Scale bar: 100 nm. 
Figure 5.5 SPR sensorgrams showing the binding signals of RSN-IgG-F complexes with receptors. 
All RSN-IgG-F complexes showed positive values of the binding with ligand. 
Figure 5.6 Cell growth inhibition by the delivery of therapeutic protein. a) Cell viability of MCF-7 
cells incubated with increasing concentrations of C18-RSN-211@98+anti-pAkt (), C18-RSN-
211@98+non-specific-IgG-A (♦)  nd C18-RSN-211@98. Data represent mean ± SD. b) Western 
blotting confirming the degradation of downstream anti-apoptotic protein, Bcl-2 in MCF-7 cells. 
Blots presented are representative of typical results. GAPDH served as an internal reference. 
Figure 5.S1 TEM images (a-g) and particle size distribution curves (f) of shell and core particles. 
Shell particles: a&h-i) 13nm, b&h-ii) 28nm, c&h-ii) 54nm, d&h-iv) 98nm, e&h-v) 135nm and f&h-
vi) 175nm. Core particle: g&h-vii) 211nm. Scale bar: 100 nm 
Figure 5.S2 The interspacing distance of RSNs. a) RSN-211@13, b) RSN-211@28, c) RSN-
211@54, d) RSN-211@98. The interspaces are measured from SEM images by recording 50 edge-
to-edge interspacing data in each sample. 
Figure 5.S3 TEM images showing the synthesis of RSN-211@28 using previous recipe after 
washing and drying process (a) and in reaction solution (b). Scale bar: 100 nm 
Figure 5.S4 TEM images of failed synthesis of RSNs with much larger shell sizes. a) Core particles 
(dotted arrow) mixed with the shell of 135 nm (solid arrow), b) Core particle (dotted arrow) mixed 
with the shell of 175 nm (dotted arrow). Scale bar: 100 nm. 
Figure 5.S5 Fourier transform infrared (FTIR) spectra of pure liquid n-ODMS (a) and a series of 
RSNs with and without hydrophobic modification (b). 
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Figure 5.S6 TEM images of hydrophobic modified RSNs. a) C18-RSN-211@13, b) C18-RSN-
211@28, c) C18-RSN-211@54 and d) C18-RSN-211@98 (d). Scale bar: 100 nm. 
Figure 5.S7 Cell viability of MCF-7 cells incubated with varying concentrations of non-specific 
IgG-A () only and anti-pAkt antibody () only, respectively. Data represent mean ± SD. 
Figure 5.S8 The comparison of anti-pAkt antibody delivery efficiency (a) and cellular uptake 
performance of C18-RSNs measured by ICPOES. (b) Data represent mean ± SD. 
Figure 6.1 TEM (a, b, d, e) and HRSEM (c) images and particle size distribution curves (f) of RSN 
(a&f-i), C18-RSN (b, c&f-ii), SSN (d&f-iii), C18-SSN (e&f-iv). Scale bar: 100 nm. 
Figure 6.2 (a) RNase A adsorption and (b) release profiles of SSN, RSN, C18-SSN and C18-RSN. 
Data represent mean ± SD. 
Figure 6.3 Cellular uptake performance of RNase A loaded nanoparticles in (a) MCF-7 and (b) 
SCC-25 cells, measured by ICPOES. Cells only were used as a control group. Data represent mean 
± SD. 
Figure 6.4 Typical TEM images of ultra-thin sections of MCF-7 cells incubated with (a) SSN, (b) 
RSN, (c) C18-SSN and (d) C18-RSN for 24 h. White arrow indicates cell membrane (CM), black 
arrow indicates nanoparticles entrapped in endosome (E) or lysosome (L), black arrowhead shows 
locally disrupted membrane of endosomes, black dash arrow indicates nanoparticles distributed in 
cytoplasm (C). "N" refers to nucleus. Scale bar: 100 nm. 
Figure 6.5 Cell viability of (a) MCF-7 and (b) SCC-25 cells treated with RNase A at a dosage of 2 
μ /mL after 24, 48, and 72 h incubation. Data represent mean ± SD. 
Figure 6.S1 TEM images (a) OH-core particle, (b) NH2-core particle and (c) shell particle. Scale 
bar: 100 nm. (d) Particle size distribution curves. 
Figure 6.S2 Fourier transform infrared (FTIR) spectra of (a) pure liquid OTMS, (b) bare 
nanoparticles, (c) RNase A and (d) nanoparticles complexed with RNase A. 
Figure 6.S3 (a, c, e) AFM images and (b, d, f) void height profiles of (a & b) RSN, (c & d) C18-
RSN and (e & f) C18-RSN + RNase A, generated by drawing a typical cross-sectional line on the 
top region, Scale bar: 100 nm. The average height values are measured and calculated by recording 
20 data. Data represent mean ± SD. 
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Figure 6.S4 Particle size distribution curves tested in PBS. (a) SSN, (b) C18-SSN, (c) RSN and (d) 
C18-RSN. 
Figure 6.S5 Silica dissolution of different nanoparticles, tested by (a) ICPOES and TEM images of 
(b) SSN, (c) C18-SSN, (d) RSN and (e) C18-RSN, after shaking in PBS for 3 days. Scale bar: 100 
nm. 
Figure 6.S6 RNase A release profiles of SSN, RSN, C18-SSN and C18-RSN at (a) acidic condition 
(pH 4.5) and (b) in DMEM under static condition at 37 °C for 4 h. Data represent mean±SD. 
Figure 6.S7 The evaluation of toxicity from pure nanoparticles (a,c,e) in MCF-7 cells and (b,d,f) in 
SCC-25 cells, at 24 h, 48 h and 72 h, respectively. Data represent mean ± SD. 
Table 2.1 Function and features of nucleic acids as therapeutic agents for gene therapy. 
Table 2.2. Function and features of different therapeutic proteins for cancer therapy. 
Table 4.S1 Physicochemical Properties of nanoparticles 
Table 4.S2 Atomic composition (%) of nanoparticles 
Table 4.S3 Characterization of PEI-modification by TGA 
Table 5.S1 Size and ζ potential characterizations of shell and core particles. 
Table 5.S2 Characterizations of RSNs with varied surface topography. 
Table 5.S3 Estimation of protein coverage on RSNs/C18-RSNs 
Table 5.S4 SPR signal intensity. 
Table 6.1 Summary of the contribution of surface roughness and hydrophobic modification 
Table 6.S1 Size and ζ pot nt  l    r  t r z t ons o  n nop rt  l s. 
Table 6.S2 DLS size measurements in PBS 
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Chapter 1 
Introduction 
1.1 Significance of the project 
Effective cellular delivery of various drugs and/or biomolecules is pivotal to satisfy the 
requirements of modern medicine.
1, 2
 Most naked biomolecules and some free drugs are poorly 
delivered to cells owing to poor stability, low solubility and/or unwanted toxicity. For these reasons, 
various natural particulates and synthetic vectors have been used as cellular delivery vehicles. 
Natural particulates, for example, enveloped viruses, have evolved sophisticated mechanisms that 
make use of or shield off cellular signalling and transport pathways to traffic within host cells and 
deliver cargos into the appropriate subcellular compartment with maximal efficiency.
3
 However, 
several limitations are associated with viral vectors, such as carcinogenesis,
4
 immunogenicity,
5
 
broad tropism,
6
 limited DNA packaging capacity
7
 and difficulty of vector production,
8
 and an 
alternative solution is required. Inspired by viruses, currently, many research attempts have focused 
on the synthesis of non-viral delivery systems by mimicking the advantages of viruses, including 
the attachment of viral receptors (e.g., Tat9), the imitation of virus core-shell structure
10
 and the 
incorporation of functional polymer to mimic endosomal escape of viruses.
11
 However, there are 
still some parameters of viruses requiring intensive study, for example, the contribution of viral 
surface topography to intracellular delivery. 
The understanding of structure–function relationships of enveloped viruses provides a useful guide 
for the design of new nanocarriers. Recent developments in state-of-the art electron tomography 
(ET)   v  prov d d “n no-  olo y”  n orm t on  or m ny  nv loped viruses, for example, 
influenza virus,
12
 herpes simplex virus (HSV),
13
 and human immunodeficiency virus (HIV),
14
 all 
showing rough surfaces patched by glycoprotein spikes. However, the influence of nanoscale 
surface roughness on cellular delivery efficiency remains unclear because it is always associated 
with receptor–ligand specific interactions in viral systems. Therefore, a systematic study to explore 
the impacts of surface roughness of nano-vectors on the improvement of cargo delivery is required. 
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1.2 Research objectives and scope 
This research aims to develop a novel approach to prepare silica-based non-viral vectors by 
mimicking the surface topography of enveloped viruses and gain insight into the roles of surface 
roughness variation and surface functionality (e.g. polyethylenimine and octadecyl-group) in 
biomolecule (e.g. siRNAs and therapeutic proteins) delivery performance. This thesis does not only 
focus on the development of facile synthesis of nanoparticles with novel structures, but also 
provides some guidelines for the design of highly efficient delivery systems for various biomedical 
applications. The objectives of this project are specified as follows:  
1) To fabricate silica nanoparticles with virus-mimicking rough morphology and particle size 
smaller than 300 nm, and to confirm the significance of VMRM in intracellular delivery of genetic 
molecules.  
2) To synthesize silica nanoparticles with varied surface roughness for controlled therapeutic 
protein adsorption and optimized protein therapeutics. 
 3) To understand the effects of the surface morphology and functionality of silica nanoparticles on 
therapeutic protein adsorption, cellular uptake, cargo release and endosomal escape. 
1.3 Thesis outline 
This thesis is written according to the guidelines of the University of Queensland. The outcomes of 
this PhD thesis are presented in the form of journal publications. The chapters in this thesis are 
presented in the following sequence: 
Chapter 1 Introduction  
This chapter introduces the background of this project and outlines the research objectives  
Chapter 2 Literature review  
This chapter presents an overview on recent advances in bio-inspired drug delivery systems and the 
current strategies to engineer silica-based nanoparticles as effective genetic molecules and 
therapeutic protein carriers.  
Chapter 3 Methodology  
This chapter summarizes the strategies utilized in the whole PhD project, including material 
synthetic methods for virus-mimicking silica nanoparticles, and the techniques for material 
characterizations and biology experiments. 
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Chapter 4 Nanoparticles Mimicking Viral Surface Topography for Enhanced Cellular 
Delivery 
This chapter reports the synthesis of novel non-viral nanoparticles mimicking virus surface 
topography by attaching small shell particles (~10nm) onto the core particles with large sizes 
(~200nm). The increase in nanoscale surface roughness improved both binding of biomolecules 
(e.g., genetic molecules) and cellular uptake, regardless of surface functionality and cell types. 
Moreover, the delivery efficiency of siRNA was significantly increased, compared to conventional 
silica nanoparticles with a smooth surface and a commercial transfection reagent.  
Chapter 5 Synthesis of Silica Nanoparticles with Controllable Surface Roughness for 
Therapeutic Protein Delivery 
This chapter reports a novel "neck-enhancing" approach to synthesize silica nanoparticles with 
controlled surface roughness. By roughening the surface of silica core particles (211 nm in 
diameter) with smaller shell particles having various sizes, a series of rough silica nanoparticles 
(RSNs) with stable structures were obtained. The interspacing distance between neighbouring shell 
particles increased from 7 to 38 nm with increasing shell particle sizes from 13 to 98 nm. Protein 
loading capacity was dependent on both protein molecule size and interspacing distance, and 
protein binding activity was not influenced. Hydrophobically modified RSNs with the interspacing 
distance of 38 nm showed effective intracellular delivery of anti-pAkt antibody in breast cancer 
MCF-7 cells, leading to significant cell growth inhibition by blocking pAkt and the downstream 
anti-apoptotic protein of Bcl-2. 
Chapter 6 Understanding the Contribution of Surface Roughness and Hydrophobic 
Modification on Silica Nanoparticles for Enhanced Therapeutic Protein Delivery 
This chapter quantitatively demonstrates both the individual and combined contributions of surface 
roughness and hydrophobic modification for the improvement of protein therapeutics. Both surface 
roughening and hydrophobic modification enhance protein (RNase A) adsorption capacity, while 
the effect of surface roughness is more dominant. Hydrophobic modification strongly retards RNase 
A release. The contribution difference to enhance cellular uptake is cell type-dependent. 
Importantly, only surface chemistry, i.e., hydrophobic modification in this work, facilitates the 
release of nanoparticle/cargo molecules from endosome/ lysosome entrapment. Collectively, 
octadecyl-functionalized rough silica nanoparticle (C18-RSN) shows the best performance in 
RNase A delivery, causing significant cell viability inhibition in both human breast cancer (MCF-7) 
Chapter 1 Introduction 
4 
 
and SCC-25 cell lines, compared to unmodified rough silica nanoparticle and smooth silica 
nanoparticles with or without octadecyl-group modification. 
Chapter 7 Conclusion and outlook 
This chapter presents a general discussion of the work in this thesis and outlook for the future work. 
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Chapter 2 
Literature Review 
This chapter reviews the advances in the rational design of bio-inspired nanocarriers for drug 
delivery. It begins with an introduction of the development of modern medicines in 2.1. Therapeutic 
proteins and genetic molecules as promising medications for cancer therapy will be introduced in 
details in this section. The recent achievements of bio-inspired drug delivery systems will be 
summarized in 2.2. Afterwards in 2.3, the engineering of silica-based nanoparticles (SiNPs) will be 
systematically described for controlled cargo delivery. Finally, a summary of current state-of-the-art 
technology and future challenges to fabricate bio-inspired SiNPs are proposed in 2.4. Part of the 
contents in this literature review has been published as a review paper. (Y. Niu, A. Popat, M. Yu, 
S. Karmakar, W. Gu, C. Yu, Therapeutic Delivery. 2012, 3, 1217 – 1237). 
2.1 Modern medications for bio-application  
Small molecule drugs are the most commonly used for cancer treatment, such as hydrophilic 
anticancer drug of doxorubicin,
1
 hydrophobic drug of tamoxifen
2
 and curcumin,
3
 as well as 
hydrophobic photosensitiser of silicon phthalocyanine 4 (Pc4) for photodynamic therapy (PDT).
4
 
However, pharmaceutical drugs have evident drawbacks of non-specific toxicity to normal cells and 
multi-drug resistance (MDR). Therefore, new drugs with better safety and high specificity are 
required. Currently, genetic and protein-based biomolecules have attracted increasing attention as 
new therapeutics. In the follow part, the classifications of both genetic and protein-based molecules 
with therapeutic potential will be summarized. 
2.1.1 Therapeutic nucleic acids for gene therapy  
With the developments in gene engineering and the understanding of pathogenesis in molecular 
level, the efficiency of gene therapy has been significantly improved, especially in the last decade. 
In this part, various therapeutic DNA/RNA molecules will be summarized. Table 2.1 summarizes 
the features of functional nucleic acids and their application in gene therapy. 
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Table 2.1 Functions and features of nucleic acids as therapeutic agents for gene therapy. 
Nu l       ds Fun t on D s r pt on Ex mpl s 
DNA 
pDNA 5-8 
 
Tr ns  r  n od n  
DNA s qu n  s 
1 to ov r 1,000 k p, 
 nt rn l z   nto   lls  lon  or 
 om  n  w t  v r l or non-
v r l v  tors 
Intr tumor l  nj  t on 
6,  nt rn l z d  y v r l 
9 or non- v r l 10 
v  tors 
Sup r o l d 
m n -  r l  
DNA 11 
Tr ns  r  n od n  
DNA s qu n  s 
L ss t  n 4k p, d vo d o  
   t r  lly or   n t d 
 mmuno  n   un-m t yl t d 
CpG mot  s, mu        r 
tr ns   t on        n y 
Tr ns  r Ad pon  t n 
DNA s qu n   w t  
PEI 12 
Junk DNA13  
D m n s  t   us    o  
 n od n  DNA 
D lut n  t    un t on l DNA 
 nd  n r  s n  t    mount o  
     t v  NPs 
D m n s  t   us    o    
r port r DNA, w  l  
s ow t   s m       t13  
RNA    
R  ozym  14-17 
 
C t lyz  RNA or  v n 
DNA  l  v    
Dou l -str nd d RNA 
Corr  t t   mut t d 
 xpr ss on o  α1-AT-
prot  n  n   p tom  
  lls, us n  
   ulov rus v  tor 18 
Ant s ns  RNA 
19-21
 
 
B  n   ompl m nt ry 
to   mRNA,  n    t n  
tr nsl t on w t  n     ll 
S n l -str nd d ol  o-RNA 
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2.1.1.1 DNA-based therapeutics 
Plasmid DNA 
A plasmid DNA (pDNA) is a double-stranded and circular DNA molecule, with the size fluctuating 
from 1 to over 1,000 kilo base pair (kbp), and it has been widely used in the fields of biology and 
medicine, for example, cancer therapy. The pDNAs are usually collected from bacteria, although 
some of them are found in eukaryotic organisms (e.g. 2 µm plasmid DNA in Saccharomyces 
cerevisiae
5
). Independent from chromosomal DNA, pDNAs are able to replicate and stably pass to 
daughter cells. 
The application of pDNA with inserted functional DNA sequences as a framework for gene therapy 
has attracted much attention during the last decade. Although some researchers reported similar 
transfection and expression efficiency of naked pDNA, compared to equipped ones
6
, it is reported 
only a thousandth of the presented naked pDNAs to cells can successfully arrive at the nucleus and 
express,
37
 because they may be quickly digested by nucleases or cleared from blood circulation.
7, 8
 
Many methods and materials have been selected as pDNA vectors. For instance, by electrostatic 
force-driven complexation with pDNA, polymer-based (e.g. poly-l-lysine [PLL]-polystyrene [PS]
38
) 
DNA vaccine has shown great induction of CD8
+
 T cell immune response to viruses. In addition, 
the expression product of a pDNA, such as GFP
39, 40
 and luciferase
10
, may exhibit fluorescent signal 
for diagnosis and simulation of gene therapy. 
Minicircle 
Minicircle is a newly discovered member of pDNA. This kind of circular DNA molecules with 
mini-size (~4 kbp) is able to avoid the disadvantages of conventional pDNA, such as a risk of 
uncontrolled dissemination of therapeutic gene or antibiotic resistance gene sequence originating 
from bacterial,
11
 because those genes, together with native regulatory gene sequences, have been 
removed, and minicircles will not replicate and be passed to daughter cells. Park et al. performed 
the adiponectin gene delivery, using a minicircle-polyethylenimine (PEI) complex to treat diet 
induced obese C57BL/6J mice, and it showed higher adiponectin expression than conventional 
pDNA in vitro and in vivo.
12
  
Junk DNA 
Apart from functional DNA, non-coding DNA molecules, known as junk DNA, have shown some 
interesting effects on improving transfection efficiency and, meanwhile, decreasing active DNA 
usage. Van Gaal et al. 
13
 confirmed that by using the same amount of PEI as the vector and the same 
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vector to cargo (DNA) ratio, similar transfer activity was observed between the loading of pure 
reporter pDNA and the mixture of reporter pDNA with junk DNA. The results have demonstrated 
the total amount of active DNA-containing vectors is more important rather than total DNA cargos. 
2.1.1.2 RNA-based therapeutics 
RNA is another big family of therapeutic nucleic acids, mainly including ribozymes, aptamers, 
microRNAs (miRNAs) and small interfering RNAs (siRNAs). Numerous RNA-based therapeutics 
are currently under clinical investigation for diseases ranging from HIV infection to genetic 
disorders to various cancers.
41
 As a result of their flexibility and versatility in structure and 
function,
42-45
 gene therapy protocols could be designed in various ways. However, due to the 
instable feature of RNA molecules, vehicles to target cells are required. 
Ribozyme 
A ribozyme is a type of double-stranded RNA molecules. Due to the unique tertiary structure,
14-16
 it 
possesses the ability to catalyse RNA or even DNA cleavage (e.g., hairpin ribozyme
14
 or 
hammerhead ribozyme
15-17
), which has the potential to regulate gene expression. For example, 
Ozaki and coworkers reported a hammerhead ribozyme was used to correct the mutated expression 
o  α1- ntryps n (α1-AT)-protein in hepatoma cells.18 In addition, using baculovirus as a vector, 
HIV-1 replication was significantly suppressed by HIV-1 U5 gene-specific ribozyme.
46
  
Antisense RNA 
An antisense RNA is a single-stranded oligo-RNA. Being complementary to a messenger RNA 
(mRNA), it is able to inhibit translation processes.
19, 20
 Antisense RNAs are confirmed to exist 
widely in nature, and up to 72% of the transcripts are demonstrated to have antisense partners in 
human and mouse transcriptomes,
21
 which show antisense RNAs have promising exploitation in 
gene therapy. For example, Zhu et al. reported that PLL-modified SiNPs could successfully 
compact and protect the antisense c-myc.
47
 After transfection, c-myc mRNA levels were 
significantly deregulated. In addition, Barnor et al. showed the replication of HIV-1 vif antisense 
RNA fragments in MT-4 and H9-infected cells and reduced HIV-1 vif mRNA transcripts.
48
  
Aptamer 
To be different from protein-based ligands (e.g. proteins
23
 and ATP
24
), aptamers are very good 
candidates for biomolecular targeting. They are RNA/DNA molecules of 20–50 nucleotides in 
length, and selected from in vitro experiments (termed SELEX: systematic evolution of ligands by 
exponential enrichment).
25, 26
 They are able to fold into the unique tertiary conformation to bind 
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with viral or cellular proteins with high affinity and specificity.
27
 Better than common protein-based 
ligands, aptamers are non-immunogenic and have evident stability in a wide range of pH (4–9), 
temperature, and organic solvents without the loss of activity. Their synthesis is an entirely 
chemical process that can decrease batch-to-batch variability when production is scaled up.
28
  
Usually, aptamers are used as ligands for cell recognition. For example, sgc8-aptamer was 
covalently connected to mesoporous silica nanoparticles (MSNs)-polyelectrolyte multilayer-
complex for specific cell recognition. 
49
 Interestingly, some aptamers also have the ability to 
specifically block protein functions, such as, transcription factors in E2F family, so that cell 
proliferation can be controlled.
50-52
  
siRNA and miRNA 
RNA interference (RNAi) is a post-transcriptional level process that suppresses the activity of 
specific genes and is referred to as "gene silencing", discovered by Fire and Mello in 1998.
31
 Two 
types of non-coding small RNA molecules – miRNA (single-stranded, originated from endogenous 
genome DNA sequences) and siRNA (double-stranded, designed and fabricated in chemical way) 
are pivots to RNAi, and both of them have the length of 20-25 nucleotides. By the activation of 
RNA-induced silencing complex (RISC), both siRNAs and miRNAs are able to cleave and degrade 
targeting mRNAs. Nowadays, they have been effective and popular agents for studying and treating 
diseases, such as cancer, respiratory disease, neuronal disease, and autoimmune disease.
29, 30
 
Due to their different origins, siRNAs and miRNAs are exploited in different ways. In cancer cells, 
some miRNAs are over expressed, and these will wrongly up- or down-regulate cell activity. In that 
case, the deregulation of miRNAs is a fundamental treatment to the pathogenesis of many cancers.
53
 
For instance, Kim et al. conjugated the miRNA-221 molecular beacon (miR-221 MB) on a 
magnetic fluorescence NP and transferred the complex into C6 (glial cell) cancer cells,
33
 and a 
significant reduction in cell viability of cancers was observed. On the contrary, siRNAs were often 
directly delivered into cells to down-regulate the expression of a specific gene. Ashley et al. 
reported a successful gene silencing using large pore MSN-lipid bilayers containing siRNAs in 
pores, leading to significant regression of protein expression and apoptosis.
54
 
Chimeraplasty 
Besides pure DNA/RNA molecules, chimeric RNA–DNA oligonucleotides (termed as 
chimeraplasts) have been designed as therapeutics. First, they will pair with related genomic DNA 
sequences, and then correct and repair the point mutation within the sequence. The designed one-
base mismatch between a chimeraplast and the mutated chromosomal DNA will activate endog-
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enous repair mechanisms, in order to produce a single nucleotide replacement.
34, 35
 For example, Li 
et al. d s  n d RNA/DNA ol  onu l ot d s  or   n  t  r py o  β–thalassemia, and nucleotide 
mut t on  n β-globin gene cluster was successfully corrected.36 However, not every study supports 
this mechanism. Tagalakis et al.
55
 have attempted to create a point mutation in the mouse ApoE 
gene by microinjection of chimeraplast, to confirm the potential to design defined mutations. 
Despite of successful transfection of chimeraplasts into one-cell mouse eggs, no evidence for 
successful conversion was observed.  
2.1.2 Therapeutic proteins for cancer therapy 
Nowadays, hundreds of proteins and peptides applied as therapeutic agents have been approved for 
clinical use by the US Food and Drug Administration (FDA). This indicates that protein-based 
therapeutics with variable functions and applications has attracted increasing attention in modern 
medicine. In this part, the classification of protein-based therapeutics and their potential for cancer 
therapy is summarized (Table 2.2). 
2.1.2.1 Enzyme 
Enzymatic proteins are superior catalysts that can specifically decompose substrates in 
physiological conditions, converting target molecules into products and amplifying following chain 
reactions.
56
 Because of these unique properties, enzymatic proteins have been considered as 
therapeutic agents in cancer therapy since the beginning of 20
th
 century.
57
  
Intracellular delivery of proteins with enzymatic activities can help to terminate protein synthesis in 
cancer cells. One of the examples is ribonuclease A (RNase A), which is a predominant form of the 
enzyme in the pancreas of Bos Taurus.
58
 After intracellular delivery of RNase A into cytosols, it 
will degrade mRNA and tRNA and inhibit protein synthesis, thus strongly influence cell functions 
and cause deleterious effects on cell viability.
59
 In addition, saporin-S6 (also known as saporin) is 
also effective to interfere with cell functions. Saporin belongs to ribosome-inactivating protein 
family, classically identified as rRNA N-glycosylase (EC 3.2.2.22). It is widely distributed among 
plant genera, and confirmed to specifically remove A4324 adenine residue in 28S rRNA in the 60S 
subunit of rat ribosome, so that it can damage ribosomes irreversibly and inhibit protein synthesis.
60
  
Many vectors have been used to deliver enzymatic proteins for cancer therapy. For instance, 
enhanced by hydrophobic modification, negatively charged silica nanoparticles were used to 
immobilize RNase A on the surface and deliver it into human breast cancer cells (MCF-7) for cell 
growth inhibition.
61
 Saporin was encapsulated in lipid-like nanoparticles, known as lipidoids, and 
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this complex inhibited cell proliferation in vitro and suppresses tumor growth in a murine breast 
cancer model.
62
 
2.1.2.2 Targeting protein 
With the help of intermolecular forces of electrostatic forces, hydrogen bonds and disulphide bonds, 
proteins or peptides can form 3-dimensional (3-D) rough and flawy structures, which are the bases 
of targeted interaction of proteins with other molecules.
63
 The targeting proteins specifically 
interacting with molecules inside or on the surface of cancer cells can block the functions of target 
molecules for cell destruction. In addition, cytotoxic drugs to cancer cells can be conjugated with 
targeting proteins for enhanced cancer therapy. Monoclonal antibodies (mAbs) with high binding 
specificity have been widely used in numerous ways, and grown to be the largest class of human 
medicine within the top ten best-selling drugs. The delivery of monoclonal antibody to pAkt (anti-
pAkt) into cytosols of cancer cells has been reported to result in apoptosis.
61
 In addition, the 
delivery of mAbs to CTLA4 to the tumor site successfully caused greater and extended inhibition of 
the tumor growth than antibody given systematically.
64
 Some cell targeting peptides have also been 
applied for cancer treatment.
64
 Cytotoxic drug-conjugated peptides can specifically recognize the 
target cells expressing its receptors and direct killing effect. One example is the application of a 
target cytotoxic somatostatin analogue AN-238, consisting of doxorubicin derivative linked to SST 
octapeptide analogue RC-121. AN-238 shows effective cell growth inhibition in multiple cancer 
cell lines.
65
 
2.1.2.3 Vaccine 
Cancer vaccines have great potential for anti-tumor immunity based on the activation of immune 
system. This strategy depends on the selection of tumor-associated antigens (TAAs), which are 
mutated protein molecules on tumor cell surface or peptides (with only 8-10 amino acids long), 
derived from the mutated proteins, signalling t   pr s n   o      ll t  t   s    om  “ or   n”. 
TAAs can be recognized by immunocytes (e.g., T-cell), which will then be activated and induce an 
effective, tumor-specific immune reaction, leading to tumor regression.
66, 67
 For example, for the 
prevention of cervical cancer and genital warts and vulvar and vaginal precancerous lesions, a 
recombinant quadrivalent vaccine (commercially GARDASILs) has been prepared from capsid 
proteins of human papillomavirus (HPV). It has been approved for commercial use in women aged 
9-26 years, without pathogenicity.
68
 Moreover, peptide vaccines have attracted increasing attention 
because of the diversity and smaller size, compared to large protein vaccines. Recently, three people 
with melanoma have received personalized treatment with a dendritic cell vaccine (an amino acid 
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substitution peptide) to alert their immune system the threats of mutated proteins in tumours, 
providing an important proof of concept for the application of vaccines in cancer therapy.
69
  
Table 2.2. Function and features of different therapeutic proteins for cancer therapy.  
Types Function Description Examples 
Enzymes 
specifically decompose 
substrates in physiological 
conditions 
terminate protein synthesis 
in cancer cells 
RNase A,
61
 Saporin
62
 
Targeting 
proteins  
specifically interact with 
molecules inside or on the 
surface of cancer cells 
block cell functions or 
targeted delivery of 
cytotoxic drug for cell 
destruction 
mAb to pAkt,
61
 mAb 
to CTLA4,
64
 AN-238
65
 
vaccines activation of immune system 
selection of TAAs and 
recognition by T-cells, 
followed by cell regression 
GARDASILs,
68
 a 
dendritic cell vaccine
69
 
 
In summary, various types of nucleic acids and protein-based molecules have been applied in 
modern medicine, especially in cancer therapy. However, because of their difficulties to cross cell 
membranes and the fragility in severe conditions, for example, the potential of proteolysis and 
degradation when they are localized in endosome/lysosome with acidic surroundings, effective 
nanocarriers are required for enhanced biomolecule delivery efficiency. 
2.2 Recent advances in bio-inspired drug delivery carriers 
2.2.1 Brief introduction of natural particulates as drug delivery vehicles 
The intracellular delivery of therapeutic drugs is crucial in modern medicine. Most naked 
biomolecules (e.g., siRNAs and therapeutic proteins) and some free drugs are poorly delivered into 
cells owing to poor stability, low solubility and/or native toxicity. Natural particulates have evolved 
to deliver cargo molecules with maximal efficiency; therefore, provide useful examples and raw 
materials for the application as nanocarriers. Until now, plenty of natural particulates have been 
engineered accordingly and used for drug delivery. Based on the sources of natural particulates used 
for drug delivery, they are classified into two groups, pathogens and mammalian cells.  
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Pathogenic particulates (e.g., bacteria and virus) can effectively invade into target cells, followed by 
cargo release and replication of themselves, without rapid clearance by immune system. For 
example, engineered lactic acid bacteria can deliver vaccines by the quick recognition and 
engulfment by immunocytes (dendritic cells).
70
 In addition, live or attenuated bacterium can 
combine with different nanoparticles for efficient vaccine/drug delivery
71
 or magneto-optical 
applications.
72
 For virus-based vectors,
73
 virus-like particles (with
74
 or without synthetic materials
75
) 
and virosomes (Figure 2.1),
76
 they have small sizes of 30-400 nm
77
 and, more importantly, the 
ligands on the spikes of enveloped viruses (e.g., influenza virus
78
 and herpes simplex virus
79
) can 
guide specific ligand-receptor interactions with host cells for effective viral entry, followed by viral 
genome release in cytosols.
80
 
Apart from pathogen-based drug delivery system, various types of mammalian cells, such as red 
blood cells (RBCs),
81
 dendritic cells
82
 and macrophages
83
 have been used as drug delivery carriers. 
Although they cannot directly deliver drugs into target cells for disease treatment, they possess 
evident advantages of excellent biocompatibility, prolonged circulation time (up to 120 days) and 
final clearance from blood by reticuloendothelial system (RES). In that case, free drugs or drug-
loaded nanoparticles can combine with mammalian cells, either inside the cells or attached on the 
surface, and can be specifically transported to the disease sites for sustained therapeutic effects.
84
 
 
Figure 2.1 Engineering strategies for virus-based vectors, virus-like particles and virosomes.
85
  
Although natural particulate-based drug delivery systems have been confirmed effective, the 
clinical application is still immature and several issues need to be resolved. One of the top 
challenges is the safety concerns of immunogenicity or even pathogenicity of pathogen-based 
carriers,
73
 unless, vaccine delivery is considered as the application. The immunogenicity would be 
the key point of pathogen-based carriers to function as adjuvants. In addition, since ex vivo 
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engineering is always required to modify cell-based vehicles, the membrane integrity is highly 
possible to be influenced, which will cause even faster clearance of the drug-loaded carriers from 
circulation. 
2.2.2 The advances of bio-inspired nanoparticles in bio-application 
The understanding of structure–function relationships of natural particulates provides a useful guide 
for the design of new nanocarriers. Currently, many research attempts have focused on the synthesis 
of new drug delivery systems by mimicking the advantages of natural particulates, such as 
structures (e.g., shape and inner structure) and surface chemical properties. In the following part, 
the current development of bio-inspired nanocarriers is summarized. 
2.2.2.1 Pathogen-mimicking strategies 
The pursuit of low toxicity and little immunogenicity, but high delivery efficiency has led to the 
development of synthetic vectors-mimicking the structure and/or composition of different 
pathogens. Lee et al., described a pH-sensitive nanogel system mimicking the core-shell structure of 
non-enveloped viruses (Figure 2.2). 
86
 The core is made of the doxorubicin (DOX)-encapsulated 
hydrophobic polymer, while the shell mimicking capsid structure is composed of bovine serum 
albumin (BSA), connected by polyethylene glycol (PEG) with the core. The surface of BSA is 
further conjugated with folate ligands for targeted delivery to tumor sites. When the surrounding pH 
changes from a physiological value (pH 7.4) to endosomal level (pH 6.4), the nanogel will 
reversibly swell from 55 nm to 355 nm, facilitating endosomal escape and DOX release for 
significant cancer killing effect. Noticeably, the nanogel will move into and kill the neighbouring 
cells in the same way, mimicking the cycles of viruses.  
 
Figure 2.2 Preparation and structure of the virus-mimicking nanogel.
86
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Researchers also tried to mimic the features of enveloped viruses for improved drug delivery. A 
virus-mimicking liposome-pDNA complex, with an onion-like core of pDNA-lipid complex and 
spikes of human transferrin (Tf) coating, has been fabricated.
87
 Tf-polyplex exhibits improved in 
vivo pDNA transfection efficiency and long-term efficacy for systemic p53 gene therapy of human 
prostate cancer in combination with conventional radiotherapy. In addition, polymer-based 
materials are also used to mimic the features of influenza viruses for enhanced siRNA delivery 
(Figure 2.3).
88
 In the system, siRNAs can compact with the cationic polymer at physiological pH. 
After endocytosis and entrapment in endosome/lysosome at acidic condition, this cationic polymer 
will degrade into negatively charged and non-toxic poly(acrylic acid) (PAA), releasing siRNAs. 
After that, another polymer will be in charge of the fusion with endosome membranes, similar to the 
function of fusion peptide (HA2) in influenza viruses, and result in endosomal escape of siRNAs for 
gene silencing.  
 
Figure 2.3 Mechanism for the assembly of influenza virus-inspired polymer, binding with siRNA 
and release of siRNA through a self-catalyzed degradation of PDMAEA.
88
 
2.2.2.2 Cell-mimicking strategies 
Cell-mimicking nanoparticles have gained promising attention to drug delivery because they 
possess plenty of excellent properties of the source cells. One of the attractive features of cell-
biomimetic nanoparticles is the long-circulating cargo delivery. Zhang and coworkers successfully 
separated erythrocyte membranes, acquiring the membrane lipids associated membrane proteins, 
and coated them on biodegradable polymeric nanoparticles of poly(lactic-co-glycolic acid) (PLGA) 
(Figure 2.4).
89
 The erythrocyte membrane-camouflaged PLGA nanoparticles can achieve sustained 
circulation in the blood of mice for 72 h following the particle injection. After that, the erythrocyte 
membrane-coated PLGA nanoparticles were used for effective removal of pore-forming toxins 
(PFTs) in mice.
90
 Following that, they inserted a model PFT of staphylococcal a-haemolysin (Hla) 
into erythrocyte membranes, and used it as a toxoid vaccine. Comparing the vaccination effect with 
heat-attenuated PFT, the PFT loaded erythrocyte membrane-coated PLGA nanoparticles showed 
superior immunogenicity without toxin-mediated adverse effects.
91
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Figure 2.4 Schematics of the preparation process of RBC-membrane-coated PLGA nanoparticles.
89
 
In addition, the membranes from other cell types have also been applied to coat nanoparticles to 
form biomimetic nanocarriers. For example, after isolation of the leukocyte membrane, the 
engineered leuko-like vectors (LLV) encapsulating a nanoporous silicon core avoided blood 
clearance by mononuclear phagocytic cells, promote active communication with endothelial cells, 
and improve the circulation time and accumulation in tumor sites, so that increase drug delivery 
efficiency.
92
 Cancer cell-derived membranes bound with tumor antigens have also been used to 
package PLGA nanoparticles for potential application of vaccine and/or drug delivery. The antigens 
d r v d  rom B16−F10 mous  m l nom    lls on n no  rr  r sur       lp to      v    n  r 
targeted delivery, due to the inherent homotypic binding phenomenon among the tumor cells. 
Importantly, the nanocarrier successfully delivers an immunological adjuvant (MPLA), promoting a 
tumor-specific immune response for the use in vaccine application.
93
 
Synthetic particles mimicking cell morphology and functions have also been developed. Different 
RBC-like particles have been fabricated using hollow polystyrene (PS) microparticle
94
 or hydrogel-
based microspheres
95, 96
 as the template, possessing the ability of deformation in capillaries. 
Noticeably, PS-based RBC-like particle is able to mimic the functions of natural RBCs to carry 
oxygen, and deliver drugs and imaging agents. Platelet-mimicking nanoparticles with the features to 
induce additional local clotting have also been developed. This particle possesses a specific binding 
affinity for activated platelets, and it is able to adhere and activate platelets at the bleeding site, so 
that it can halt bleeding.
97
 To be different, the iron oxide nanoparticles coated with a homing 
peptide, CREKA (Cys-Arg-Glu-Lys-Ala), is applied to simultaneously recognize clotted plasma 
proteins at vessel walls and selectively homes to tumors stroma, amplifying tumor imaging, and 
potentially enhance drug delivery efficiency.
98
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2.2.2.3 Other strategies 
Besides pathogen- and mammalian cell-mimicking strategies, creatures in nature will also inspire 
the development of nanoparticles with unique properties. Learning from the functions of jellyfish 
with long tentacles in catching prey from surroundings, affinity DNA polymers (DPs) and DNA 
polymers with aptamers (PAs) on iron nanoparticles have been synthesized for drug sequestration 
and detoxification.
99
 It is demonstrated the model drugs of DOX and thrombin were effectively 
sequestered from solution. More importantly, the toxic effect of DOX to human umbilical vein 
endothelial cells (HUVECs) is largely decreased, and the coagulation time is also shortened, 
indicating the ability of different nanoparticles in mitigating biological effect of different drugs.  
2.3 Strategies to engineer silica-based nanoparticles as effective gene and protein carriers 
The key factors for successful gene and protein therapy are effective intracellular delivery of 
cargos, overcoming in a number of barriers before the released genetic molecules and therapeutic 
proteins exhibit their functions. First, NP-cargo complexes must penetrate across cell membrane, 
usually via endocytic pathways (Figure 2.5), which predominantly include phagocytosis, clathrin-
mediated endocytosis (CME), caveolae-mediated endocytosis (CvME) and macropinocytosis.
100-102
 
These cell-penetration processes can be regulated and improved by surface charge adjustment or 
ligand conjugation. In addition, engineered surface modification with polymers, peptides or 
coupling with some other materials helps the escape of cargos captured in endosomes or lysosomes, 
and may even assist to direct nuclear targeting or entry.  
Silica-based nanoparticles (SiNPs) are promising materials for genetic molecule or protein delivery. 
Through the sol-gel processing route, surface properties, particle size and shape, which may have 
different impacts on cell activity and transfection efficiency, can be easily controlled. In addition, 
after the additions of surfactants, the nanoparticles with different pore sizes and pore volumes have 
been fabricated, providing access to load cargo molecules inside the pores for multifunctional 
applications. In this part, the effects of different surface modifications to SiNPs from simple surface 
charge adjustments to conjugation with functional molecules, on particle endocytosis efficiency, 
endo/lysosomal escape and nuclear targeting will be introduced at first. Then, particle parameters, 
with respect to endocytosis efficiency and the interaction with cells, will be discussed. 
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Figure 2.5 Endocytic pathways traversed by nonviral carriers. (A) Macropinocytosis of cationic 
particles. (B) Nonviral vectors can also be internalized by other pathways such as clathrin-mediated 
endocytosis, which is a receptor-mediated pathway. (C) Caveolae-mediated endocytosis proceeds 
by oligomerization of caveolin, actin-dependent internalization of caveolae to form cavicles and 
merger with the degradable lysosomal compartment, or non-degradable trafficking to the nucleus 
via caveosomes. Each pathway relies on microtubules for rapid transport of endocytic vesicles. 
HSPG: Heparan sulfate proteoglycans.
102
 
2.3.1 Surface engineering 
Surface properties are an important factor to influence the upload and release of genetic molecules 
and proteins into cells on cancer therapy. For gene therapy, negatively charged genetic molecules 
are able to complex with amine-modified SiNPs with a positive charge,
103
 either on the surface or 
inside the pores. In addition, the conjugation/hybridation of silica materials with polymers
39
 or other 
inorganic materials
104, 105
 will acquire some new properties. For protein therapeutics, different 
strategies are required to achieve protein loading, due to the variable sizes and isoelectric points 
(IEPs) of protein molecules. This section focuses on the development in surface modification of 
SiNPs and the impact on cargo delivery and cellular response. 
2.3.1.1 Surface charge 
Electrostatic force is the most widely applied approach to interact with cargo molecules, NPs and 
cell membrane. Due to the negatively charged cell membrane and phosphate backbone of genetic 
molecules, NPs with positive charges have been considered more effective to immobilize 
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DNA/RNA and achieve cell uptake than those, which are negatively charged or neutral.
30, 39, 106
 
However, since SiNPs have an intrinsically negative charge on the surface, derived from silanol 
groups, surface charge modification is required, for example, by attaching amine-groups on particle 
surface. An amino-modified SiNP (45 nm) showed better GFP pDNA adsorption and expression 
behavior.
103
 In addition, cationic polymer-coated SiNPs (e.g., PEI-MSN or PLL-MSN) can also 
acquire a positive charge on the surface and provided enhanced cell uptake and transfection 
compared to unmodified SiNPs.
39, 107, 108
 However, the nature of protein molecules with variable 
IEPs suggests different surface charge controls. For example, pristine mesoporous silica 
nanospheres were first used for delivery of cytochrome c with a IEP of 10.5 into cervical cancer 
cells (HeLa),
109
 where cytochrome c possessed positive charges in physiological buffer of 
phosphate buffered saline (PBS, pH 7.4). On the contrary, positively charged surface is required for 
the adsorption of therapeutic proteins with low IEP values (e.g., insulin, IEP 5.3).
110
  
Noticeably, by varying the surface charge value, endocytic pathways will change. Slowing et al. 
reported that by changing the grafted groups, SiNPs acquired positive charge with zeta potential 
(ZP) values.
111
 In the order from 3-aminopropyl (AP), guanidinopropyl (GP), 3-[N-(2-
guanidinoethyl)-guanidino]propyl (GEGP) to N-folate-3-aminopropyl (FAP) groups, the ZP value 
of the original MSNs (-34 mV) increased from -4.68 to +12.81 mV. FAP-MSN and negatively 
charged pure MSNs were taken up into cells via a clathrin-pitted mechanism, and AP- and GP-
MSNs were internalized via a caveolae-mediated pathway. However, the pathway for GEAP-MSNs 
was unclear, since none of the pathway inhibitors had dramatically slowed down or decreased the 
internalization. Strangely, in this research, negatively charged MSNs exhibited better endo-
/lysosomal escape compared with positively charged MSNs. It was explained that the groups of 
SiO
-
 on negative charged MSNs can neutralize more H
+
, leading to better behavior of the proton 
sponge effect. Moreover, surface charge-related endocytosis was reported to be cell type-dependent. 
Chung and co-workers claimed that unmodified (negative charged) MSNs were internalized 
through a clathrin-mediated and an actin-dependent endocytosis in both murine adipocytes (3T3-
L1) and human mesenchymal stem cells (hMSCs).
112
 However, when using positive-charged 
MSNs, such a pathway was only applied by 3T3-L1 cells, while the pathway for hMSCs have 
switched to an unknown one. These results suggested that a threshold of positive surface charge was 
responsible for MSN uptake by hMSC, and the surface charge-related MSN uptake was cell type-
specific. 
In addition to the effect on endocytosis, surface charge is related to cytotoxicity. Usually, pure 
SiNPs show more toxicity than amino-modified ones, and many researchers have given possible 
explanations, such as reactive oxygen species (ROS) induced by the hydroxyl groups, denaturation 
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of membrane proteins through electrostatic interactions with silicate and the high affinity of silicate 
for binding with the tetra-alkyl ammonium groups that are abundant in the membranes of RBCs.
113
 
Although the exact mechanism is still under investigation, most researchers agree that cytotoxicity 
is related to ROS induced by surface silanol groups, causing membrane damage, for example, 
hemolysis of RBC.
114
 Shi et al. confirmed that when SiNPs were treated with alkaline media 
(NH4OH), hemolysis was significantly reduced.
115
 This reduction was possibly related to the shift to 
SiO
-
 from Si-OH where hydroxyl groups were neutralized. Moreover, when SiNPs were incubated 
with plasma or whole blood, hemolysis and cytotoxicity were also inhibited because of a protective 
protein corona layer over the surface of silica particles. This result showed that the interaction of 
SINPs with serum proteins was an important event that should be considered in the first place in 
future clinical application. 
2.3.1.2 Surface hydrophobicity 
Hydrophobic interaction has been considered as an important property for enhanced genetic 
molecule or therapeutic protein delivery. Nanocarriers with hydrophobic modification are believed 
to either improve cell membrane interactions
116
 or strengthen the interactions between nanoparticle 
and cargo molecules by excluding water molecules around hydrophobic moieties.
117
 Alshamsan et 
al. have tried to modify branched PEI with stearic/oleic acid, which has a fatty acid chain of 18 
carbon atoms, and the hydrophobically modified PEI increased siRNA delivery up to 3-folds 
compared to the parent PEI.
116
 Bale and co-workers
61
 developed an octadecyl (C18)-group 
functionalized solid silica nanoparticle. They absorbed therapeutic proteins, such as the antibody to 
pAkt, on the surface and delivered them into MCF-7 breast cancer cells. The loaded therapeutic 
protein resulted in significant cell growth inhibition without extended entrapment in endosomes. 
Moreover, Zhang and co-workers confirmed a significant cell growth inhibition to human squamous 
carcinoma cells (SCC-25) by the delivery of RNase A using C18-functionalized silica hollow 
spheres.
118
 Therefore, hydrophobic feature is one of the promising factors to control nanoparticle 
behaviors for successful drug delivery. 
2.3.1.3 Influence of serum protein 
Prolonged blood circulation before being cleared via nonspecific binding to serum protein is of 
utmost importance to achieve sustained release of cargos, improved retention with cell membrane, 
as well as enhanced penetration into targeted cells.
119
  
Surface properties are one of the key influential factors for serum protein adsorption. For example, 
the adsorption behavior of BSA at pH 5 was tested on siliceous mesocellular foams (MCF) 
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functionalized with chloromethyl (CM), mercaptopropyl (MP), octyl (Oc) or AP groups.
120
 The 
results showed that positively charged MCF-AP exhibited the highest adsorption capacity with 
negatively charged BSA, because of electrostatic interaction. However, hydrophobicity and steric 
hindrance of functional groups may significantly decrease serum protein loading amount and 
adsorption rate, for example, octyl-group or high amounts of CM-groups. Cell culture media with or 
without fetal calf serum (FCS) can have different effects. Related investigation showed that less dis-
tinct particle aggregation was observed in serum-free conditions, while the presence of FCS led to 
increased aggregation. Meanwhile, the decreased cytotoxicity in 3T3 fibroblast cells was seen after 
interacting with FCS. 
121
 It is possible that large agglomerates significantly consumed NPs, so only 
a small quantity of small agglomerates or primary particles could be internalized into cells. 
Therefore, attention should be paid to increase cargo loading efficiency and proper decoration of 
NPs in order to reduce aggregation, SiNP dosage and cytotoxicity. For example, PEG, with low 
cytotoxicity and good hydrophilicity, has been conjugated to enhance biocompatibility and mitigate 
nonspecific adsorption of SiNPs to proteins.
122, 123
 
2.3.2 Modification with other materials 
With the purpose to fabricate smart drug carriers, NPs have been used to overcome a series of 
obstacles for the successful transfection into planned sites. However, simply modified silica-NP 
alone cannot complete the entire work. The complexation of SiNPs with other materials has proven 
to be extremely necessary.
108
 A variety of complexation materials have been utilized in order to 
improve the specificity and efficiency of cargo delivery.  
2.3.2.1 Organic materials 
A wide variety of organic polymers have been coupled with SiNPs for effective genetic molecules 
and therapeutic protein delivery, such as cationic polymers (e.g., PEI,
39, 114, 124
 PLL
30, 125, 126
 and 
polyarginine
127, 128
), hydrophilic polymer (e.g., PEG
107, 126, 129
) dendrimers (e.g., polyamidoamine 
[PAMAM] dendrimers
130, 131
), carbohydrate-based polymers (e.g., chitosan
132, 133
 and dextran
134-136
) 
and polypeptide.
137-139
 
Although most of the organic materials alone are capable of effectively directing cargo molecules 
into cytosols or even nucleus, the combination with SiNPs have shown supplementary advantages, 
providing an excellent platform for enhanced cargo delivery performance for multifunctional 
applications. For example, after the connection of solid silica NPs with Tat
138
 or MSN with 
octaarginines (R8),
139
 successful cell internalization was observed. Following cell uptake, 
endosomal escape is the second process affecting transfection efficiency, and various 
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polymers/peptides are experienced in overcoming these obstacles. For instance, non-covalent 
attachment of 10 kD PEI with pDNA/siRNA showed efficient endocytosis, expression, and gene 
silencing effect.
39
 The PEI-grafted enzymes (superoxide dismutase and catalase) encapsulated in 
hollow silica nanoparticles were delivered into cytosols to neutralize the generated superoxide, 
protecting cells.
124
 In addition, fusogenic peptides (FP) are also effective for endosomal escape. 
They are classified into three types: anionic amphiphilic, cationic amphiphilic and histidine-rich 
peptides. Anionic FPs contain glutamate residues that protonates in low pH conditions (~5) in 
endosome and then the formation of alpha-helix causes the disruption of endosome membrane. The 
basic residues in cationic FPs are responsible for loading DNA/RNA via electrostatic force. These 
basic residues have lytic activity due to the proton-sponge effect and will trigger membrane lysis, 
causing related cytotoxicity. Similar to cationic FPs, histidine-rich peptides will also be protonated 
at pH values of approximately 5.6–6, so that to achieve endosomal escape.140-142 Ye et al. reported a 
successful synergistic application of CPP and fusogenic peptide, and this system exhibited 
enhanced cell uptake, pDNA–silica NP complex transfection and gene expression.143  
The complexation of silica NPs with a single material may not satisfy all the requirements for 
effective transfection. For example, the strong positive charge of polycationic polymers may lead to 
aggregation in the presence of serum protein. Extra molecules may also be necessary for special 
purposes, such as cell recognition. In addition, polycationic polymers, such as PEI with a large 
molecular weight, may cause significant cytotoxicity, due to powerful proton pump activity in 
endosome/lysosomes, where excessive hydrogen ions may cause endosomal osmotic-swelling, 
rupture and cell death by a mitochondrial dysfunction.
5, 37
 Hence, proper alleviation or modification 
is required. For example, by reducing PEI molecule weight
39
 or coupling with other polymers, such 
as hydrophilic polymer of PEG,
107
 or the cell-specific ligands of mannose,
108
 cytotoxicity resulting 
from proton pump activity was significantly reduced. Apart from simply reducing cytotoxicity, cell 
recognition and enhanced transfection efficiency could be achieved by the connection of cell 
specific ligands, for example, mannose.
108
 Remarkably, a fascinating carrier system has been 
synthesized recently, where the composites of SiNPs and QDs were loaded with anticancer-drugs 
and siRNA inside the pores, followed by coating with liposomes forming protocells (Figure 2.6). 
Then, the protocell surface was conjugated with different functional molecules, including PEG, 
targeting peptides (specific to hepatosarcoma cells) and FPs. Results showed a 10,000-fold higher 
affinity to hepatosarcoma cells, compared with hepatocytes, endothelial cells or immune cells. More 
importantly, it is capable of killing the drug-resistant human hepatocellular carcinoma cells, 
representing a 10
6
-fold improvement over comparable liposomes.
144
 This research provided a well-
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designed strategy to synthesize multifunctional SiNPs, so that all the requirements for successful 
gene therapy can be met, even comparable to viral carriers. 
 
Figure 2.6 Steps of multivalent binding and internalization of targeted protocells, followed by 
endosomal escape and nuclear localization of protocell encapsulated cargo. (1) DOPC protocells  
particles binds to cell surface with high affinity due to attachment of targeting peptides; (2) then 
goes through cell memberane via receptor-mediated endocytosis; (3) release drugs into cytosol on 
endosome acidification and protonation of H5WYG fusogenic peptide. (4) Finally, NLS-attached 
cargo is transported in the nucleus. DOPC: 1,2-Dioleoyl-sn-glycero-3-phosphocholine; NLS: 
Nuclear localization signal.
144
 
The cargo release behavior is also an important factor for nanocarriers, thus stimuli-responsive and 
controlled cargo release has attained considerable eminence. Many physicochemical factors are 
responsible for triggering cargo release, for example, light-irradiation,
145
 cleavage of disulfide,
145
 
enzymatic cleavage,
146
 temperature
147
 and pH.
148
 For example, Sauer et al. reported a successful 
release of ATTO633-labeled cysteine into cytoplasm of HuH7 cells by the cleavage of disulfide 
from inner surface of MSNs, after endosomal escape.
145
 For enzymatic cleavage, a co-delivery 
system was designed, consisting of PLL-modified hollow MSNs loaded fluorescein inside and CpG 
ODN on the surface. The enzyme of alpha-chymotrypsin is used as a model. Fluorescein and CpG 
ODN can simultaneously release from the particles stimulated by alpha-chymotrypsin that can 
induce PLL polymer degradation.
146
 Compared with others stimuli, pH-response is the most logical 
trigger, because of the intrinsic pH value differences in different cells or cell compartments, for 
example, approximately 5 in endosome, 6.8 in tumor tissues and 7.4 in normal tissues. Chen et al. 
reported a pH-sensitive drug (ibuprofen) delivery system of chitosan-coated MSNs, where the 
release of encapsulated drug could be controlled by the narrow difference between pH 6.8 and 
7.4,
148
 avoiding nonspecific drug leakage in normal cells. 
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After cargo release, genetic molecules (e.g., pDNA) or even some proteins (e.g., saporin
60
) should 
go into nucleus to show their functions. Usually, free diffusion is a common route for cargo release, 
however, the efficiency is not guaranteed. To be different, targeted nuclear delivery will be more 
effective for gene/protein therapy, with the help of nuclear localization signal (NLS). Based on 
sequence differences, NLS is divided into classical and non-classical groups. After the binding of 
NLS w t  t    mport r   ptors o   mport n α  nd β,  nd t    ollow n   nt r  t on w t  nu l  r por  
complex (NPC), cargo translocation will be initiated.
149
 Shi and co-workers first reported the 
connection of NLS with MSNs (MSN–Tat complex) for nuclear targeting and nuclear entry (Figure 
2.7).
150
 Tat showed significant nuclear membrane targeting behavior and the DOX absorbed into 
MSNs–Tat complex exhibited cancer cell killing effect. This work opens new avenues of SiNPs for 
improved gene therapy.  
2.3.2.2 Inorganic materials 
Inorganic materials have also coupled with SiNPs, aiming at either improving localization of NPs at 
tumor sites, or helping to track NPs in vivo. Magnetic NPs have been extensively studied, because 
of their application in efficient magnetic targeting, imaging and bio-separations.
105, 151
 Using 
different protocols, the encapsulation of magnetite (Fe3O4) nanospheres onto or into porous SiNPs 
has been reported for the improvement of drug delivery efficiency.
105, 151-153
 
Another type of inorganic material, semi-conductor QDs, has also attracted great research interest in 
nanomedicine, because they are effective optical probes for in vivo imaging.
154, 155
 When silica 
materials coat onto QDs, silanol groups on the surface can be accessible to conjugate with other 
functional molecules. For example, silica-coated QDs (e.g., CdSe
104
) connecting with single-
stranded oligonucleotide hybridizations will work as molecular beacons (MBs), where QDs are 
used as fluorophores, and they show fluorescent signals after DNA pairing with a target sequence. 
This MB has shown excellent behavior for DNA recognition.
156
 
Although gold and silver NPs themselves have been effective to be used as genetic molecule
157
 and 
protein
158
 vectors, studies on their combination with silica NPs have been paid increasing attention, 
recently. Christen et al. reported that SiO2–Ag-NPs induced an increased endoplasmatic reticulum 
(ER)-stress response and reduced cytochrome P4501A activity of human liver cells (Huh7) and 
pimephales promelas (fathead minnow) fibroblast cells (FMH).
159
 SiO2–Au-NPs-oligonucleotide 
could also be used as a fast colorimetric DNA.
160
 In addition, the co-delivery of BSA and pDNA 
using gold NP-functionalized MSNs to plant tissues has also been reported.
161
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As a brief conclusion, the strategies to combine inorganic/organic materials with SiNPs hold a 
potential to possess all the necessary abilities for highly improved gene/protein delivery, as efficient 
as natural particulates. However, other parameters of SiNPs, such as pore size and particle sizes, 
need to be further studied. 
2.3.3 Particle nanotechnology 
2.3.3.1 Particle size 
Control over particle size at nanoscale is an important aspect in nanotechnology and has significant 
impact on particle endocytosis
162-164
 and cytotoxicity.
165
  The size of SiNPs can be adjusted from a 
few to hundreds of nanometers.
163
 There are plenty of evidence showing that cell internalization of 
most of non-viral NPs, such as liposomes,
166
 quantum dots,
167
 gold nanoparticles
162
 and SiNPs
165
 is 
particle size-dependent. For example, phagocytosis, performed by immune cells, has been 
tr d t on lly  sso   t d w t  t   upt k  o  p rt  l s l r  r t  n 1 μm, r  o nizing by specific 
receptors. Similarly, macropinocytosis has been exploited for non-specific uptake of large particles, 
which is also approxim t ly 1 μm.168 In addition, clathrin- and caveolae-mediated pathways allow 
the entry of NPs (e.g., SiNPs) from 30 to 300 nm.
 43, 61
 In detail, cell uptake efficiency was reported 
in the sequence of 50 > 30 > 110 > 280 > 170 nm. The uptake of 50 nm fluorescein-5-
isothiocyanate (FITC)-MSNs was approximately 2.5-times that of 30 nm ones, four-times that of 
110 nm ones, 20-times that of 170 nm ones and 11 times that of 280-nm particles.
164
 Similar trends 
have also been found in other materials, such as QDs
167
 and gold NPs.
162, 169
 Moreover, particles 
with small sizes are easier to target to tumor sites, due to the leaky behaviour of vessels in tumor 
tissues compared with healthy tissue, leading to uptake of NPs via enhanced permeation and 
retention (EPR) effect.
170, 171
  
On top of the behavior of internalization, particle size is further responsible for systemic 
cytotoxicity. Independent research groups have studied the relationship of hemolytic activity or 
cytotoxicity with particle size.
115, 163, 165
 All the results showed that SiNPs caused hemolysis or cell 
death (human hepatoma cells) in a size-dependent manner, that is, smaller particles that have larger 
surface areas, may cause more cell damage resulting from the ROS. However, Zhao et al. provided 
a converse result, where the 600 nm MSNs showed more toxicity than 100 nm MSNs.
172
 The 
authors claimed that membrane wrapping followed by the MSN engulfment is related to particle 
curvature rather than particle size. Smaller particle possesses larger curvature, thus more free 
energy is required for the membrane bending and binding with MSNs, resulting in 
thermodynamically favorable cell uptake of larger MSNs. It is possible that a threshold of particle 
size exists for hemocompatible MSNs (below 225 nm).
163, 172
 Moreover, particle size for nuclear 
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entry should be limited within 20–70 nm, being consistent with the diameter of NPC. Shi and co-
workers (Figure 2.7) firstly confirmed the silica-based nuclear entry of MSN–NLS–Tat complex, 
where the threshold size is 50 nm.
150
 
 
Figure 2.7 Nuclear-targeted drug delivery of Tat peptide-conjugated MSNs. (A) Preparing amino 
group- and Tat-FITC peptide-conjugated MSNs. (B) Transport of DOX@MSNs-Tat across nuclear 
membrane. (C) CLSM images of MSNs-Tat with diameters of (1) 25, (2) 50, (3) 67 and (4) 105 nm 
  t r  n u  t on w t  H L    lls  or ( ) 4, (  ) 8  nd (   ) 24  . S  l    rs: 5 μm. APTES: 
Aminopropyl triethoxy silane; CTAC: Hexadecyltrimethylammonium chloride; MSN: Mesoporous 
silica nanoparticle; TEA: Tetraethyl amine; TEOS: Tetraethyl orthosilicate.
150
 
2.3.3.2 Pore size and pore structure 
Conventional MSNs have relatively small pore sizes within 2–4 nm173, 174 and only small molecule 
drugs can be loaded inside the pores. For example, Bhattarai et al.
175
 and Meng et al.,
176
 
respectively, reported the co-delivery of siRNAs (luciferase-targeted siRNA or P-Glycoprotein 
siRNA) and anticancer drugs (chloroquine or doxorubicin) into different cancer cell lines (mouse 
melanoma cell line or epidermoid carcinoma cell line), where the small drugs were loaded into the 
pores of MSNs (2–3 nm) and siRNAs were adsorbed on the external surface. It is noted that MSNs 
with small pores suffer from disadvantages of low encapsulation efficiency, and large bio-
molecules such as siRNAs, DNAs and proteins can hardly be adsorbed into pores. This limits the 
potential advantages of MSNs over solid silica spheres in cargo loading and protection. 
SiNPs with different pore sizes and pore structures can be synthesized by varying silica 
precursors,
177
 surfactant types (e.g., hexadecyltrimethylammonium bromide [CTAB],
177
 Pluronic 
F127 [EO106PO70EO106, EO = ethylene oxide, PO = propylene oxide]
178
 and Pluronic P123 
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[EO20PO70EO20]
179
), as well as adding swelling agents (e.g., 1,3,5-trimethylbenzene
180
). Related 
products with various pore parameters have been fabricated, such as SBA-15 (large-pore 2d 
hexagonal),
181
 MCM-48 (gyroid cubic Ia3d),
182
 KIT-6 (large-pore gyroid cubic Ia3d),
181
 FDU-12 
(ultra-large-pore, Fm3m type)
178, 183, 184
, macroporous (~110nm in diameter) ordered siliceous foams 
(MOSF)
179
 and periodic mesoporous organosilica (PMO).
87, 88
 It is notable that some surfactants 
show cytotoxicity to cells. He and Shi reported as-synthesized MSNs (without removing surfactant) 
could kill cancer cells at a much higher efficiency by the release of surfactant molecules than 
common anticancer drugs.
185
 In other words, surfactants must be totally removed prior to bio-
application. 
Large pore SiNPs are another type of attractive candidates for genetic molecule or protein delivery. 
Due to their high pore volume and much lower density, large amount of therapeutic agents can be 
loaded while reducing native cytotoxicity of silica. For example, HMSNs of ~250 nm size were 
combined with a chitosan-antibody decoration, and the material enabled a pH-controlled release of 
TNF-a, which significantly suppressed the growth of cancer cells and even killed them with high 
therapeutic efficacy.
185
 Although conventional FDU-12 possesses large pores up to 40 nm,
174
 the 
particle size is in micrometer range, which is not suitable for cell uptake. Hartono et al. successfully 
prepared a PLL-conjugated FDU-12-type SiNP with particle size of ~100–200 nm and pore size of 
~28 nm.
30
 After the intracellular delivery of siRNA loaded NPs in inner pores, significant decrease 
of osteosarcoma cancer cell viability was observed (Figure 2.8). Apart from the good performance 
of SiNPs in cargo delivery, the intrinsic cytotoxicity of both porous and nonporous SiNPs has also 
been investigated. The damage to cell membrane of RBCs
163, 186
 and human promyelocytic 
leukemia cells (HL-60)
186
 have been investigated, where porous SiNPs exhibited lower cytotoxicity 
than nonporous counterparts of similar size. It is claimed that the external surface area is important 
in determining cytotoxicity. Porous SiNPs have smaller external surface areas, thus less silanol 
groups on the cell-contactable surface, compared to nonporous SiNPs, resulting in less ROS and 
reduced toxicity.
113
 
2.3.3.3 Particle shape and surface morphology 
The shapes and surface morphologies of SiNPs can be adjusted by changing synthesis parameters 
such as chemical ratios,
188, 189
 initial temperature,
190
 stirring rate,
190
 micelle packing parameter,
165, 
191
 additives,
105, 192, 193
, or post-modification,
194, 195
. For instance, anisotropic ellipsoid-like MSNs 
were fabricated via the organic–inorganic cooperative assembly in the presence of additive agents 
(KCl and ethanol
105
). In addition, the delivery of Cy3-oligo-DNA into tumor cells showed its 
potential in drug/gene delivery.
105
 Silica nanotubes were made using anodic aluminum oxide 
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membrane as a template. By coating the inner surface of amino-groups, such materials efficiently 
loaded pDNA of GFP and expressed in COS-7 cell.
196
 
Endocytosis performance of SiNPs is also influenced by particle shapes. For instance, the 
relationship between cell uptake and three rod-like MSNs with similar particle diameter, chemical 
composition and surface charge, but with different aspect ratios (ARs, 1, 2 and 4) were investigated. 
The results indicated that these different-shaped particles were readily internalized in human 
melanoma (A375) cells by non-specific cell uptake. Among them, the particles with larger ARs 
were taken up in larger amounts and had faster internalization rates, however, showing a greater 
impact on cell proliferation, apoptosis, cytoskeleton formation, adhesion and migration.
189
 A pos-
sible explanation for this behavior could also be attributed to curvature of SiNPs, since larger AR 
means larger contact and interaction area with the cell membrane, causing higher cytotoxicity from 
ROS. Evidence showed bio-distribution, clearance and biocompatibility of MSNs will also be 
affected by different shapes of MSNs. For example, short-rod MSNs (AR = 1.5) were confirmed to 
be easily distributed in the liver, while long-rod MSNs (AR = 5) stayed in the spleen. The main 
excretion route was observed by urine and feces. Moreover, short-rod MSNs showed a more rapid 
clearance rate. Although in this investigation, hematology, serum biochemistry and histopathology 
results indicated that MSNs did not cause significant toxicity in vivo, but systemic side effects may 
be caused by the accumulation of MSNs in those organs,
188
 especially in the long-term. 
The surface morphology or topology is another interesting factor for effective modification. By 
investigating the features of plenty of surface morphologies, from viruses to plants to animals, 
researchers have noticed that morphologies of living creatures in microcosmic scale seldom showed 
homogeneousness. For example, the lotus leaves have tiny raspberry-like structures on the surface. 
The bubble-like structures between the shells show super-hydrophobicity and hence resistance to 
water.
197
 Nel et al.
198
 depicted the effect of heterogeneous structures, for example, local protrusions 
or depressions with radii smaller than that of the particle, may have the potential to strengthen NP–
cell interactions. Although some silica-based bimodal or heterogeneous structures have been 
fabricated, for example, the raspberry-like structure,
84, 100, 104
 that is, the combination of a large core 
and plenty of small shells on the surface, only a few studies have focused on the relationship 
between topology and gene/protein delivery efficiency. 
2.4 Conclusions and future perspective 
Various therapeutic agents with good specificity, such as genetic molecules and therapeutic 
proteins, have been applied in modern medicine. However, effective carriers are required for 
enhanced intracellular delivery of cargos. Although natural particulates have superior properties for 
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genetic molecules and therapeutic protein delivery, some intrinsic issues prevent their wide 
applications, which propels the development of synthetic vectors mimicking the features of natural 
particulates. For example, silica-based nanoparticles (SiNPs) have emerged as excellent candidates.  
Although several successful delivery systems based on SiNPs have been studied, the investigation 
in other parameters, for example, the effect of surface morphology by mimicking enveloped viruses 
(objective 1 in this thesis), is required for further improved cargo delivery efficiency. The virus-
mimicking silica nanoparticles (VMSNs) are expected to enhance biomolecule delivery efficiency 
in various bio-applications. For instance, the VMSNs are expected to increase siRNA loading 
amount and cellular uptake effect, causing significantly enhanced gene silencing efficiency 
(objective 1 in this thesis). Following that, the systematic investigation of VMSNs with varied 
surface roughness in drug delivery efficiency will be very important, highlighting the roles of 
surface topography (objective 2 in this thesis). Furthermore, intensive investigation to one given 
VMSN is extremely necessary in understanding the individual contribution of surface roughness 
and surface modification to the therapeutic drug delivery processes (objective 3 in this thesis). 
The research on bio-inspired nanoparticles for biomedical applications is taking off and has 
demonstrated tremendously positive results. The opportunities could be realized by mimicking the 
surface topography of enveloped viruses, and combining interdisciplinary knowledge in chemistry, 
biology, material science and clinical medicine. 
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Chapter 3 
Methodology 
This chapter summarizes the strategies utilized in the whole PhD project, including synthetic 
methods for virus-mimicking silica nanoparticles (VMSNs) and the techniques for material 
characterizations and biological evaluations. 
3.1 Materials synthesis 
Mono-dispersed solid SiNPs with different sizes are synthesized by the hydrolysis and condensation 
of silicon alkoxides in either aqueous solutions or in alcohol/water mixtures using amino acid and 
ammonia as a catalyst, respectively. The silica particle diameter can be well-tuned from 10 nm to 
300 nm, simply by varying catalyst and precursor concentrations or reaction temperatures. 
3.1.1 Synthesis of monodispersed solid silica nanoparticles as core particle  
Uniform nonporous silica nanoparticles with a size of ~200 nm were synthesized using a well-
known method developed by Stöber.
1
 Typically, absolute ethanol (50 mL) was mixed with 
deionized (DI) water (3.8 mL) and ammonium hydroxide solution (2 mL, 28%) at 25°C. Then, 
tetraethyl orthosilicate (TEOS, 2.8 mL, 98%) was added to the solution under vigorous stirring. 
After 6 hours, as-synthesized nanoparticles were separated by centrifugation, and washed with 
ethanol and DI water. The final product was obtained by drying at 100°C overnight. 
3.1.2 Synthesis of monodispersed solid silica nanoparticles as shell particles 
Shell nanoparticles with the mean sizes of 28, 54, 98, 135 and   175 nm were also fabricated using 
Stöber method with the same recipe as the core particle, except for reacting at 70, 60, 50, 40 and 30 
°C, respectively. The reactions were first carried out for 20 minutes for the formation of shell 
particles (28, 54, 98 and 135 nm). For the shell particle of 175 nm, the reaction time was 2 h. In 
addition, a modified Stöber method was used to fabricate shell particle of ~13 nm diameter.
2
 First, 
L-arginine (87 mg) was dissolved in DI water (69.5 mL) containing octane (5.23 mL). Then, TEOS 
(0.5 mL) was added under vigorous stirring to react at 60 °C for 3.5 h for the formation of shell 
particles. 
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3.1.3 Synthesis of virus-mimicking silica nanoparticles (VMSNs) 
 
Figure 3.1 Schematic illustration of VMSN, followed by amine-group and PEI modification.  
The amine-modified core particle (200 mg, modification method can be found in section 3.1.4.1) 
was suspended (2 mL) in DI water (for the synthesis of VMSN with small shell particles) or ethanol 
(for the synthesis of VMSNs with larger shell particles). The suspensions were added into different 
shell particle solution keeping the original volume and condition, reacting for another 2 h. The as-
synthesized VMSNs were washed three times with ethanol and isolated by centrifugation at 4750 
rpm for 10 min (shell particles cannot be recovered by centrifugation under these conditions), 
followed by drying in a fume cupboard at 25 °C overnight. Finally, VMSNs were obtained after 
calcination treatment at 550 °C for 5 h to remove organic components in silica frameworks (Figure 
3.1).  
3.1.4 Functionalization of silica nanoparticles 
3.1.4.1 Amine-group modification 
Amine silane was grafted onto the surface of core particle or VMSN to create positively charged 
surface. First, core particles or VMSNs (200 mg) were suspended in toluene (30 mL). Then, 3-
aminopropyltriethoxysilane (APTES, 0.19 mL, 0.8 mmol) was added. The mixture was refluxed for 
20 hours at 383 K. Then, amine-group modified core particles or VMSNs were obtained by 
centrifugation, washing with ethanol and deionized water and drying in a vacuum oven at 25°C 
overnight.  
3.1.4.2 Hydrophobic modification 
Smooth or VMSNs were functionalized with n-octadecyl-trimethoxy silane (n-ODMS, 90%). 
Different nanoparticles (200 mg) were suspended in toluene (25 mL) containing 0.5% (v/v) n-
ODMS. Then, the mixture was refluxed for 20 h at 110 °C, followed by centrifugation at 10000 
rpm, washing with ethanol and drying in a fume cupboard at 25 °C overnight. 
3.1.4.3 PEI attachment  
In order to achieve efficient endosomal escape for successful cargo delivery into cytosols, 10 kDa 
polymer of PEI was attached to both smooth and VMSNs, through a linker of 3-glycidoxypropyl 
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trimethoxysilane (3-GPS). First, epoxysilane was connected onto the surfaces of smooth and 
VMSNs by suspending the silica solid (100 mg) in toluene (30 mL) and stirring for 15 minutes at 
343 K. Then, 3- GPS (1.5 mL) was added into the solution, which was further stirred for 24 hours at 
the same temperature. The solid products were centrifuged, washed three times with toluene and 
methanol and dried. Solid products (50 mg) were mixed with 10 kDa PEI (250 mg) in carbonate 
buffer (100 mL, 50 mM, pH 9.5) for 24 hours at 298 K. In this step, PEI is attached to the 
nanoparticles via epoxy-groups. The products were washed with NaCl solution (20 mL, 1.0 M), 
followed by three washes with deionized water, and were then recovered by centrifugation. At the 
final stage, the solid products were re-suspended in ethanolamine (20 mL, 1.0 g/L, pH 9) and stirred 
at 25°C for 6 hours to block free epoxy groups. The solids were then washed again with NaCl 
solution (20 mL, 1.0 M) and deionized water (20 mL). 
3.2 Characterizations  
3.2.1 Transmission electron microscopy 
Transmission electron microscopy (TEM) images were taken using a JEOL 1010 microscope 
operated at 100 kV. TEM specimens were dispersed in ethanol, and transferred to a copper grid.  
3.2.2 High resolution scanning electron microscopy 
High resolution scanning electron microscopy (HRSEM) images were obtained on a JEOL JSM 
7800 FE-SEM equipped with an in-column upper electron detector (UED) and gentle beam 
technology. HRSEM was operated at a low accelerating voltage of 0.8-1.5 kV with 20% specimen 
bias. HRSEM samples were prepared by dispersing the powder samples in DI water, after which 
they were dropped to aluminium foil pieces and attached to conductive carbon film on SEM 
mounts. The SEM mounts were dried in a vacuum oven at 70 °C for 8 hours before observations.  
3.2.3 Electron tomography 
 
Figure 3.2 Illustration of two-stage tomography process with (left) acquisition of an ensemble of 
images (projections) about a single tilt axis and (right) the back-projection of these images into 3D 
object space. 
3
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Electron tomography (ET) has been adopted rapidly as an advanced TEM technique for the study of 
the morphologies and chemical compositions of nanostructures three-dimensional (3D) views. The 
ET processing includes two steps. First, multiple 2-dimentsional projections must be acquired to 
reveal quantitative 3D information. Then, in combination with automation and analysis software, 3-
dimentional structure of materials will be reconstructed by back-projection techniques, resulting in 
the need for challenging and often lengthy experiments (Figure 3.2).
3
  
ET data was collected with a FEI Tecnai F30 transmission electron microscope operating at 300 kV. 
ET specimens were prepared in the same way of the TEM specimens. All TEM images for ET were 
recorded at a given defocus in a bright-field mode to show the thickness contrast. The tomographic 
tilt series were obtained by tilting the specimen inside the microscope around a single axis under the 
electron beam. TEM images were recorded over a tilt range of +57 to -57° at an increment of 1°. 
Images of the tilt-series were aligned with respect to a common origin and rotation axis using the 
fiducially markers.  
3.2.3 Dynamic light scattering 
Dynamic Light Scattering (DLS) is used to measure particle and molecule size. This technique 
measures the diffusion of particles moving under Brownian motion, and converts this to size and a 
size distribution using the Stokes-Einstein relationship. Non-Invasive Back Scatter technology 
(NIBS) is incorporated to give the highest sensitivity simultaneously with the highest size and 
concentration range.
4
 DLS measurements were carried out at 25 °C using a Zetasizer Nano-ZS from 
Malvern Instruments. The samples were dispersed in deionized water or ethanol by ultra-sonication 
before analysis. 
3.2.4 Zeta (ζ) potential analysis  
The ζ-potential of colloidal dispersions is routinely measured using the technique of micro 
electrophoresis. In this technique, a voltage is applied across a pair of electrodes at either end of a 
cell containing the particle dispersion. Charged particles are attracted to the oppositely charged 
electrode and their velocity is measured and expressed in unit field strength as their mobility.
5
 ζ -
potential was carried out at 25 °C using a Zetasizer Nano-ZS from Malvern Instruments. The 
samples were dispersed in deionized water or PBS by ultra-sonication before analysis. 
3.2.5 Nitrogen sorption 
Nitrogen sorption isotherms of the samples were obtained at -196 °C using a Micrometrics Tristar II 
system. Before the measurements, the samples were degassed at 180 °C overnight in vacuum. The 
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Brunauer–Emmett–Teller specific surface area (SBET) was calculated using experimental points at a 
relative pressure of P/P0 = 0.05-0.25.  
3.2.6 Attenuated total reflectance-Fourier transform infrared spectroscopy 
Attenuated total reflectance (ATR)-Fourier transform infrared (FTIR) spectroscopy was utilized to 
trace functional group modifications of different SiNPs. The powder of samples was simply added 
onto the crystal to obtain optimal contact. The surface functional groups, for example, methyl 
groups, were investigated by ATR-FTIR. ATR-FTIR spectra were collected using the Thermo 
S   nt    ™ N  ol t™ 6700 FT-IR spectrometers. Each spectrum was obtained using dried powder 
against a background measured under the same condition. For each spectrum, 128 scans were 
collected at a resolution of 4 cm
-1
 over the range 400–4000 cm-1. 
3.2.7 Elemental analysis  
Elemental analysis (EA) was carried out on a CHNS-O Analyzer (Flash EA1112 Series, Thermo 
Electron Corporation) to determine the percentages of carbon (C), according to the dynamic flash 
combustion (modified Dumas method). The samples of octadecyl-group modified rough silica 
nanoparticles with 10-20 milligrams were tested. Cysteine with 29.99% the element of carbon was 
used as the standard control. 
When the sample enters the reactor, inserted in the special furnace heated at 950°C, a small volume 
of pure Oxygen (250mL/min) is added to the system and helps to burn the material, converting the 
sample into elemental (simple) gases. A separation column and TCD detector allows to determine 
element concentrations without using a complex splitting system, aliquot dosing device or purge & 
trap absorbers. 
3.2.8 Atomic force microscopy measurements  
 
Figure 3.3 An atomic force microscope probes a molecule adsorption onto a surface, using a carbon 
monoxide molecule at the tip for sensitivity.
6
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Atomic force microscope (AFM) is one kind of scanning probe microscopes (SPM). SPMs are 
designed to measure local properties, such as height, friction, magnetism, with a probe. To acquire 
an image, the SPM raster-scans the probe over a small area of the sample, measuring the local 
property simultaneously (Figure 3.3).
6
 
In the thesis, the surface morphology changes of rough silica nanoparticles before and after 
incubating with the protein of IgG-F were investigated. IgG-F was mixed with RSN-211@54 (500 
µg) in PBS pH 7.4 for 2 h at 4 °C, at a protein concentration of 1 mg mL
-1
. After incubation, the 
samples were washed with DI water to remove free and loosely attached proteins and salts in 
solution by centrifugation and pipetting. Then, the suspension (10 µL) was placed onto silicon 
wafers. The wafer was evaporated at 25 °C before AFM observation. RSN-211@54 without protein 
incubation was used as a control. A Cypher S AFM (Asylum Research, an Oxford Instruments 
company) was used for all the measurements. The images were obtained by employing the tapping 
mode of the AFM in air by using Al-coated silicon probe with tip radius of 2 nm 
(NANOSENSORS™, Sw tz rl nd). 
3.2.9 Inductively coupled plasma optical emission spectroscopy  
Inductively coupled plasma optical emission spectroscopy (ICPOES) is a trace-level, elemental 
analysis technique that uses the emission spectra of a sample to identify, and quantify the elements 
present. Samples are introduced into the plasma in a process that desolvates, ionises, and excites 
them. The constituent elements can be identified by their characteristic emission lines, and 
quantified by the intensity of the same lines.
7
 In this thesis, ICPOES was applied to quantitatively 
compare cellular uptake between smooth nanoparticle and VMSNs by testing silicon concentration. 
At first, 2×10
5
 cells (including HeLa, KHOS, MCF-7 or SCC-25 cells) were seeded in 6-well plates 
on  d y    or  tr ns   t on. N nop rt  l s (50 μ /mL) alone or nanoparticle-cargo complexes were 
incubated with cells under serum free condition for 4 hours. Afterwards, the cells were washed with 
PBS three times and harvested with trypsin. After centrifugation, the cell pellets were washed twice 
and dried. Cell lysis buffer was added to allow dissolution of the cells with ultrasound. The 
supernatants (containing cell components) were removed by centrifugation at 13,000 rpm for 5 
minutes, followed by two washes with PBS. Aqueous NaOH solution (1 M) was then added to 
allow dissolution of the nanoparticles with ultrasound. The silicon concentrations in the final 
solutions were measured by ICPOES using a Vista-PRO instrument (Varian Inc, Australia), which 
were then converted to be silica amount.  
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3.2.10 Surface plasmon resonance measurements  
Surface plasmon resonance (SPR) is a fast and real-time detection technique used to examine the 
interaction between wide ranges of biological targets. Based on detecting small changes in the 
refractive index, SPR is able to specifically monitor the interaction between analytes (e.g., antibody 
or peptide) and the ligand molecules (e.g., peptide), which have been immobilized onto an inert 
surface (e.g., gold surface). "Resonance units" (RU, equal to a critical angle shift of 10
−4
 deg) is 
used to describe binding signals between analytes and ligands (Figure 3.4).
8, 9
 
 
Figure 3.4 Schematic illustration of a SPR system.
9
 
 
The interaction between the domain antibody of IgG-F and complementary antigen was monitored 
utilizing a SPR-based biosensor (Biacore
TM
 T200, GE Healthcare). IgG-F was incubated with one 
of VMSNs (500 µg) in PBS pH 7.4 for 2 h at 4 °C, and the final protein concentration was 0.5 mg 
mL
-1
. Following that, IgG-F-RSNs complexes were washed several times until the supernatant 
showed the same UV-vis absorbance at 280 nm as PBS only. Then, IgG-F-RSNs complexes were 
suspended in HBS-EP buffer (Biacore
TM
 T200, GE Healthcare). Biotinylated peptide was 
immobilized via streptavidin capture on a sensor chip CAP (GE Healthcare) pre-immobilized with 
ssDNA-streptavidin (Biotin CAPture kit, GE Healthcare) to yield the peptide surface densities in 
the range of 2500-5000 R.U. A reference flow cell was generated by omitting only ssDNA-
streptavidin onto the chip surface. Interaction analyses were performed by injecting IgG-F-RSNs 
complexes over the reference and peptide surfaces in series for 120 seconds at a flow-r t  o  10μl 
min
-1
. Complex dissociation was monitored for 120 seconds. The binding intensity was determined 
at the peak point 128 seconds after sample injection. Surface regeneration was performed at the end 
of each analysis cycle by injecting guanidine (8 M) mixed with NaOH (1 M) at the ratio of 3:1, 
followed by washing with the mixture of acetonitrile (30%), NaOH (0.25 M) and SDS (0.05%). 
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3.2.11 Thermogravimetric analysis 
Thermogravimetric analysis (TGA) is used to monitor the thermal decomposition of epoxy-group 
and PEI attachment in air. Around 10-15 mg of epoxy-group/PEI-modifed nanoparticles was loaded 
in an aluminum pan and heated from 25 to 900°C at a heating rate of 2 °C min
-1
 at an air flow of 20 
mL min
-1
. TGA was conducted using a TGA/DSC 1 Thermogravimetric Analyzer (Mettler-Toledo 
Inc).   
3.2.12 X-ray photoelectron spectroscopy 
X-ray photoelectron spectroscopy (XPS) was used to characterize the amount of Carbon (C), 
Nitrogen (N), Oxygen (O) and Silicon (Si) on the external surface of smooth and rough silica 
n nop rt  l s. XPS w s r  ord d on   Kr tos Ax s Ultr  w t    mono  rom t   Al Kα X-ray 
source. Each spectrum was recorded at a survey scan from 0 to 1200 eV with a dwell time of 100 
ms, and pass energy of 160 eV at steps of 1 eV with 1 sweep. C1s with a binding energy of 285 eV 
was used.
10
 
3.3 Biological techniques  
3.3.1 Agarose gel electrophoresis 
In the field of nanomedicine, an electrophoretic mobility shift assay (EMSA) is electrophoretic 
separation of a nanoparticle–DNA or nanoparticle–RNA mixture on an agarose gel for a short 
period. It is also referred as mobility shift electrophoresis, a gel shift assay, gel mobility shift assay, 
band shift assay, or gel retardation assay, and is a common affinity electrophoresis technique used 
to study nanoparticle–DNA or nanoparticle–RNA interactions. This procedure can determine if a 
nanoparticle is capable of binding to a given DNA or RNA sequence. The speed at which different 
molecules move through the gel is determined by their size and charge, and to a lesser extent, their 
shape (see gel electrophoresis). The control lane (DNA probe without nanoparticle present) will 
contain a single band corresponding to the unbound DNA or RNA fragment. Under the correct 
experimental conditions, the interaction between the DNA (or RNA) and nanoparticle is stabilized 
and the ratio of bound to unbound nucleic acid on the gel reflects the fraction of free and bound 
probe molecules as the binding reaction enters the gel. By comparison with a set of standard 
dilutions of free probe run on the same gel, the number of moles of protein can be calculated.
11
 
In this thesis, gel electrophoresis analysis was performed to examine the holding ability of VMSNs 
to genetic molecules. For Cy3-oligoDNA, t     omol  ul  (25 pmol, 100 μM) w s m x d w t  
amino-mod    d smoot  n nop rt  l s or VMSNs (50 μ ). M  nw  l , PLK1-siRNA (100, 50 and 
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25 pmol) were coupled with PEI-mod    d smoot  n nop rt  l s or VMSNs (50 μ ), r sp  t v ly. 
For control, Cy3-oligoDNA (25 pmol of) or PLK1-siRNA (25 pmol) was prepared in the absence of 
nano-carriers. Four hours later, the complexes were loaded into each well of a 2% agarose gel, 
which was then run in Tris-acetate-EDTA  buffer containing SYBR® Safe DNA gel Stain at 80 V 
for 40 min. Genetic molecule bands were visualized using a GelDoc UV illuminator. For 
comparison, software of ImageJ was used to calculate the pixel values of each genetic molecule 
band in a fixed area. Genetic molecule amount was estimated after comparing with control group.  
3.3.2 Confocal laser scanning microscopy 
Confocal laser scanning microscopy (CLSM) is a technique for obtaining high-resolution optical 
images with depth selectivity. The key feature of confocal microscopy is its ability to acquire in-
focus images from selected depths, a process known as optical sectioning. Images are acquired 
point-by-point and reconstructed with a computer, allowing three-dimensional reconstructions of 
topologically complex objects.
12
  
In this thesis, high quality fluorescent images were acquired by CLSM. After seeding 1×10
5
 HeLa 
cells onto 24-mm glass coverslips in 6 well-plates, Cy3-oligoDNA-treated (100 nM) and the 
complexes of amino-mod    d smoot  n nop rt  l s  nd VMSNs (50 μ /mL) +Cy3- oligoDNA 
(100 nM)-treated cells were washed with PBS. DNase I solution was added to digest the Cy3-
oligoDNA outside the cells. Cells were washed twice with PBS then incubated at 25°C with 
tr  tm nt solut on (500 μl), w      ont  ns 1 mM C Cl2, 0.5 mM MgCl2, 0.1% (w/v) Bovine serum 
albumin (BSA, Sigma) and 20 Units of DNase I (Sigma) in PBS. After 30 minutes, the cells were 
washed 3 times with PBS and fixed with PFA/PBS (1 mL, 4%) at 4°C for 30 minutes. The liquid 
was removed and cells were pre-incubated with PBS containing 1% BSA for 20–30 minutes prior to 
 dd n  t   st  n n  solut on. T  n, st  n n  solut on (200 μl)  ont  n n  1% (w/v) BSA  nd Hum n 
CD24 FITC Conju  t  (5 μl)  n PBS w s  dd d  or 2  ours  t 25°C. A t r t  t, t    ov rsl ps w r  
washed three times with PBS and mounted onto glass slides by fluoroshield with DAPI (Sigma). 
The slides were viewed using confocal microscopy (LSM ZEISS 710).  
3.3.3 MTT assay  
The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) cell proliferation assay 
measures cell proliferation rate and conversely, when metabolic events lead to apoptosis or 
necrosis, reduction in cell viability. The yellow tetrazolium MTT is reduced by metabolically active 
cells, in part by the action of dehydrogenase enzymes, to generate reducing equivalents such as 
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NADH and NADPH. The resulting intracellular purple formazan can be solubilized and quantified 
by spectrophotometric means.
13
  
The cell growth inhibition by delivering therapeutic proteins or siRNAs using VMSNs as 
nanocarriers was tested in multiple cell lines, including HeLa, KHOS, MCF-7 and SCC-25 cell 
lines. One day before the test, 3000-5000 cells were seeded in each well of 96-well plates. The 
complexes of therapeutic drug-nanoparticles were dispersed in culture medium supplemented with 
10% FBS and 1% penicillin-streptomycin and added into each well. After the incubation at 37 °C 
for 24 to 72 hours, cell viability was measured by adding MTT agent and reading the absorbance at 
540 nm using a Synergy HT Microplate Reader. Results were compared to cells not exposed to 
nanoparticles.  
3.3.4 Flow cytometry  
Flow cytometry is a laser-based, biophysical technology employed in cell counting, cell sorting, 
biomarker detection and protein engineering, by suspending cells in a stream of fluid and passing 
them by an electronic detection apparatus. It allows simultaneous multi-parametric analysis of the 
physical and chemical characteristics of up to thousands of particles per second.
14
 
In this thesis, HeLa cells were seeded in 6 well-plates at 2×10
5
 cells per well one day before the 
assay. Cy3-oligoDNA was used as a model for siRNA, and it was pre-mixed with amino-modified 
smooth nanoparticles and VMSNs for 4 hours, followed by incubation with cells for another 4 
hours, and the con  ntr t on o  n nop rt  l s  s 50 μ /mL and Cy3-oligoDNA is 100 nM. To 
discriminate between cell-association and actual internalization, extracellular Cy3-oligoDNA was 
degraded by addition of a high concentration DNase I solution. For this treatment, the cells were 
w s  d tw    w t  PBS t  n  n u  t d  t 25°C w t  tr  tm nt solut on (500 μl), w      ont  ns 1 
mM CaCl2, 0.5 mM MgCl2, 0.1% (w/v) Bovine serum albumin (BSA, Sigma) and 20 Units of 
DNase I (Sigma) in PBS. After 30 minutes, the cells were washed 3 times with PBS and harvested 
by trypsination. After two more washes with PBS, the cells were re-suspended in paraformaldehyde 
(M r k)  n PBS (PFA/PBS, 600 μl, 2%)  or FACS t st us n  BD LSR-II Analyzer (USA). The 
results were analysed using FlowJo software.  
3.3.5 Western-blot analysis  
The western blotting (sometimes called the protein immunoblot) is a widely used analytical 
technique used to detect specific proteins in a sample of tissue homogenate or extract. It uses gel 
electrophoresis to separate native proteins by 3-D structure or denatured proteins by the length of 
the polypeptide. The proteins are then transferred to a membrane (typically nitrocellulose or 
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PVDF), where they are stained with antibodies specific to the target protein. The gel electrophoresis 
step is included in western blotting analysis to resolve the issue of the cross-reactivity of 
antibodies.
15
 
In this thesis, western blotting was used to define the degradation of pro-apoptotic protein of Bcl-2. 
MCF-7 cells were seeded in 6-well plates at a seeding density of 3×10
5
 cells per well. The anti-
pAkt antibody and the non-specific IgG antibody were incubated with hydrophobically modified 
VMSNs in PBS pH 7.4 at 4 °C for 2 h. Then, protein-nanoparticle complexes, along with 
nanoparticle only group were mixed with serum containing culture medium and incubated with 
  lls  or 24  . T     n l  on  ntr t on o  n nop rt  l s  s 50 μ  mL-1 and protein is 1 µg mL-1. At 
the end of incubation, cells were washed with PBS and lysed. The solutions containing cell lysates 
were heated at 95 °C for 15 min followed by characterization by SDS-PAGE. The protein bands 
were transferred to a PVDF membrane. Targeting protein of Bcl-2 was targeted using Bcl-2 
monoclonal antibody mAb as the primary antibody, and HRP-linked anti-rabbit IgG antibody as the 
secondary antibody. GAPDH mAb was used as an internal reference. Bands were visualized on a 
ChemiDoc MP System (Bio-Rad). 
3.3.6 TEM study on nanoparticle-cell interaction 
MCF-7 cells were seeded in 3-cm petri-dishes at a cell number of 3×10
5
 for 24 h. Cells were then 
incubated with a suspension of nanoparticle (SSN, RSN, C18-SSN and C18-RSN) for 24 hours. 
Cells were washed with PBS buffer three times and then fixed with 2.5% glutaraldehyde at 25°C for 
30min, before they were postfixed in 1% osmium tetraoxide in microwave condition. After that, the 
cells were washed with PBS and embedded into 2% agarose gel cube. The cell cubes were 
dehydrated in acetone of increasing concentration (50%, 70%, 90%, 100% and 100%) in a 
sequential manner in microwave condition. Then, dehydrated cell cubes were embedded in epon 
resin, and solidified in 60°C for 2 days. Microtome (Leica, EM UC6) was then used to cut the 
embedded cell-resin cube into thin slices (70–90 nm in thickness). The samples were collected on 
copper grids and double stained with the aqueous solution of uranyl acetate (2%) and commercially 
available aqueous solutions of lead citrate. The ultra-thin slides were transferred to a form-bar 
coated copper grid. TEM images were taken using a JEOL 1010 microscope operated at 80 kV. 
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This chapter reports the synthesis of novel non-viral nanoparticles mimicking virus surface 
topography by attaching small shell particles (~10nm) onto the core particle with a large size 
(~200nm). We show that increases in nanoscale surface roughness improve both binding of 
biomolecules (e.g., protein or genetic molecules) and cellular uptake; thus, the cargo delivery 
efficiency is significantly increased, compared to conventional silica nanoparticles with a smooth 
surface. We further demonstrate that the contribution of surface roughness is general, regardless of 
surface functionality and cell types. Finally, gene delivery efficiency was tested, and the biomimetic 
nanoparticles showed a better performance than a commercial transfection reagent. This work has 
been published and highlighted as frontispiece paper in Advanced Materials (2013, 
Communication). 
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4.1 Introduction  
Delivery of various drug molecules into cells is crucial in modern medicine.
1, 2
 Most naked 
biomolecules and some free drugs are poorly delivered to cells owing to poor stability, low 
solubility and/or unwanted toxicity. For these reasons, various natural and synthetic vectors have 
been used as cellular delivery vehicles. Compared to viral vectors having a high delivery 
efficiency,
3, 4
 non-viral vectors such as nanoparticles are safer delivery tools,
5
 but their cellular 
delivery efficiency is far from satisfactory.
6
 It remains an ongoing challenge to develop non-viral 
carrier systems having both good safety and high delivery efficiency.  
Understanding structure-function relationship in natural systems, such as enveloped viruses, 
provides useful guides for the design of new nano-carriers. Enveloped viruses have sizes around 30-
400 nm, which appears to be ideal for cellular uptake.
7
 Their high infectivity is mainly attributed to 
receptor-specific interactions, facilitating subsequent viral fusion or cellular uptake.
3, 8
 This concept 
has been used in the design of nano-carriers.
9, 10
 Recent developments in state-of-the-art electron 
tomo r p y (ET)   v  prov d d “n no-  olo y”  n orm t on  or m ny  nv lop d v rus s,  or 
example, influenza virus,
8
 HSV
11
 and HIV,
12
 all showing rough surfaces patched by glycoprotein 
spikes. However, the influence of nanoscale surface roughness on cellular delivery efficiency 
remains unclear because it is always associated with receptor-ligand specific interactions in viral 
systems. 
Synthetic nanoparticles mimicking the surface topography of enveloped viruses may provide useful 
tools to study the roles of surface roughness while excluding the influence of receptor-specific 
interaction. Cellular delivery efficiency of nano-vectors is dependent on both the binding capability 
to cargo molecules and subsequent cellular uptake. It was reported that the saturation uptake of 
biomolecules on roughened films increased by up to 70%, higher than the increase of surface area 
(20%).
13
 The enhanced adsorption is attributed to a change in geometrical arrangement and 
accumulation of biomolecules in a multi-layered manner on the rough surface.
13, 14
 Unfortunately, 
the impact of surface roughness on biomolecule binding has not been reported for nano-vectors. 
Moreover, there exist a small number of literature reports investigating the roles of surface 
roughness of polymer nanoparticles in cellular uptake of nanoparticles themselves,
15
 however, the 
contribution from surface roughness fluctuated and may have been interfered by inconsistent 
material compositions. A study the impacts of surface roughness of nano-vectors on both binding 
ability to cargo molecules and cellular uptake performance has not been reported to our knowledge. 
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Figure 4.1 Illustration of (a) the synthesis procedure and (b) the comparison of cellular delivery 
performance between two nano-carriers. a) Sample 1 represents silica nanoparticles, which can be 
further modified with positively charged amine groups. Sample 2 comprises the negatively charged 
silica nanoparticles with small diameters. Sample 3 was prepared by using amino-modified 1 as the 
core and 2 as the shell particles after calcination, which is modified with amine groups. b) 
Compared to smooth nano-carriers, rough ones exhibit both higher binding for biomolecules (e.g. 
proteins and genetic molecules) and increased cellular uptake efficiency, independent of surface 
functionality. 
Herein we report the synthesis of novel non-viral nanoparticles mimicking virus surface topography 
(Figure 4.1a). We show that increase in nanoscale surface roughness promotes both binding of 
biomolecules (e.g. protein or genetic molecules) and cellular uptake, so thst the cargo delivery 
efficiency is significantly increased (Figure 4.1b). We further demonstrate that the contribution of 
surface roughness is general, hardly dependent on the surface functionality of the silica 
nanoparticles and the types of cells used in this work. Finally, gene delivery efficiency was tested, 
where the biomimetic nanoparticles showed a better performance than a commercial product. 
4.2 Results and discussion 
Silica-based nanoparticles were chosen in our study due to their high biocompatibility 
16
 and ease of 
functionalization.
17
 The synthesis procedure is illustrated in Figure 4.1a. The solid silica 
nanoparticle (Sample 1) was prepared by the Stöber method
18
 (see Supplementary Information, 
Materials and Methods). The solid nature of these nanoparticles is important in avoiding any 
influences of internal porosity on adsorption behavior, making them ideal for studying the influence 
of outer surface roughness. Transmission electron microscopy (TEM) images showed that 1 had a 
uniform diameter of 209±20 nm (Figure 4.S1a). After surface modification of negatively charged 1 
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(ζ pot nt  l o  -24 mV) by amine groups, 1-NH2 was obtained with a similar size (211±19 nm, 
Figure 4.S1b) but a positively charged surface (+51 mV). By using a modified Stöber method to 
prepare silica nanoparticles,
19
 2 w s o t  n d w t    ζ pot nt  l o  -42 mV and a small diameter of 
~13 nm (Figure 4.S1d). The association between 1-NH2 as the core and 2 as the shell particle gave 
rise to sample 3 after calcination, which was negatively charged (-36 mV) and showed a rough 
surface (Figure 4.S1e).  
 
Figure 4.2 Surface characteristics of 3. a, b) SEM images show the virus-mimicking rough surface. 
c) A zero-tilt TEM projection from a tilt series. d) Reconstructed surface rendering of a single 
particle. The core particle is shown in blue and the shell spikes in yellow. Scale bar: 100 nm. 
Scanning electron microscopy (SEM) images (Figure 4.2a & b) clearly showed that the core 
particles (~200 nm) of 3 were studded with shell particles (~10 nm). This surface topography is 
similar to that of the envelope-spike structure in some viruses, such as HSV.
11
 3 was also modified 
with amine groups to produce 3-NH2 (224 ±16 nm) with a rough (Figure 4.S1f) and positively 
charged surface (+54 mV). Moreover, 1 and 3 were conjugated with polyethylenimine (PEI) with 
little change in surface topography (1-PEI: Figure 4.S1c, 220±13 nm, +47mV; 3-PEI: Figure 4.S1g, 
226±16 nm, +43mV). The size distribution of all samples measured using the dynamic light 
scattering (DLS) method is shown in Figure 4.S1h, indicating that all the samples are monodisperse 
(see Table 4.S1 and 4.S2 for the polydispersity index, PDI). The surface area of 1 and 3 was 
measured to be 19 and 24 m
2
/g, respectively (Figure 4.S2). It is noted that 1 and 3 (similarly, 1-NH2 
and 3-NH2, 1-PEI and 3-PEI) possess similar sizes, surface charges and chemical compositions, 
except their surface topographies. 
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Precision information of the nanoscale surface roughness is important in understanding the impact 
o  “n no-  olo y”.11 Conventional electron microscopy techniques cannot readily be used to 
quantitatively determine the surface coverage of shell particles. Therefore, an ET technique was 
applied using developed protocols.
20
 Tilt series were recorded on a 300 kV microscope from virus-
mimicking nanoparticles (3); a bright field TEM image at zero-tilt is shown in Figure 4.2c. The core 
diameter was measured to be 168 nm, and the shell particles protruding from the core surface were 
clearly visible. The tomographic reconstructed structure of the rough nanoparticle is shown in 
Figure 4.2d, reconstructed from 1151 tomogram slices (each 0.15 nm in thickness). 
Useful and quantitative information can be obtained from the ET data. By following consecutive ET 
slices, a total number of ~320 spikes were found. The size of spikes lay in a broad range of 3.2 to 
10.6 nm with an average diameter of 6.4 nm, which we attribute to the calcination treatment in the 
preparation of 3. The packing density of the shell particles was variable. The centre-to-centre 
distance varies from ~10 to ~40 nm. The structure shown in Figure 4.2d is comparable to the 
surface features of some enveloped viruses, such as HSV with a spherical shape (~ 225 nm in 
diameter) and 600-750 spikes (~10 nm) in one virion.
11
 Using the information from ET, the weight 
ratio of shell to core particles was estimated to be ~1.8% (see SI). This information will be used in 
the evaluation of cellular delivery performance. 
The comparison of cellular delivery performance between smooth and rough nano-carriers was first 
tested using 1-NH2 and 3-NH2. The cyanine dye (Cy3)-labeled oligoDNA (Cy3-oligoDNA) was 
used as a model biomolecule. After coupling 1-NH2 and 3-NH2 (50 µg/mL) with negatively charged 
Cy3-oligoDNA (100 nM), the complexes were incubated with HeLa cells for 4 h. Confocal 
microscopy showed very weak Cy3 signals (red color) in the sample using 1-NH2 (Figure 4.3a). In 
contrast, strong Cy3 signals (Figure 4.3b) localized within the cell borders (green color) were 
observed using 3-NH2 as the vector. In addition, no Cy3 signals were observed when the same 
amount of Cy3-oligoDNA alone was incubated with cells (Figure 4.S3), indicating the inability of 
genetic molecules themselves to penetrate into cells. Fluorescein-activated cell sorting (FACS) 
analysis was used to quantitatively evaluate the delivery efficiency of Cy3-oligoDNA (Figure 4.S4). 
By comparing the median fluorescence intensity (MFI; Figure 4.3c), it was shown that 3-NH2 
delivered ~5.6 times Cy3-OligoDNA into cells compared to 1-NH2, indicating a higher cargo 
delivery efficacy of the nano-carrier with a rough surface. 
In order to exclude the possibility that the improved cellular delivery performance is attributed to 
the unexpected detachment of shell particles, fluorescence microscopy was used. Similar to the 
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results from confocal microscopy, very weak signals were observed in the groups of naked Cy3-
oligoDNA (Figure 4.S5a-c), Cy3-oligoDNA coupled with 2-NH2 (0.9 µg/mL, dosage calculated 
from ET results, Figure 4.S5d-f) and 1-NH2 (Figure 4.S5g-i). Only 3-NH2 induced evident Cy3 
signals across all groups (Figure 4.S5j-l). These results further confirmed the enhanced delivery is 
attributed to the surface roughness. 
 
Figure 4.3 Virus-mimicking nanoparticles enhance cellular delivery performance in HeLa cells. a, 
b) Confocal microscopy images of Cy3-oligoDNA (red color) delivery by (left) 1-NH2 & (right) 3-
NH2. The nuclei are stained in blue (DAPI) and the cell membranes in green (FITC). Scale bar: 20 
μm.  ) FACS  n lys s o  Cy3-oligoDNA delivery, showing higher increase of Cy3-signals in MFI 
using 3-NH2 than 1-NH2.  d) Identification of Cy3-oligoDNA binding for 1-NH2 & 3-NH2. e) 
Investigation of biomolecule holding ability by gel retardation assay. f) Comparison of cellular 
uptake efficiency of the complexes (1-NH2/3-NH2+Cy3-oligoDNA) measured by ICPOES. For bar 
charts, data represent mean ± s.e.m.**p<0.01,***p<0.001, ****p<0.0001 (t-test). 
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To understand why surface roughness improved cellular delivery of biomolecules, we separately 
investigated the impact of surface roughness on either binding towards cargo molecules or cellular 
uptake. Figure 4.3d shows that 3-NH2 absorbed ~85% more Cy3-oligoDNA (1.29 nmol/mg) than 1-
NH2 (0.69 nmol/mg). Moreover, agarose gel electrophoresis was used to evaluate the cargo holding 
ability of nano-carriers to mimic the release behaviour. 25 pmol of Cy3-oligoDNA was mixed with 
50 µg of nanoparticles, a feed ratio (0.5 nmol/mg) lower than the saturation adsorption amount of 
both 1-NH2 and 3-NH2. As shown from Figure 4.S6a, in the absence of nano-carriers (Lane 0), all 
naked Cy3-oligoDNA migrated to the positive electrode. In the case of 1-NH2, a small amount of 
released Cy3-oligoDNA was observed (Lane 1). For 3-NH2, nearly no release could be seen by 
naked eyes (Lane 2). After quantitative analysis (ImageJ, see SI), the released amount of Cy3-
oligoDNA was calculated to be 15.1 and 3.9 pmol for 1-NH2 and 3-NH2, respectively (Figure 4.3e). 
To quantitatively study the cellular uptake performance, cells were collected after incubating with 
the complexes of 1-NH2 /3-NH2 + Cy3-oligoDNA. Because small oxide suspensions rapidly 
agglomerate in biological fluids, and this will influence the transport of nanoparticles to cells in a 
time dependent manner,
21, 22
 we fixed the cell incubation time to be 4 h in all experiments. The mass 
of silica internalized per cell was measured using inductively coupled plasma optical emission 
spectrometry (ICPOES). As shown in Figure 4.3f, 290 pg/cell was detected for 3-NH2 while 178 
pg/cell for 1-NH2 (63% increase). Our results have demonstrated that the nanoscale surface 
roughness improves both binding towards biomolecules (enhancing adsorption and reducing release 
of bound biomolecules simultaneously) and cellular uptake, all aspects contributing to the highly 
increased cellular delivery performance. 
In addition to 1-NH2 and 3-NH2, pure silica nano-carriers 1 & 3 with negatively charged surfaces 
were also investigated. Using a positively charged protein, Cytochrome C (pI= 9.8
23
), as the model 
molecule, its adsorption amount is 2.71 nmol/mg on 3, nearly 2 times higher than that on 1 (0.88 
nmol/mg, Figure 4.S7a). In addition, compared to 1, cellular uptake of 3 increased by 108% in 
KHOS cells (an osteosarcoma cell line, Figure 4.S7b) and 29.4% (Figure 4.S7c) in HeLa cells. 
Dose-dependent cytotoxicity of nano-carriers (1 and 3, 1-NH2 and 3-NH2) was investigated for 
further cellular delivery tests by a standard MTT assay in HeLa and KHOS cells. As shown in 
Figure 4.S8a-d, generally the cell viability decreases with increasing dose. It is important to notice 
that at each dose, the rough particles caused higher toxicity than the smooth ones, independent of 
the surface charge or cell types. For example, the cell viability was 91% for KHOS and 93% for 
HeLa after incubating with 1 at the dose of 50 µg/mL, but to 82% and 88% after incubation with 3. 
The cytotoxicity of 1-PEI and 3-PEI was also tested in KHOS cells for cellular delivery application, 
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which is higher compared to that of pure and amino-functionalized particles (Figure 4.S8e). 
Similarly, 3-PEI was more toxic compared to 1-PEI at all doses. The higher toxicity of rough 
particles compared to smooth ones is consistent with the higher cellular uptake induced by the 
surface roughness. The above results have shown that the impacts of surface roughness are general 
and independent of surface charge, cargos or cell types. 
 
Figure 4.4 Gene delivery performance of virus-mimicking nanoparticles in KHOS cells. a) The 
inhibition of cell viability by PLK1-siRNA transfection. S10-siRNA was used as a negative control. 
Both 1-PEI and 3-PEI were used as vectors, and a commercial reagent, Oligofectamine
TM
, was also 
applied as a further control. b) PLK1-siRNA adsorption ability of 1-PEI and 3-PEI. c) Comparison 
of cellular uptake efficiency of the complexes (1-PEI/3-PEI+PLK1-siRNA) measured by ICPOES. 
Data represent mean ± s.e.m.*P<0.05, ***p<0.001 (t-test) 
To demonstrate the potential of nanoparticles mimicking virus surface as effective cellular delivery 
vehicles, a functional siRNA against polo-like kinase 1 (PLK1) was delivered into KHOS cells. 
PLK1 gene is highly expressed in cancer cell lines, such as KHOS (osteosarcoma),
16, 22
 MCF-7 
(breast cancer)
24
 and HeLa (cervical cancer).
25
  Silencing PLK1 gene with siRNAs can decrease 
PLK1-mRNA and PLK1-protein levels, thus will inhibit cell viability. Due to the inability of 
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amino-modification to achieve endosomal escape (see Figure 4.S9), both smooth and rough 
nanoparticles were modified with PEI to induce proton sponge effect to trigger cargo release.
2, 16, 17
 
The characterizations for PEI-modification were shown in Table 4.S2, 4.S3 and Figure 4.S10. An 
ineffective siRNA, S10, was chosen as a negative control. 
In Figure 4.4a, the negative group using S10-siRNA and the sample using only naked PLK1-siRNA 
did not impact cell viability. In contrast, the cell viability was significantly decreased in the groups 
using nano-carriers to deliver PLK1-siRNA in a dose-dependent manner (12.5, 25, 50 nM). This 
observation is in accordance with literature reports.
24
 Importantly, 3-PEI promoted stronger 
inhibition effects (29%, 43%, 61%) than 1-PEI (21%, 25%, 40%), and the differences were 
statistically significant at PLK1-siRNA concentrations of 25 and 50 nM. Notably, the reduction in 
cell viability using 3-PEI (61%) was higher compared to that using a commercial non-viral vector, 
Oligofectamine
TM
 (50%). 
To study the effect of the surface roughness on enhanced gene delivery efficiency, it was measured 
that 3-PEI fixed 1.41 nmol/mg PLK1-siRNA while 1-PEI fixed 0.82 nmol/mg (Figure 4.4b). 
Moreover, gel electrophoresis results showed that the rough surface of 3-PEI has stronger binding 
ability compared to 1-PEI (Figure 4.S6b & c). In addition, the internalized amount was 186 pg/cell 
for 3-PEI and 121 pg/cell for 1-PEI (Figure 4.4c). Our results have further confirmed that the 
nanoscale surface roughness improves binding towards biomolecules and cellular uptake, leading to 
the enhanced gene delivery efficiency. 
We have systematically studied the synthesis parameters to obtain and adjust the virus-mimicking 
morphology. When the feed volume of sample 2 solution was varied from 0.68 mL (Figure 4.S11a) 
to 1.35 mL (Figure 4.S11b), the surface coverage of shell particles was lower compared to sample 3 
obtained at a volume of 2.7 mL (Figure 4.S1e). When the feed volume was further increased to 5.4 
mL (Figure 4.S11c) and finally to 6.75 mL (Figure 4.S11d), excess unbound shell particles were 
observed in addition to the desired morphology. The calcination treatment in the preparation of 3 is 
also an important step. TEM images (Figure 4.S12) showed that without calcination, the shell 
particles were easily peeled off after ultra-sonication, which is a common treatment in sample 
preparation. 
4.3 Conclusion 
In summary, nanoparticles mimicking virus surface topography have been successfully synthesized. 
It is demonstrated that nanoscale surface roughness enhances both binding towards biomolecules 
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(more binding and less release) and cellular uptake efficacy, thus the cellular delivery performance 
can be improved. This understanding is important in the rational design of new cellular delivery 
vectors. By combining both the nanoscale surface roughness and receptor-specific binding moieties, 
or by introducing rough surfaces or core particles having other compositions and structures, a 
platform of synthetic vectors with high cellular delivery performance is on the horizon. 
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Supplementary Information 
Material and Methods 
4.S1. Synthesis of Samples 
 
Sample 1. Uniform nonporous silica nanoparticles with a smooth surface were synthesized using a 
well-known method developed by Stöber et al.
18
 Typically, 50 mL of ethanol was mixed with 3.8 
mL of deionized water and 2 mL of 28% ammonium hydroxide solution (Sigma-Aldrich) at 308 K. 
Then, 2.8 mL of 98% tetraethyl orthosilicate (TEOS, Aldrich) was added to the solution under 
vigorous stirring. After 6 hours, the as-synthesized nanoparticles were separated by centrifugation, 
and washed with ethanol and deionized water. The final product 1 was obtained by drying at 373 K 
overnight.  
Sample 1-NH2. Amine silane was grafted onto the surface of 1 to create positively charged smooth 
silica nanoparticles. First, 0.2 g of sample 1 was suspended in 30 mL toluene. Then, 0.19 mL of (0.8 
mmol) of 3-aminopropyltriethoxysilane (APTES, Sigma-Aldrich) was added. The mixture was 
refluxed for 20 hours at 383 K.
10
 Then, 1-NH2 was obtained by centrifugation, washing with ethanol 
and deionized water and drying in a vacuum oven at 313 K overnight. 
Sample 2. Silica nanoparticles with a small diameter were prepared using a modified Stöber 
method.
19
 First, 87 mg of L-arginine (Sigma-Aldrich) was dissolved in a solution containing 69.5 
mL of deionized water and 5.23 mL of 98% octane (Sigma-Aldrich) with stirring overnight at 333 
K. Then, 0.5 mL of TEOS was added to the mixture and stirred for a further 5 hours. The solution 
containing as-synthesized 3 was used immediately in the synthesis of sample 3 (see below). 
Sample 3. As-synthesized 2 (2.7 mL solution) was mixed with 50 mg of 1-NH2 dispersed in 30 mL 
of deionized water and stirred for 20 hours at 333 K. The as-synthesized 3 was isolated by 
centrifugation at 10000 rpm for 10 min (sample 2 cannot be recovered by centrifugation under these 
conditions), followed by drying in a vacuum oven at 313 K overnight. Finally, 3 was obtained by 
calcination treatment at 823 K for 5 hours. 
Sample 3-NH2. The positively charged 3-NH2 was synthesized by amino-modification of 3, using 
the procedure described in the preparation of 1-NH2. 
Sample 1-PEI & 3-PEI. In order to achieve endosomal escape for successful gene silencing, 10 
kDa polymer of PEI (BioScientific Pty Ltd) was attached to 1 and 3, through a linker of 3-
glycidoxypropyl trimethoxysilane (3-GPS, Sigma-Aldrich).
16
 First, epoxysilane was connected onto 
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the surfaces of sample 1 and 3 by suspending 100 mg of solid in 30 mL of toluene and stirring for 
15 minutes at 343 K. Then, 1.5 mL of 3-GPS was added into the solution, which was further stirred 
for 24 hours at the same temperature. The solid products were centrifuged, washed three times with 
toluene and methanol and dried. Solid products (50 mg) were mixed with 250 mg of 10 kDa PEI in 
100 mL of carbonate buffer (50 mM, pH 9.5) for 24 hours at 298 K. In this step, PEI is attached to 
the nanoparticles via epoxy-groups. The products were washed with 20 mL of 1.0 M NaCl, 
followed by three washes with deionized water, and were then recovered by centrifugation. At the 
final stage, the solid products were re-suspended in 20 mL of 1.0 M ethanolamine (pH 9) and stirred 
at 298 K for 6 hours to block free epoxy groups. The solids were then washed again with 20 mL of 
1.0 M NaCl and 20 mL of deionized water. 
4.S2. Characterizations 
 
TEM images were taken using a JEOL 1010 microscope operated at 100 kV. The TEM specimens 
were dispersed in ethanol, and then transferred to a copper grid. The HRSEM images were obtained 
on a JEOL7800F microscope operated at 1 kV with a through-the-lens system and gentle beam 
technology.
26
 T   HRSEM sp   m ns w r  un o t d  or o s rv t on. DLS  nd ζ pot nt  l 
measurements were carried out at 298 K using a Zetasizer Nano-ZS from Malvern Instruments. The 
samples were dispersed in deionized water by ultrasonication before analysis. ET data was collected 
with a FEI Tecnai F30 transmission electron microscope operating at 300 kV. ET specimens were 
prepared in the same way of the TEM specimens. All TEM images for ET were recorded at a given 
defocus in a bright-field mode to show the thickness contrast. The tomographic tilt series were 
obtained by tilting the specimen inside the microscope around a single axis under the electron beam. 
TEM images were recorded over a tilt range of +57 to -57° at an increment of 1°. Images of the tilt-
series were aligned with respect to a common origin and rotation axis using the fiducially markers. 
Alignment and tomogram generation were performed with IMOD software.
20
 Nitrogen sorption 
isotherms of the samples were obtained at 77 K using a Quantachrome's Quadrasorb SI analyzer. 
Before the measurements, the samples were degassed overnight in vacuo. The BET surface area 
was calculated using experimental points at a relative pressure of P/P
0
 = 0.05-0.25. TGA analysis 
was conducted using a TGA/DSC 1 Thermogravimetric Analyzer (Mettler-Toledo Inc) at a heating 
rate of 2 K/min. X-ray photoelectron spectroscopy (XPS) were recorded on a Kratos Axis Ultra 
w t    mono  rom t   Al Kα X-ray source. Each spectrum was recorded at a survey scan from 0 to 
1200 eV with a dwell time of 100 ms, and pass energy of 160 eV at steps of 1 eV with 1 sweep. C1s 
with a binding energy of 285 eV was used. 
Chapter 4 Nanoparticles Mimicking Viral Surface Topography for Enhanced Cellular Delivery 
70 
 
4.S3. Estimation of shell / core ratio from ET data 
 
The weight ratio of shell to core particles in 5 can be estimated from the ET data by assuming both 
core and shell particles are spheres and that they have the same density. The weight ratio is then the 
same as the volume ratio. To calculate the volumes, the diameters of core and shell particles are 
measured from ET (Figure 4.2d), giving 168 and 6.45 nm, respectively. The number of shell 
particles is measured to 320 from ET. The volume ratio is calculated to be 
(320×4/3×3.14×3.225
3
×10
-21
) / (4/3×3.14×83.7
3
×10
-21
) = 1.83%. 
4.S4. Biological experiments 
 
Cell culture: Cell culture reagents were purchased from GIBCO Invitrogen Corporation/Life 
Technologies Life Sciences unless otherwise specified. Cell lines used including cervical cancer 
cell lines HeLa (ATCC, CCL-2) and osteosarcoma cell line KHOS/NP (CRL-1544) were purchased 
from ATCC (American Type Culture Collection). Cells were maintained as monolayer cultures at 
310 K and 5% CO2 in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin-streptomycin. The final concentration is 100 u/mL for 
penicillin, 100 u/mL for streptomycin. Twenty-one-nucleotide (oligo) DNA conjugated with 
cyanine dye (Cy-3), fetal bovine serum, paraformaldehyde, antifade fluorescent mounting medium 
w t  4’-6-diamidino-2-phenylindole (DAPI) and MTT (3-4,5-dimethylthiazol-2-yl-2,5-
diphenyltetrazolium bromide; thiazolyl blue) were purchased from Sigma-Aldrich. A Cell-Titer-Glo 
cell viability assay kit was from Promega. The sequences of human PLK1-siRNA (Ambion at 
Applied Biosystems, Foster City, California) are PLK1-S: 5’-CCAUUAACGAGCUGCUUAATT-3’ 
and PLK1-AS: 5’-UUAAGCAGCUCGUUAAUGGTT-3’. T   s qu n  s o  synt  t   S10-siRNA 
(Proligo, Lismore, Australia) are as follows: S10-S, 5’-GCAACAGUUACUGCGACGUUU-3’  nd 
S10-AS, 5’-ACGUCGCAGUAACUGUUGCUU- 3’. T   Cy3-oligoDNA has the same sequence as 
S10-siRNA, except the base of U is replaced with T. 
Biomolecule adsorption assay: The adsorption ability of nanoparticles with biomolecules (Cy3-
oligoDNA, PLK1-siRNA and Cytochrome C) was first evaluated. Final results were given as an 
 v r    o  tr pl   t  m  sur m nts. For t    dsorpt on o    n t   mol  ul s, 4 μl o  Cy3-oligoDNA 
(100μM) or PLK1-s RNA PBS solut on (100 μM) w r  m x d w t  50 μ  o  1-NH2/ 3-NH2 or 1-
PEI/ 3-PEI  n 30 μl o  p osp  t   u   r d s l n  (PBS, pH=7.4), r sp  t v ly. In  dd t on, 1 μl o  
Cytochrome C (5 mg/mL), a positively charged protein, was coupled with 50 μ  o  1 or 3 in PBS 
(25 μl). In  ontrol  roup, no n nop rt  l s w r   dd d. T   m xtur s w r  d sp rs d  y vort x n  
for 30 seconds and then incubated at 277 K for 4 hours. After this time, the mixtures were 
Chapter 4 Nanoparticles Mimicking Viral Surface Topography for Enhanced Cellular Delivery 
71 
 
centrifuged at 13000 rpm, and the supernatants were collected for testing. The absorbance of 
genetic molecules was determined using a NANODROP 1000 spectrophotometer (Thermo 
Scientific), while protein adsorption was tested using a Synergy HT Microplate Reader at 409 nm.  
Agarose gel electrophoresis: To examine the holding ability, gel electrophoresis analysis was 
performed. For Cy3-oligoDNA, 25 pmol of it was mixed with 50 µg of 1-NH2 or 3-NH2. 
Meanwhile, 100, 50 and 25 pmol of PLK1-siRNA were coupled with 50 µg of 1-PEI or 3-PEI, 
respectively. For control, 25 pmol of Cy3-oligoDNA or 25 pmol of PLK1-siRNA was prepared in 
the absence of nano-carriers. Four hours later, the complexes were loaded into each well of a 2% 
agarose gel (UltraPure
TM
 Agarose, invitrogen), which was then run in Tris-acetate-EDTA (TAE, 
UltraPure
TM
, invitrogen) buffer containing SYBR
®
 Safe DNA gel Stain (invitrogen) at 80 V for 40 
min. Genetic molecule bands were visualized using a GelDoc UV illuminator (Bio-rad 
Laboratories). For comparison, software of ImageJ was used to calculate the pixel values of each 
genetic molecule band in a fixed area. The genetic molecule amount was estimated after comparing 
with the control group. 
Cellular delivery assay: HeLa cells were seeded in 6 well-plates at 2×10
5
 cells per well one day 
before the assay. Cy3-oligoDNA was used as a model for siRNA, and it was pre-mixed with 1-NH2 
and 3-NH2 for 4 hours, followed by incubation with cells for another 4 hours. The final 
concentration of nanoparticles is 50 µg/mL and Cy3-oligoDNA is 100 nM. To discriminate between 
cell-association and actual internalization, extracellular Cy3-oligoDNA was degraded by addition of 
a high concentration DNase I solution. For this treatment, the cells were washed twice with PBS 
t  n  n u  t d  t 298 K w t  500 μl o  tr  tm nt solut on, w      ont  ns 1 mM C Cl2, 0.5 mM 
MgCl2, 0.1% (w/v) Bovine serum albumin (BSA, Sigma) and 20 Units of DNase I (Sigma) in PBS. 
After 30 minutes, the cells were washed 3 times with PBS and harvested by trypsination. After two 
more washes with PBS, the cells were re-susp nd d  n 600 μl o  2% p r  orm ld  yd   n PBS 
(PFA/PBS) for FACS test using BD LSR-II Analyzer (USA). The results were analysed using 
FlowJo software.  
Microscopy: For fluorescent imaging, HeLa cells were seeded at 1×10
5
 cells per well in 24 well-
plates one day before the assay. Cy3-oligoDNA alone (100 nM) or the complexes of 50 µg/mL 1-
NH2/ 3-NH2+Cy3 (100 nM), or 1.8 μ  o  2-NH2+Cy3 (100 nM) were added to wells containing 
serum free medium, and incubated at 310 K for 4 hours. Afterwards, cells were washed twice with 
PBS and fixed with 1 mL of 4% PFA/PBS at 277 K for 30 minutes. Subsequently, the cells were 
washed again with PBS and t   l qu d w s dr  n d. A 200 μl port on o   nt -fade fluorescent 
mounting medium with DAPI was added to stain the nuclei, and the cells were viewed under an 
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Olympus IX51 fluorescent microscope. High quality fluorescent images were acquired by confocal 
laser scanning microscopy (CLSM). After seeding 1×10
5
 HeLa cells onto 24-mm glass coverslips 
(PST, Australia) in 6 well-plates, Cy3-oligoDNA-treated (100 nM) and the complexes of 50 µg/mL 
1-NH2/ 3-NH2+Cy3 (100 nM)-treated cells were washed with PBS and fixed with 1 mL 4% 
PFA/PBS at 277 K for 30 minutes. The liquid was removed and cells were pre-incubated with PBS 
containing 1% bovine serum albumin (BSA) for 20–30 minutes prior to adding the staining solution. 
T  n, 200 μl o  st  n n  solut on  ont  n n  1% (w/v) BSA  nd 5 μl o  Hum n CD24 FITC 
Conjugate in PBS was added for 2 hours at 298 K. After that, the coverslips were washed three 
times with PBS and mounted onto glass slides by fluoroshield with DAPI (Sigma). The slides were 
viewed using confocal microscopy (LSM ZEISS 710). 
Detection of cellular uptake: To quantitatively compare cellular uptake between smooth and virus-
mimicking silica nanoparticles, 2×10
5  
HeLa or KHOS cells were seeded in 6-well plates one day 
   or  tr ns   t on. N nop rt  l s (50 μ /mL) alone (sample 1 and 3) or complexes (1-NH2/3-
NH2+Cy3-oligoDNA or 1-PEI/3-PEI+PLK1-siRNA) were incubated with cells under serum free 
condition for 4 hours. Afterwards, the cells were washed with PBS three times and harvested with 
trypsin. After centrifugation, the cell pellets were washed twice and dried. Cell lysis buffer (Cell 
Signaling Technology) was added to allow dissolution of the cells with ultrasound. The 
supernatants (containing cell components) were removed by centrifugation at 13,000 rpm for 5 
minutes, followed by two washes with PBS. Aqueous NaOH solution (1 M) was then added to 
allow dissolution of the nanoparticles with ultrasound. The silicon concentrations in the final 
solutions were measured by ICPOES using a Vista-PRO instrument (Varian Inc, Australia), which 
were then converted to be silica amount. 
MTT assay: The cytotoxicity of nanoparticles was tested in both HeLa and KHOS cell lines. One 
day before the test, 5000 cells were seeded in each well of 96-well plates. Nanoparticles (1, 1-NH2, 
3, 3-NH2) were dispersed in 2-fold series, from 400 μ /mL to 12.5 μ /mL, in culture medium 
supplemented with 10% FBS and 1% penicillin-streptomycin. Because PEI attachment brought 
relatively higher toxicity, the concentrations for PEI-modified nanoparticles (1-PEI and 3-PEI) were 
determined from 50 to 1.56 μ /mL. After 24 hours incubation at 310 K, the liquid was replaced 
with fresh medium and the cells were cultured for another 24 hours. Cell viability was measured by 
adding MTT agent and reading the absorbance at 540 nm using a Synergy HT Microplate Reader. 
Results were compared to cells not exposed to nanoparticles. 
Gene silencing assay: Osteosarcoma KHOS cells were seeded in 96-well plates at 5000 cells/well 
one day before transfection. PLK1-siRNA or S10-siRNA was pre-mixed with either 1-NH2/3-NH2 
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(50 µg/mL) or 1-PEI/3-PEI (20 µg/mL) in PBS at 277 K for 4 hours. Then, nanoparticle-siRNA 
(12.5, 25 or 50 nM) complexes were incubated with cells. After 24-hour incubation, the transfection 
medium was replaced with fresh medium, followed by another 24 hours culture. The cell 
proliferation was determined using Cell-Titer-Glo assay. The positive controls comprised cells 
treated with PBS alone. Both S10-siRNA and PLK1-siRNA (50 nM) were also delivered using a 
commercial transfect reagent, Oligofectamine
TM
, as a separate control. 
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Supplementary Figures and Tables 
 
 
 
Figure 4.S1 TEM images of all samples and size distribution. a, e) sample 1 & 3. b, f) 1-NH2 & 3-
NH2. c, g) 1-PEI & 3-PEI. d) sample 2 (shell particle). h) size distribution curves obtained by the 
dynamic light scattering (DLS) method.  
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Figure 4.S2 Surface area tested by Nitrogen sorption. The surface area of 1 (with a smooth) and 3 
(with a rough surface) was measured to be 19 and 24 m
2
/g, respectively. 
 
 
Figure 4.S3 Confocal microscopy image shows no Cy3 signals is observed when the same amount 
of Cy3-oligoDNA alone is incubated with cells, indicating the inability of genetic molecules 
t  ms lv s to p n tr t   nto   lls. S  l    r: 20 μm. 
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Figure 4.S4 FACS analysis showing the peak shifts in the MFI from HeLa cells incubated with the 
complexes of 1-NH2 (blue colour)/ 3-NH2 (yellow colour) +Cy3-oligoDNA. The Cy3-oligoDNA in 
the absence of nano-carriers (red colour) is used as a control. 
 
  
Chapter 4 Nanoparticles Mimicking Viral Surface Topography for Enhanced Cellular Delivery 
77 
 
 
Figure 4.S5 Comparison of cellular delivery of cargos among different nanoparticles. a, b, c) Very 
weak signals were observed in the groups of naked Cy3-oligoDNA, Cy3-oligoDNA coupled with d, 
e, f) 2-NH2 (0.9 µg/mL, dosage calculated from ET results) and g, h & i) 1-NH2. j, k & l) Only 3-
NH2 induced evident Cy3 signals across all groups. 
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Figure 4.S6 Agarose gel analysis. a) The complex of amino-modified nanocarriers with Cy3-
oligoDNA. Lane 0: 25 pmol Cy3-oligoDNA only. Lane 1: 25 pmol Cy3-oligoDNA coupled with 50 
µg of 1-NH2. Lane 2: 25 pmol Cy3-oligoDNA coupled with 50 µg of 3-NH2. In the case of 1-NH2, a 
small amount of released Cy3-oligoDNA was observed. For 3-NH2, nearly no release could be seen 
by naked eyes. b, c) the complexes of PEI-modified nano-carriers with PLK1-siRNA. Lane 0: 25 
pmol PLK1-siRNA only. Lane 1, 2, 3: 100, 50 and 25 pmol PLK1-siRNA are coupled with 50 µg 
of 1-PEI and 3-PEI, respectively. In each lane from 1 to 3, the PLK1-siRNA release was evident in 
the case of 1-NH2, compared to that of 3-NH2. 
 
 
 
Figure 4.S7 Investigation of pure silica nano-carriers in adsorption and cellular uptake. a) 
Cytochrome C adsorption. The adsorption amount is 2.71 nmol/mg on 3, and 0.88 nmol/mg on 1. b) 
cellular uptake into KHOS cells. 128 pg/cell was internalized for 3, while 62 pg/cell for 1. c) 
cellular uptake into HeLa cells. 242 pg/cell was internalized for 3, while 187 pg/cell for 1. Data 
represent mean ± s.e.m of three independent experiments. *p<0.05, ***p<0.001,****p<0.0001 (t-
test).  
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Figure 4.S8 Cytotoxicity of nanoparticles. a, b) sample 1 & 3 in HeLa (left) and KHOS (right) cells. 
c, d) 1-NH2 & 3-NH2 in HeLa (left) and KHOS (right) cells. e) 1-PEI & 3-PEI in KHOS cells. Pure 
and amino-modified silica nanoparticles have relatively mild cytotoxicity to both HeLa and KHOS 
cells, and the ones with rough surface are more toxic due to the improved cellular uptake. However, 
the attachment of PEI caused a high toxicity to cells, so that the concentrations of 1-PEI & 3-PEI 
will be decreased to 20 µg/mL in gene silencing experiment. Data represent mean ± s.e.m of three 
independent experiments.  
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Figure 4.S9 Gene delivery performance of virus-mimicking nanoparticles in KHOS cells using 
amino-modified nanoparticles. Neither PLK1-siRNA nor S10-siRNA delivered by 1-NH2 and 3-
NH2 induced the decrease of cell viability by gene silencing effect. In the bar chart, data represent 
mean ± s.e.m of three independent experiments, and were analyzed using t-test.   
 
 
 
Figure 4.S10 TGA of PEI-conjugation. In both a) 1–PEI and b) 3-PEI, the TGA curves of (i) 
represent pure silica nanoparticles, (ii) show epoxy-group modified nanoparticles, (iii) are the PEI-
conjugated separately. 
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Figure 4.S11 Morphology adjustment of virus-mimicking nanoparticles. After fabricating the virus-
mimicking nanoparticles by mixing shell particles with core particles, morphology changes were 
traced by TEM images. On adjusting the feed volumes of shell particle solutions from a) 0.68 mL to 
b) 1.35 mL, to 2.70 mL (Figure 4.S1e), to c) 5.40 mL and finally to d) 6.75 mL, the surface 
morphologies changed significantly, with the best sample being obtained when the feed volume was 
2.70 mL. It is noted that a failure to obtain optimized virus-mimicking morphologies can be 
attributed to either insufficient or excessive feed amount of shell particles, where only a proper feed 
amount will lead to successful synthesis. Scale bar: 100 nm. 
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Figure 4.S12 The influence of calcination treatment. TEM image a) shows that without calcination, 
shell particles peeled off on ultrasonication. In contrast, b) shows that the calcined sample 3 
maintained its morphology after ultrasonication. Scale bar: 100 nm. 
 
Table 4.S1 | Physicochemical Properties of nanoparticles 
Sample 
ID 
Average Particle size (nm) 
PDI 
ζ pot nt  l 
(mV) TEM
a
 DLS 
1 209 ± 20 249 0.006  -24 
1-NH2 211 ± 19 291 0.120  +53 
1-PEI 220 ± 13 472 0.403 +47 
2 13 ± 2 15 0.105  -42 
3 226 ± 18 279 0.135  -36 
3-NH2 224 ± 16 298 0.159  +54 
3-PEI 226 ± 16 473 0.437 +43 
a
 The particle sizes are obtained by measuring 100 particles from TEM images and shown in 
mean±SD. 
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Table 4.S2 | Atomic composition (%) of nanoparticles 
Sample C Si O N 
1 2.61 29.74 67.64 -- 
1-NH2 24.72 21.24 49.41 4.63 
1-PEI  37.86  16.79  37.42  7.92  
3 1.65 30.92 67.43 -- 
3-NH2 23.46 22.38 49.69 4.47 
3-PEI  36.89  17.49  38.11  7.51  
Uncalcined-2 4.22 29.11 66.67 -- 
Calcined-2 0.84 29.83 69.33 -- 
 
Table 4.S3 | Characterization of PEI-modification by TGA  
 1-PEI 3-PEI 
Weight loss % 
1 1-epoxy 1-PEI 3 3-epoxy 3-PEI 
1.75 3.17 0.44 2.78 3.24 0.32 
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Chapter 5  
Synthesis of Silica Nanoparticles with 
Controllable Surface Roughness for 
Therapeutic Protein Delivery 
 
 
 
 
 
 
 
 
 
This chapter reports a novel "neck-enhancing" approach to synthesize silica nanoparticles with 
controllable surface roughness. By roughening the surface of solid silica core particles (~211 nm) 
with smaller shell particles having various sizes, a series of rough silica nanoparticles (RSNs) are 
obtained, where the shell and core particles are stably connected by bigger "necks", compared to our 
previous method. The surface roughness is correlated to the core-to-shell size ratio (from 16.2:1 to 
2.2:1), and the interspacing distance between neighboring shell particles increases from 7 to 38 nm 
with the increased shell particle sizes from 13 to 98 nm. Protein loading capacity of RSNs is 
dependent on the protein size relative to the interspacing distance. The optimal interspacing distance 
of RSNs for high protein loading capacity is 7, 21 and 38 nm for cytochrome c (~3nm), IgG-
fragment (IgG-F, ~10nm) and non-specific rabbit IgG antibody (IgG-A, ~20nm), respectively. 
Using surface plasmon resonance (SPR), it is demonstrated that the IgG-F maintained efficient 
binding function after loading on RSNs. After hydrophobic modification of octadecyl-groups (C18), 
C18-RSN with the interspacing distance of 38 nm shows effective intracellular delivery of anti-
pAkt antibody in breast cancer MCF-7 cells, leading to significant cell growth inhibition by 
blocking pAkt and downstream anti-apoptotic protein of Bcl-2. This work has been accepted for 
publication by Journal of Materials Chemistry B (2015, full paper). 
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5.1 Introduction 
Protein therapeutics has attracted increasing attention in cancer therapy due to the high 
specificity and less interference with normal biological processes.
1
 By introducing proteins 
that specifically recognize and influence target molecules, deactivation or activation of key 
signalling pathways within cells can be manipulated, which strongly affect cell functions.
2
 
However, proteins are poorly delivered into cells owing to poor stability and inability to 
cross cell membranes.
3
 It remains an on-going challenge to develop delivery systems to 
efficiently compact and deliver therapeutic proteins for enhanced cancer therapy.
4
 
In the past decade, various nano-carriers have been generated to deliver therapeutic proteins 
into cells, including liposomes,
5-7
 polymers,
8-11
 inorganic nanoparticles
12-14
and protein-based 
carriers.
15
 Among them, silica-based nanomaterials are a promising delivery platform for 
protein therapeutics. Bale et al.
16
 reported a successful delivery of the antibody to phospho-
Akt (anti-pAkt) into MCF-7 cells with a significant cell growth inhibition where anti-pAkt 
antibody was absorbed on the surface of solid silica nanoparticles modified by n-
octadecyltrimethoxy silane (n-ODMS) . A recent study has demonstrated that there was an 
optimized pore size in the shell of silica hollow spheres for high loading and improved 
intracellular delivery of a therapeutic protein, Ribonuclease A.
17
 The size of protein 
molecules may vary from several nanometres (e.g. cytochrome c
18
) to dozens of nanometres 
(e.g. IgG antibodies
19
). Therefore, it is highly desired to fabricate silica nanoparticles with 
adjustable voids to optimize the loading/release ability toward therapeutic proteins having 
various sizes. 
Besides the interaction with cargo molecules, efficient cellular uptake performance of silica 
nanoparticles is a prerequisite factor for successful cellular delivery. Recently, silica 
nanoparticles mimicking the surface topography of enveloped viruses
20
 were prepared by 
attaching shell particles with a smaller size onto core particles with a larger size.
21
 The 
interspaces between neighbouring shell particles provide the void space for the entrapment 
of biomolecules (e.g. siRNA). Compared to nanoparticles with smooth surfaces, silica 
nanoparticles with rough surfaces exhibited higher loading, sustained release and enhanced 
cellular uptake performance, consequently delivering siRNA successfully into cells. 
However, systematic control over core-to-shell size ratios of silica nanoparticles and their 
protein delivery efficacy has not been reported. If the surface roughness is adjustable on a 
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nanoparticle, nano-carriers with advantages of both rough surface and controllable void 
space would be crucial for exploring the impact of interspacing distance on protein delivery 
efficiency. For silica nano-carriers with rough surface, it is also important to investigate the 
bioactivity of proteins, for example, the binding activity of antibody, after loading into void 
space. Answers to these questions will provide fundamental knowledge to the rational 
design of silica nano-carriers for therapeutic protein delivery.  
Various approaches have been developed to fabricate rough nanoparticles by attaching small 
shell particles on a large core, including the electrostatic interaction
22, 23
 and covalent 
bonding pathways.
24
 However, the synthesis of inorganic and/or organic rough nanoparticles 
with uniform sizes generally have larger particle sizes ( 400 nm), which is not ideal for 
cellular delivery.
25, 26
 Although rough nanoparticles with particle size of  300 nm can be 
synthesized,
27-29
 the surface morphologies are not uniform. More importantly, in all previous 
literature reports, the core-to-shell size ratio is larger than 5.6:1. Therefore, it is a challenge 
to attach shell particles with relatively large sizes onto core particles. 
Herein we report a novel "neck-enhancing" approach to synthesize silica nanoparticles with 
controlled surface roughness. By roughening the surface of solid silica core particles (211 
nm in diameter) with smaller shell particles (Figure 5.1a) having various sizes, a series of 
rough silica nanoparticles (RSNs) are obtained. By forming a big "neck", shell particles with 
large sizes can be stably connected to the core particles. The surface roughness is correlated 
to the core-to-shell size ratios (from 16.2:1 to 2.2:1), and the interspacing distance between 
neighbouring shell particles increases from   7 to   38 nm w t   n r  s n  s  ll p rt  l  s z s 
 rom   13 to   98 nm. T   prot  n lo d n    p   ty o  RSNs  s d p nd nt on t   prot  n s z  
relative to the interspacing distance. The optimal interspacing distance of RSNs for high 
protein loading capacity is    7,   21 and    38 nm for cytochrome c (M.W. 12 kDa), IgG-
fragment (IgG-F, domain antibody, M.W.76 kDa) and non-specific rabbit IgG antibody 
(IgG-A, M.W. 150 kDa), respectively. Using surface plasmon resonance (SPR), it is 
demonstrated that the IgG-F maintains efficient binding function after loading on RSNs. As 
shown in Figure 5.1c, after hydrophobic modification of octadecyl-groups (C18), the C18-
RSN with the interspacing distance o    38 nm s ows      t v   ntr   llul r d l v ry of anti-
pAkt antibody (having a similar structure and animal source with non-specific rabbit IgG-A) 
in human breast cancer (MCF-7) cells, leading to significant cell growth inhibition by 
blocking pAkt and the downstream anti-apoptotic protein of Bcl-2. 
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Figure 5.1 Schematic illustrations of the synthesis of RSNs using a "neck-enhancing" approach (a) 
and a conventional interaction approach (b). Scheme c shows the cellular delivery of therapeutic 
anti-pAkt antibody using C18-RSNs and the cell growth inhibition mechanism. 
5.2 Experimental section 
5.2.1 Materials  
Ammonium hydroxide solution (28%), L-arginine, octane (98%), 3-
aminopropyltriethoxysilane (APTES), cytochrome c (95%, from bovine heart), fetal bovine 
serum (FBS) and trypan blue solution (0.4%) were purchased from Sigma-Aldrich. 
Tetraethyl orthosilicate (TEOS, 98%) and n-octadecyl-trimethoxy silane (n-ODMS, 90%) 
were purchased from Aldrich. Toluene was purchase from Merck. Dulbecco's Modified 
Eagle Medium (DMEM), penicillin-streptomycin (10000 U mL
-1
) and trypsin-EDTA 
(0.25%) were purchased from GIBCO or Invitrogen, Life Sciences, Life Technologies. The 
monoclonal antibodies (rabbit source) to Bcl-2 and GAPDH and HRP-linked anti-rabbit IgG 
antibody were purchased from Cell Signalling. MCF-7 (HTB-22™)   ll l n  w s pur   s d 
from American Type Culture Collection (ATCC). IgG-F for adsorption and SPR 
m  sur m nt w s k ndly prov d d  rom P t r P Gr y’s  roup. All    m  als were used 
without further purifications. 
5.2.2 Synthesis of different nanoparticles 
Synthesis of core particle  
Uniform nonporous silica core particles were synthesized using a well-known method 
developed by Stöber et al.
30
 Typically, absolute ethanol (50 mL) was mixed with deionized 
(DI) water (3.8 mL) and ammonium hydroxide solution (2 mL) at 25 °C. Then, TEOS (3 
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mL) was added to the solution under vigorous stirring. After 6 h, the as-synthesized 
nanoparticles were separated by centrifugation at 20000 rpm, and washed with ethanol. The 
final product was obtained by drying at 100 °C overnight. After that, amine-silane was 
grafted to create positively charged surface. First, dried samples (200 mg) were suspended in 
toluene (30 mL) and APTES (0.19 mL, 0.8 mmol) was added. The mixture was refluxed for 
20 h at 110 °C.
31
 Then, amino-modified nanoparticles were obtained by centrifugation at 
20000 rpm, washing with ethanol and drying in fume cupboard at 25 °C overnight.  
Synthesis of shell particles  
Shell nanoparticles with the mean sizes of 28, 54, 98, 135 and 175 nm were also fabricated 
using Stöber method with the same recipe as the core particle, except for reacting at 70, 60, 
50, 40 and 30 °C, respectively. The reactions were first carried out for 20 minutes for the 
formation of shell particles (28, 54, 98 and 135 nm). For the shell particle of 175 nm, the 
reaction time is 2 h. In addition, a modified Stöber method was used to fabricate the shell 
particle of 13 nm diameter.
32
 First, L-arginine (87 mg) was dissolved in deionized water 
(69.5 mL) containing octane (5.23 mL). Then, the mixture was sonicated and TEOS (0.5 
mL) was added to react at 60 °C for 3.5 h for the formation of shell particles.  
Synthesis of RSNs with varied shell sizes  
The amino-modified core particle (200 mg) was suspended (2 mL) in DI water (for the 
synthesis of RSN-211@13) or ethanol (for the synthesis of other RSNs). The core particle 
suspensions were added into different shell particle reaction solutions as described above 
(including 69.5 mL of DI water, 87 mg of L-arginine, 5.23 mL of octane and 0.5 mL of 
TEOS for the synthesis of RSN-211@13; 50 mL of absolute ethanol, 3.8 mL of DI water, 2 
mL of ammonium hydroxide solution and 3mL of TEOS for the synthesis of other RSNs), 
reacting for another 2 h at the original temperatures for shell particle synthesis. The as-
synthesized RSNs were washed three times with ethanol and isolated by centrifugation at 
4750 rpm for 10 min (shell particles cannot be recovered by centrifugation under these 
conditions), followed by drying in a fume cupboard at 25 °C overnight. Finally, RSNs were 
obtained after calcination treatment at 550 °C for 5 h to remove organic components in silica 
frameworks, enabling all RSNs to have a similar surface composition (amorphous silicon 
oxide) and surface property (zeta potential).  
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Hydrophobic modification to RSNs  
RSNs were functionalized with n-ODMS. Different RSNs (200 mg) were suspended in 
toluene (25 mL) containing 0.5% (v/v) n-ODMS. Then, the mixture was refluxed for 20 h at 
110 °C, followed by centrifugation at 10000 rpm, washing with ethanol and drying in a fume 
cupboard at 25 °C overnight.  
5.2.3 Characterizations  
Transmission electron microscopy (TEM) images were taken using a JEOL 1010 
microscope operated at 100 kV. The TEM specimens were dispersed in ethanol, and then 
transferred to a copper grid. The high resolution scanning electron microscopy (HRSEM) 
images were obtained on a JEOL JSM 7800 FE-SEM equipped with an in-column upper 
electron detector (UED) and gentle beam technology. HRSEM was operated at a low 
accelerating voltage of 0.8-1.5 kV with 20% specimen bias.
33
 For FE-SEM measurements, 
the samples were prepared by dispersing the powder samples in DI water, after which they 
were dropped to the aluminium foil pieces and attached to conductive carbon film on SEM 
mounts. The SEM mounts were dried in a vacuum oven at 70 °C for at least 8 hours before 
observations. Dynamic light scattering (DLS) and zeta potential (ZP) measurements were 
carried out at 25 °C using a Zetasizer Nano-ZS from Malvern Instruments. The samples 
were dispersed in DI water or ethanol by ultra-sonication before analysis. Nitrogen sorption 
isotherms of the samples were obtained at -196 °C using a Micrometrics Tristar II system. 
Before the measurements, the samples were degassed at 180 °C overnight in vacuum. The 
Brunauer–Emmett–Teller specific surface area (SBET) was calculated using experimental 
points at a relative pressure of P/P0 = 0.05-0.25. Fourier transform infrared (FTIR) spectra of 
rough silica nanoparticles before and after hydrophobic modification were collected using 
t   T  rmo S   nt    ™ N  ol t™ 6700 FT-IR spectrometers. Each spectrum was obtained 
using dried powder against a background measured under the same condition. Atomic force 
microscopy (AFM) measurement was conducted, where IgG-F was mixed with RSN-
211@54 (500 µg) in PBS pH 7.4 for 2 h at 4 °C, at a protein concentration of 1 mg mL
-1
. 
After incubation, the samples were washed with DI water to remove free and loosely 
attached proteins and salts in solution by centrifugation and pipetting. Then, the suspension 
(10 µL) was placed onto silicon wafers. The wafer was evaporated at 25 °C before AFM 
observation. RSN-211@54 without protein incubation was used as a control. A Cypher S 
AFM (Asylum Research, an Oxford Instruments company) was used for all the 
measurements. The images were obtained by employing the tapping mode of the AFM in air 
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by using Al- o t d s l  on pro   w t  t p r d us o  2 nm (NANOSENSORS™, Sw tz rl nd). 
The interaction between IgG-F and complementary antigen was monitored utilizing a SPR-
based biosensor (Biacore
TM
 T200, GE Healthcare). IgG-F was incubated with RSNs (500 
µg) in PBS pH 7.4 for 2 h at 4 °C, and the final protein concentration was 1 mg mL
-1
. 
Following that, IgG-F-RSNs complexes were washed several times until the supernatant 
showed the same UV-vis absorbance at 280 nm as PBS only. Then, IgG-F-RSNs complexes 
were suspended in HBS-EP buffer (Biacore
TM
 T200, GE Healthcare). Biotinylated peptide 
was immobilized via streptavidin capture on a sensor chip CAP (GE Healthcare) pre-
immobilized with ssDNA-streptavidin (Biotin CAPture kit, GE Healthcare) to yield the 
peptide surface densities in the range of 2500-5000 R.U. A reference flow cell was 
generated by omitting only ssDNA-streptavidin onto the chip surface. Interaction analyses 
were performed by injecting IgG-F-RSNs complexes over the reference and peptide surfaces 
in series for 120 seconds at a flow-r t  o  10μl m n-1. Complex dissociation was monitored 
for 120 seconds. The binding intensity was determined at the peak point 128 seconds after 
sample injection. Surface regeneration was performed at the end of each analysis cycle by 
injecting guanidine (8 M) mixed with NaOH (1 M) at the ratio of 3:1, followed by washing 
with the mixture of acetonitrile (30%), NaOH (0.25 M) and SDS (0.05%).  
5.2.4 Biological experiments  
Protein adsorption assay  
The adsorption ability of RSNs with different proteins (cytochrome c, IgG-F and IgG-A) 
was evaluated. Different proteins were mixed with RSNs (100 µg) in PBS pH 7.4 for 2 h at 
4 °C, and final protein concentration is 1 mg mL
-1
. IgG-A was also incubated with C18-
RSNs. After this time, the mixtures were centrifuged at 15000 rpm, and the supernatants 
were collected for testing. The adsorption of protein molecules was determined using a 
NANODROP 1000 spectrophotometer (Thermo Scientific) at 280 nm. 
Protein therapeutics assay  
Cells were maintained as monolayer cultures at 37 °C and 5% CO2 in DMEM supplemented 
with 10% FBS and 1% penicillin-streptomycin. MCF-7 cells were seeded in 24 well-plates 
at 5×10
4
 cells per well and incubated for 4~6 h. The dose-dependent cytotoxicity of C18-
RSN-211@98+anti-pAkt composite was tested. The anti-pAkt antibody (1 mg mL
-1
, sigma) 
was incubated with C18-RSN-211@98 in PBS pH 7.4 at 4 °C for 2 h. Following this, 
protein-nanoparticle complexes were suspended in serum containing culture medium in two-
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 old d lut ons. T        st n nop rt  l   on  ntr t on  s 50 μ  mL-1, corresponding to 1 µg 
mL
-1
 of anti-pAkt antibody on the surface of the nanoparticle. Non-specific rabbit IgG-A 
and nanoparticle only were used as control. After incubation for 24 h, cells were detached by 
incubating with trypsin/EDTA mixture. Detached cells were then suspended in the medium 
previously collected from the sample. Cell suspension was diluted with trypan blue solution 
in a 1:1 ratio, and live and dead cells were counted on a hemacytometer.  
The comparison of protein therapeutics among all the C18-RSNs was also evaluated. The 
same amount of C18-RSNs (50 μ ) w s m x d w t   nt -pAkt  nt  ody (1 μ )  n PBS pH 
7.4 at 4 °C for 2 h and the complexes were incubated with MCF-7 cells in serum containing 
culture medium for 24 h at the nanoparticle concentration of 15 µg mL
-1
. Non-specific rabbit 
IgG-A and C18-RSNs only were used as control. The cell viability was also determined by 
counting live and dead cells. 
Detection of cellular uptake performance of C18-RSNs  
To quantitatively compare cellular uptake performance of C18-RSNs, 3×10
5
 MCF-7 cells 
were seeded in 6-well plates one day before transfection. C18-RSNs (50 μ  mL-1) were 
incubated with cells under serum free condition for 4 h. Afterwards, the cells were washed 
with PBS three times and harvested with trypsin. Cell number for each sample was recorded. 
After centrifugation, the cell pellets were washed twice and dried. DI water was added to 
allow dissolution of the cells under ultra-sonication condition. The supernatants (containing 
cell components) were removed by centrifugation at 15000 rpm for 5 min. Aqueous NaOH 
solution (1 M) was then added to allow dissolution of silica nanoparticles with ultrasound. 
The silicon concentrations in the final solutions were measured by inductively coupled 
plasma optical emission spectrometry (ICPOES) using a Vista-PRO instrument (Varian Inc, 
Australia), which were then converted to be the mass of silica per cell.  
Western-blot analysis  
MCF-7 cells were seeded in 6-well plates at a seeding density of 3×10
5
 cells per well. The 
anti-pAkt antibody and the non-specific IgG-A were incubated with C18-RSN-211@98 in 
PBS pH 7.4 at 4 °C for 2 h. Then, protein-nanoparticle complexes, along with C18-RSN-
211@98 only group, were mixed with serum containing culture medium and incubated with 
  lls  or 24  . T     n l  on  ntr t on o  n nop rt  l s  s 50 μ  mL-1 and protein is 1 µg mL-
1
. At the end of incubation, cells were washed with PBS and lysed. The solutions containing 
cell lysates were denatured at 95 °C for 15 min followed by characterization by SDS-PAGE. 
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The protein bands were transferred to a PVDF membrane. Bcl-2 bands were targeted using 
Bcl-2 monoclonal antibody (mAb) as the primary antibody, and HRP-linked anti-rabbit IgG 
antibody as the secondary antibody. GAPDH mAb was used as an internal reference. Bands 
were visualized on a ChemiDoc MP System (Bio-Rad). 
5.3 Results and Discussion 
Preparation of RSNs  
Three relatively large silica shell particles (28±3 nm, Figure 5.S1b, ZP -42±8.3 mV; 54±5 
nm, Figure 5.S1c, ZP -53±2.6 mV; 98±7 nm, Figure 5.S1d, ZP -53±1.0 mV) were prepared 
by the classical Stöber method.
30 
The smallest silica shell particle (13±2 nm, Figure 5.S1a, 
ZP -42±2.4 mV) was synthesized by a modified Stöber method.
32
 The silica core particle 
(diameter of 211±11 nm, Figure 5.S1g, ZP +31±0.2 mV) was also fabricated using the 
classical Stöber method, followed by amino-modification to generate positive charges on the 
surface. The particle size distribution curves measured by the DLS method are narrow for all 
silica particles (Figure 5.S1h), indicating that the nanoparticles are monodispersed in size 
(see Table 5.S1 for the polydispersity index, PDI).  
To fabricate RSNs with varied shell sizes, the core particles were suspended and added into 
the reaction solution of different shell particles. After reaction for 2 h and washing, the final 
calcined samples were denoted as RSN-211@13, RSN-211@28, RSN-211@54 and RSN-
211@98, possessing ZP values of -30, -26, -29 and -29 mV, respectively. The numbers 
before and after @ refer to the mean size of core particle and shell particles measured from 
TEM images (Figure 5.S1). The core-to-shell size is 16.2:1, 7.5:1, 3.9:1 and 2.2:1, 
respectively.  
TEM images of four RSNs are shown in Figure 5.1. The particle size of RSN-211@13, 
RSN-211@28, RSN-211@54 and RSN-211@98 is 254±26, 270±15, 297±20 and 380±39 
nm, respectively (Figure 5.2a-d). HRSEM images (Figure 5.2e-h) clearly show that core 
particles are uniformly studded by different shell particles, and the interspacing distance 
  tw  n n     our n  s  ll p rt  l s  nl r  s  s t   s  ll p rt  l  s z   n r  s   rom    13 
to    98 nm. The interspacing distance between shell particles is crucial to the accumulation 
of cargo molecules. Although the interspacing distances for RSNs are not uniform and 
difficult to measure precisely, the values were determined by measuring 50 edge-to-edge 
interspacing between adjacent shell particles to allow a semi-quantitative comparison. As 
shown in Figure 5.S2 and Table 5.S2, the average interspacing distance of RSN-211@13, 
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RSN-211@28, RSN-211@54 and RSN-211@98 is 7±2, 14±4, 21±9 and 38±22 nm, 
respectively. The particle sizes of the four samples from DLS measurements are close to that 
obtained from TEM measurements and the small PDI values confirm that all RSNs are 
uniform and well-dispersed (Table 5.S2). 
 
Figure 5.2 TEM (a-d) and HRSEM (e-h) images of RSNs with varied shell particle sizes: 
a&e) RSN-211@13, b&f) RSN-211@28, c&g) RSN-211@54, d&h) RSN-211@98 and the 
r d  rrows  nd   t  t    orm t on o       r “n  ks”  onn  t n  s  ll  nd  or  p rt  l s. 
Scale bar: 100nm. 
The nitrogen sorption analysis was further utilized to measure SBET of RSN-211@13, RSN-
211@28, RSN-211@54 and RSN-211@98, which is 25.4, 26.9, 25.2 and 22.4 m
2
 g
-1
, 
respectively (Table 5.S2). For RSN-211@28, RSN-211@54 and RSN-211@98 prepared by 
the same protocol, SBET of RSNs decreases with increasing shell particle size. The lower 
SBET of RSN-211@13, compared to that of RSN-211@28, can be attributed to the difference 
in synthesis methods: a longer reaction time (3.5 h vs. 20 min) of shell particles may lead to 
more condensed structures and thus reduced surface area. 
Using our previous protocol,
21 s  ll p rt  l s o     13 nm w r  su   ss ully  tt    d on t   
 or  p rt  l s o  211 nm. How v r, l r  r s  ll p rt  l s,  or  x mpl , w t  t   s z  o    28 
nm, are easily peeled off from core particles during washing and drying processes (Figure 
5.S3a), even when core-shell structures were formed in solution (Figure 5.S3 ). In t   
 urr nt  ppro   , t   l r   s  ll p rt  l s (  28,   54  nd    98 nm) w r   orm d using the 
classical Stöber method after reaction of 20 min, as the particle sizes were barely changed 
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after about 15 min.
30
 Afterwards, positively charged core particle suspension was added into 
the above shell particle reaction solution. By comparing the difference of current synthesis 
strategy to the previous one (shown in Figure 5.1), the pH value of reaction medium (11.0 
vs. 9.4) and the weight ratio of shell to core particles (4:1 vs. <1:1) is increased (Figure 
5.1a(i) vs. b(i)).  
The driving force for the attachment of negatively charged shell particles onto positively 
charged core particles is electrostatic interaction
21, 22
 (Figure 5.1a(ii) and 1b(ii)), however 
less attention has been paid to how to stabilize the formed core-shell structure and hence it is 
difficult to synthesize rough particles with relatively large shell sizes. The focus of this study 
is to address this challenge through silicate chemistry.
34
 At pH 9.4 the silica solubility is 
reduced with both SiO(OH)3
-
 (~50%) and Si(OH)4  (~50%) presenting in solution (Scheme 
2b(i)). In contrast, at a stronger basic condition of pH 11, SiO(OH)3
-
 is the predominant 
silicate species with a relatively high concentration and thus more negative charges (Figure 
5.1a(i)). When shell particles attach to core particles, a space with surfaces of negative 
curvature is generated as indicated by a violet arrow in Figure 5.1a(ii). The solubility of a 
surface with negative curvature is lower than that with positive curvature (i.e., normal 
surface of spheres). Therefore, the net result is silica migration and deposition into the space 
near the point of contact between core and shell particles,
35
 leading to the formation of a 
bigger "neck" connecting core and shell particles (indicated by a violet arrow in Figure 
5.1a(iii)).  
The solubility difference between surfaces with positive and negative curvatures increases 
with pH (e.g., 11.0 vs. 9.4), thus a higher pH favours the formation of bigger "necks"
35
 
stabilizing the rough particle morphology. If the neck size is small and not strong enough 
(e.g., at pH of 9.4) to hold core and shell particles (especially shell particles with relatively 
larger sizes), the shell particles adhered on core particle surface mainly through electrostatic 
interaction would easily peel off (iii in Figure 5.1b) during the subsequent treatments 
(washing, drying, sonication, etc.). In addition to the increase of pH, the shell particle 
concentration is also increased in our synthesis, which is beneficial for the attachment 
between core and shell particles and eventually the enhanced neck formation. 
The "neck-enhancing" mechanism for core-shell connection is supported by experimental 
observations. The formation of neck regions between shell and core particles can be directly 
seen using RSN-211@98 as an example (indicated by red arrows in Figure 5.2h). 
Noticeably, there is a limitation for our current method. When shell size was further 
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increased to 135 nm (Figure 5.S1e, 135±8nm, ZP -33±1.9 mV) and 175nm (Figure 5.S1f, 
175±8nm, ZP -32±0.9 mV), the even larger shell particles failed to attach on the surface of 
core particles (Figure 5.S4). 
Protein adsorption behaviours on RSNs  
To investigate the influence of interspacing distance of RSNs on protein adsorption capacity, 
three model proteins with various molecular weights, including cytochrome c, IgG-F and a 
non-specific rabbit IgG-A were used. Non-specific rabbit IgG-A was chosen because it has a 
similar structure and animal source with anti-pAkt antibody, which will be utilized as the 
therapeutic protein in the following biological study. Among the three proteins, cytochrome 
c has an isoelectric point (IEP) of ~10, a diameter of ~3 nm and the smallest molecular 
weight of ~12 kDa.
36
 IgG-A with the largest molecular weight of 150 kDa has a diameter of 
~20 nm
19
 and the IEP of ~9. The IgG-F is a domain antibody and exists as a dimer, which 
has an IEP value of ~8 and a molecular weight of 76 kDa with an estimated diameter of 10 
nm. All proteins can be directly loaded onto RSNs at pH 7.4 in a phosphate buffer solution 
(PBS) due to the electrostatic interaction between negatively charged silica nanoparticles 
(Figure 5.S5) and the positively charged proteins. All RSNs demonstrate higher adsorption 
ability in three tested proteins compared to the smooth core particles (data not shown), 
which is consistent with previously reported results.
21
  
Figure 5.3 shows protein adsorption capacity of RSNs with various interspacing distances. 
RSN-211@98 with the interspacing distance o     38 nm  x    ts t        st  dsorpt on 
ability (22.6 µg mg
-1
) of IgG-A. RSN-211@54 (18.1 µg mg
-1
) and RSN-211@28 (17.2 µg 
mg
-1
) with small interspacing distances show lower adsorption amount. In addition, the IgG-
A adsorption ability of RSN-211@98 is ~78% higher than RSN-211@13 (12.7 µg mg
-1
), 
which has the smallest interspacing distance. For IgG-F, the adsorption behaviour becomes 
different. RSN-211@54 exhibits the highest protein entrapment ability (48.8 µg mg
-1
). RSN-
211@98 shows a lower loading capacity of 42.5 µg mg
-1
, because the interspacing distance 
of RSN-211@98 is too large to hold the relatively small protein molecules in the voids.
17
 
The lower adsorption ability of RSN-211@28 (40.1 µg mg
-1
) and RSN-211@13 (36.7 µg 
mg
-1
) is attributed to the smaller void size compared to RSN-211@54. 
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Figure 5.3 Protein adsorption profiles ( IgG-A;  IgG-F; ▲  yto  rom  c). Solid lines 
represent different protein adsorption onto unmodified rough silica nanoparticles. The dash 
line also represents the IgG-A adsorption onto different rough silica nanoparticles, except 
they are all modified with C18-groups. Data represent mean ± SD. Specific surface area 
variations (×) of different unmodified rough silica nanoparticles are displayed to compare 
with protein adsorption trend. 
Noticeably, adsorption trend depends on the void size but not the surface area of RSNs 
(Figure 5.3, solid line with cross symbol). As calculated in Table 5.S3, the protein coverage 
(adsorption capacity versus surface area) is 63%, 80%, 91% and 127% for IgG-A, 91%, 
94%, 122% and 117% for IgG-F on RSN- 211@13, RSN-211@28, RSN-211@54 and RSN-
211@98, respectively. The multilayer deposition behaviour of IgG-A on RSN-211@98 and 
IgG-F on both RSN-211@54 and RSN-211@98 suggests that the adsorption occurs in the 
interspace of particles with rationally controlled surface roughness.
37
  
To confirm this hypothesis, RSN-211@54 was chosen to explore the surface topography 
changes before and after IgG-F adsorption using AFM, due to its highest protein adsorption 
capacity among the three cases. As shown in Figure 5.4, at the top region, shell particle 
height of pure RSN-211@54 (Figure 5.4a, b) is 34-39 nm. After IgG-F adsorption, the shell 
particle height (Figure 5.4c, d) decreases to 16-19 nm, suggesting that protein molecules are 
entrapped and accumulated into the shell interspaces of RSN-211@54. 
When protein size is much smaller than the interspacing distance, the surface area change 
dominates protein adsorption behaviour. For the adsorption of cytochrome c, RSN-211@28 
(7.5 µg mg
-1
) shows the highest adsorption ability, followed by RSN-211@54 (6.9 µg mg
-1
). 
The adsorption ability of RSN-211@13 and RSN-211@98 are only 5.2 and 3.6 µg mg
-1
, 
respectively. This adsorption trend is consistent with SBET variations (Figure 5.3, solid line 
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with cross symbol) of different RSNs. In addition, the coverage is calculated to be at most 
9% (RSN-211@28, Table 5.S3). These results demonstrate that the interspacing distances of 
RSNs are too large to confine very small protein molecules. 
 
Figure 5.4 Surface topography studies. AFM images of RSN-211@54 before (a) and after 
(c) the adsorption of IgG-F. A cross-sectional line is drawn to characterize the height 
changes of shell particles on the top region before (b) and after (d) protein adsorption. Scale 
bar: 100 nm. 
Desired surface functionality (e.g., octadecyl-group
16
) is of significance for high loading and 
efficient delivery of therapeutic proteins into cells. All RSNs were hydrophobically-
modified on the surface, referred to as C18-RSN-211@13, C18-RSN-211@28, C18-RSN-
211@54 and C18-RSN-211@98 with slightly increased ZP values of -23, -18, -25 and -25 
mV, respectively. They are used to further investigate the interspacing distance influence of 
C18-RSNs on IgG-A adsorption capacity for the following application in therapeutic protein 
delivery. FTIR results confirm the successful conjugation of octadecyl-groups for all C18-
RSNs (Figure. 5.S5). No significant topography changes are observed under TEM images 
for all samples (Figure. 5.S6).  
The IgG-A adsorption ability of C18-RSNs is displayed in Figure 5.3 (dash line). C18-RSNs 
show highly improved adsorption capacity, compared to unmodified RSNs. The protein 
coverage is calculated to be 179% for C18-RSN-211@13 (37 µg mg
-1
), 229% for C18-RSN-
211@28 (49 µg mg
-1
), 277% for C18-RSN-211@54 (55 µg mg
-1
) and 337% for C18-RSN-
211@98 (60 µg mg
-1
). The results are interpreted as IgG-A adsorption in a multi-layered 
fashion, both on surface and in voids, where some proteins did not necessarily have strongly 
physical contact with the silica surface.
19
 In addition, the adsorption amount of IgG-A to 
C18-RSNs is much higher than the results in literature,
16
 where IgG-A loading capacity of 
octadecyl-group modified smooth solid silica nanoparticles is only 1.25 µg mg
-1
. 
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The surface chemistry and nanoscale roughness play important roles in the immobilization 
of biomolecules. The adsorption of positively charged IgG-A in PBS onto negatively 
charged RSNs is mainly attributed to the electrostatic attraction.
38
 For C18-RSNs, the 
hydrophobic modification leads to partially reduced charge density compared to 
corresponding RSNs, however the IgG-A adsorption capacity was increased as much as 2-3 
times than that of RSNs. For example, C18-RSN-@211@13 shows 2.8 times of IgG 
antibody adsorption compared to RSN-211@13 without C18 modification (Figure 5.3), 
indicating that the hydrophobic interaction is more important than the electrostatic 
interaction in this case.
38, 39
 However, when comparing the adsorption capacity of either 
RSNs or C18-RSNs with the same surface chemistry but tunable surface roughness (Figure 
5.3), it shows that the size of surface voids (or core-to-shell ratios) is also important, e.g. the 
IgG-A adsorption capacity of C18-RSN-@211@98 is 1.7 times compared to C18-RSN-
@211@13, which is attributed to protein immobilization in the void spaces of rough 
surfaces.
37
 
Evaluation of protein binding ability  
Protein secondary structures are possibly disturbed after absorbed onto nanoparticle 
surface.
40
 It is very important to maintain the activity of protein molecules loaded into nano-
carriers for therapeutic applications. Therefore, SPR measurements were conducted to 
evaluate whether the binding capability of IgG-F with its complementary antigen will be 
maintained after contacting rough nanoparticles.  
SPR is a fast and real-time detection technique used to examine the interaction between wide 
ranges of biological targets. Based on detecting small changes in the refractive index, SPR is 
able to specifically monitor the interaction between analytes (e.g., antibody or peptide) and 
the ligand molecules (e.g., antigen), which have been immobilized onto an inert surface. 
"Resonance units" (RU, equal to a critical angle shift of 10
−4
 deg) is used to describe binding 
signals between analytes and ligands.
41
 Unmodified RSNs were used to absorb IgG-F in this 
test, because IgG-F is immobilized on unmodified RSNs generally in a monolayer manner, 
so that the SPR results can be directly compared with the protein binding ability. After 
sample injection, the negative signals from the control groups demonstrate that bare RSNs 
and PBS did not exhibit any binding events. In comparison, all RSN-IgG-F complexes show 
positive signals in binding with the antigen, which has been immobilized to the sensor chip 
as the ligand, indicating the binding activity of IgG-F is maintained after complexing with 
all RSNs (Figure 5.5 and Table 5.S4). It is noted that the trend of SPR signal intensity 
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(peaked at 128 seconds after sample injection) of various RSNs-IgG-F complexes is 
consistent with the adsorption trend of IgG-F onto various RSNs (Figure 5.3). 
 
Figure 5.5 SPR sensorgrams showing the binding signals of RSN-IgG-F complexes with 
receptors. All RSN-IgG-F complexes showed positive values of the binding with ligand. 
Typically, there is a linear relationship between the SPR signal intensity and the surface 
concentration of immobilized molecules.
41
 In our test, equal amount of RSNs was mixed 
with excessive amount of IgG-F in PBS solution to achieve a saturated adsorption of IgG-F 
on complexes. After removing free IgG-F and re-suspending into the injection buffer, the 
SPR test for each sample is generally finished after 10 min of re-suspending the IgG-
F/RSNs complexes to ensure a minimized release of IgG-F from RSNs.
42
 The IgG-F 
coverage of RSN-211@54 is 122%; however, RSN-211@13 and RSN-211@28 with 
relatively low IgG-F adsorption are not fully covered. Therefore, higher IgG-F density on 
the surface of RSNs favours the binding with ligands on the sensor chip
43
 and generates 
higher SPR signal intensity. As a result, RSN-211@54 shows the highest SPR signal 
intensity followed by RSN-211@28, and RSN-211@13 has the lowest SPR signal intensity. 
Besides the influence of protein coverage on particle surface, higher shell particle density 
provides more voids for accommodating IgG-F. RSN-211@98 with the largest shell particle 
size and thus the lowest void density on the surface has less binding sites with ligands, 
leading to an even lower SPR intensity, compared to RSN-211@28. 
Intracellular delivery of therapeutic protein  
It has been reported that pAkt plays an important role in transcriptional activation of 
proteins involved in cell growth.
44
 Delivering anti-pAkt antibody into cytosols inactivates 
pAkt and induces the decrease of anti-apoptotic protein (e.g. Bcl-2
45
), resulting in apoptosis 
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in some human cancer cell lines, for example, ovarian cancer, breast cancer and pancreatic 
cancer.
46-48
 Hydrophobic-modified silica nanoparticles have been reported to deliver 
therapeutic proteins successfully into cytoplasm.
16, 17
 In this study, C18-RSN-211@98 was 
used to deliver anti-pAkt antibody (Figure 5.1c) into human breast cancer cells (MCF-7) due 
to its highest antibody adsorption ability. 
 
Figure 5.6 Cell growth inhibition by the delivery of therapeutic protein. a) Cell viability of 
MCF-7 cells incubated with increasing concentrations of C18-RSN-211@98+anti-pAkt (), 
C18-RSN-211@98+non-specific-IgG-A (♦)  nd C18-RSN-211@98. Data represent mean ± 
SD. b) Western blotting confirming the degradation of downstream anti-apoptotic protein, 
Bcl-2 in MCF-7 cells. Blots presented are representative of typical results. GAPDH served 
as an internal reference. 
Dose-dependent cell growth inhibition is observed for the complex of C18-RSN-
211@98+anti-pAkt, and a maximum exposure of 1 µg mL
-1
 of immobilized anti-pAkt 
antibody at 50 µg mL
-1
 of nanoparticle shows an increase in cell growth inhibition up to 
85% (Figure 5.6a). This cell growth inhibition of anti-pAkt antibody is greater than the 
literature report, where   80% of cell growth inhibition was induced by using as high as 800 
µg mL
-1
 of a C18-modified silica nanoparticle (15 nm in diameter) to deliver 1 µg of anti-
pAkt antibody. In the absence of silica nano-carrier, free anti-pAkt antibody is unable to 
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cause cell growth inhibition, indicating its poor cell internalization ability (Figure 5.S7). In 
addition, when cells were treated with C18-RSN-211@98+non-specific rabbit IgG-A or 
nanoparticle only, no obvious cell growth inhibition is observed (Figure 5.6a). The anti-pAkt 
antibody delivery efficiency was also evaluated using other C18-RSNs (as shown in Figure 
5.S8), and C18-RSN-211@98 holds the best performance.   
To further test the downstream effects after blocking pAkt, Bcl-2 degradation was evaluated 
using western blotting. As shown in Figure 5.6b, Bcl-2 degradation in MCF-7 cells is only 
observed following cytosolic delivery of the C18-RSN-211@98+anti-pAkt, compared to cell 
only, nanoparticle only and nanoparticle with non-specific IgG-A groups, indicating that cell 
growth inhibition is associated with the degradation of Bcl-2 levels in MCF-7 cells. 
5.4 Conclusion 
In summary, rough silica nanoparticles (RSNs) with varied topographies were successfully 
synthesized using a novel "neck-enhancing" approach. Relatively high pH value and shell 
particle concentration favour the formation of bigger "necks", which is crucial for the 
generation of RSNs with controllable core-to-shell ratios. The increase of shell particle sizes 
from    13 to    98 nm while keeping the core particle size at    211 nm enlarges the shell 
particle interspacing distance  rom    7 to   38 nm, where proteins with comparable sizes are 
favourably accumulated without influencing its binding ability. The rough silica 
nanoparticles with an optimized loading capacity demonstrate a high efficiency of 
intracellular delivery of therapeutic proteins in cancer cells, causing a significant cell growth 
inhibition. The "neck-enhancing" approach provides new understanding in the rational 
design of cellular delivery vectors with controllable surface roughness for the delivery of 
therapeutic proteins. 
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Supplementary Figures and Tables 
 
 
Figure 5.S1 TEM images (a-g) and particle size distribution curves (f) of shell and core particles. 
Shell particles: a&h-i) 13nm, b&h-ii) 28nm, c&h-ii) 54nm, d&h-iv) 98nm, e&h-v) 135nm and f&h-
vi) 175nm. Core particle: g&h-vii) 211nm. Scale bar: 100 nm. 
 
Figure 5.S2 The interspacing distance of RSNs. a) RSN-211@13, b) RSN-211@28, c) RSN-
211@54, d) RSN-211@98. The interspaces are measured from SEM images by recording 50 edge-
to-edge interspacing data in each sample. 
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Figure 5.S3 TEM images showing the synthesis of RSN-211@28 using previous recipe after 
washing and drying process (a) and in reaction solution (b). Scale bar: 100 nm. 
 
 
 
Figure 5.S4 TEM images of failed synthesis of RSNs with much larger shell sizes. a) Core particles 
(dotted arrow) mixed with the shell of 135 nm (solid arrow), b) Core particle (dotted arrow) mixed 
with the shell of 175 nm (dotted arrow). Scale bar: 100 nm. 
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Figure 5.S5 Fourier transform infrared (FTIR) spectra of pure liquid n-ODMS (a) and a series of 
RSNs with and without hydrophobic modification (b).  
 
The RSNs before and after modification of octadecyl group is characterized by FTIR technique. 
Figure 5.S5a shows the FTIR spectrum of pure liquid n-ODMS, where the six characteristic peaks 
at 809, 1085, 1190, 1465, 2856 and 2926 cm
-1
   n     ttr  ut d to ν(S -O), ν(C-O)+ ν(C-C), 
ρ(CH3), δ(C-H)
1
 and symmetric and anti-symmetric -CH2- stretching,
2, 3
 respectively. All the 
spectra of silica nanoparticles show the same characteristic bands at 802 cm
-1
 and broad band 
centrated at 1058 cm
-1
, suggesting –Si-O-Si- bonding.4 In the spectra of all silica nanoparticles after 
hydrophobic modifications (Figure 5.S5b i, iii, v, vii), two extra peaks at 2856 and 2926 cm
-1
 can be 
observed, shown as the curves enlarged by 5-folds, which can be attributed to symmetric and anti-
symmetric -CH2- stretching, respectively, indicating the successful modification of octadecyl 
groups.
5
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Figure 5.S6 TEM images of hydrophobic modified RSNs. a) C18-RSN-211@13, b) C18-RSN-
211@28, c) C18-RSN-211@54 and d) C18-RSN-211@98 (d). Scale bar: 100 nm.  
 
 
Figure 5.S7 Cell viability of MCF-7 cells incubated with varying concentrations of non-specific 
IgG-A () only and anti-pAkt antibody () only, respectively. Data represent mean ± SD. 
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Figure 5.S8 The comparison of anti-pAkt antibody delivery efficiency (a) and cellular uptake 
performance of C18-RSNs measured by ICPOES (b). Data represent mean ± SD. 
 
C18-RSN-211@13, C18-RSN-211@28 and C18-RSN-211@54 were also used apart from C18-
RSN-211@98 to deliver anti-pAkt antibody into cells. Both C18-RSNs alone or loaded with non-
specific IgG-A did not cause significant cell growth inhibition. Equal amount of C18-RSNs (50 µg) 
was mixed with excessive amount of anti-pAkt antibody (1 µg) in PBS solution to ensure a 
saturated adsorption. At the nanoparticle concentration of 15 µg mL
-1
, cell viability decreases to 
50%, 51% and 46% using C18-RSN-211@13, C18-RSN-211@28 and C18-RSN-211@54 as nano-
carriers, respectively, while C18-RSN-211@98+anti-pAkt induces a lower cell survival rate to 31% 
(Figure 5.S8a). This difference is attributed to the combined effects of two factors: the cellular 
uptake efficiency and protein adsorption ability. As shown in Figure 5.S8b, averagely 127, 139, 121 
and 88 pg of silica from C18-RSN-211@13, C18-RSN-211@28, C18-RSN-211@54 and C18-RSN-
211@98 is taken up by each cell, respectively, because nanoparticles with larger sizes have lower 
cell penetration.
6-8
 This trend is opposite to the adsorption trend (Figure 5.3), where C18-RSN-
211@98 shows the highest adsorption ability to large protein (IgG-A). Consequently, the opposite 
trends of adsorption and cellular uptake lead to the highest cell growth inhibition of C18-RSN-
211@98+anti-pAkt.  
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Table 5.S1 Size and ζ potential characterizations of shell and core particles.  
 
 
 
 
 
 
 
 
 
 
a
Mean size±SD of shell/core particles by recording 50 data from TEM images. 
b
Number mean size 
±SD of shell/core particles by DLS method. 
c
Polydispersity index.  
Table 5.S2 Characterizations of RSNs with varied surface topography. 
Sample ID 
Size(nm) 
PDI
c
 
SBET 
(m
2
 g
-1
)
 d 
Interspace 
e 
(nm) TEM
a
 DLS
b
 
RSN-211@13 254±26 287±5 0.16±0.07 25.4 7±2 
RSN-211@28 270±15 371±13 0.23±0.05 26.9 14±4 
RSN-211@54 297±20 398±16 0.13±0 25.2 21±9 
RSN-211@98 380±39 480±13 0.22±0.04 22.4 38±22 
a 
Mean size±SD of RSNs by recording 50 data from TEM images. 
b
Number mean size ±SD of 
RSNs by DLS method. 
c
Polydispersity index of RSNs. 
d 
BET specific surface area of RSNs. 
e 
Mean 
interspacing distance ±SD of RSNs by recording 50 data from SEM images.  
Sample 
size (nm) 
PDI
c
 ζ-potential (mV) 
TEM
a
 DLS
b
 
Shells 
13±2 10±0.3 0.11±0.01 -42±2.4 
28±3 33±0.4 0.03±0.02 -42±8.3 
54±5 54±0.7 0.01±0.01 -53±2.6 
98±7 96±1.3 0.03±0.01 -53±1.0 
135±8 179±3.6 0.02±0.02 -33±1.9 
175±8 219±2.4 0.03±0.03 -32±0.9 
Core 211±11 241±1.4 0.01±0.01 +31±0.2 
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Table 5.S3 Estimation of protein coverage on RSNs/C18-RSNs 
Protein Sample ID Nmax
a
 Nads
b
 Coverage %
c
 
Cytochrome c 
RSN-211@13 3.59×10
18
 2.55×10
17
 7.11 
RSN-211@28 3.81×10
18
 3.65×10
17
 9.59 
RSN-211@54 3.56×10
18
 3.38×10
17
 9.49 
RSN-211@98 3.18×10
18
 1.77×10
17
 5.58 
IgG-F 
RSN-211@13 3.23×10
17
 2.94×10
17
 91.07 
RSN-211@28 3.43×10
17
 3.22×10
17
 94.02 
RSN-211@54 3.20×10
17
 3.92×10
17
 122.23 
RSN-211@98 2.86×10
17
 3.41×10
17
 117.65 
IgG-A 
RSN-211@13 8.08×10
16
 5.08×10
16
 62.90 
RSN-211@28 8.56×10
16
 6.88×10
16
 80.40 
RSN-211@54 8.02×10
16
 7.26×10
16
 90.59 
RSN-211@98 7.15×10
16
 9.07×10
16
 126.87 
C18-RSN-211@13 8.08×10
16
 1.44×10
17
 178.57 
C18-RSN-211@28 8.56×10
16
 1.97×10
17
 229.49 
C18-RSN-211@54 8.02×10
16
 2.22×10
17
 276.83 
C18-RSN-211@98 7.15×10
16
 2.41×10
17
 336.88 
 
a
Nmax represents the theoretical number of protein molecules that is assumed to fully cover the 
surface of 1 gram of RSNs in a single-layered fashion.  
     
      
      
         
     
  (1) 
b
Nads represents the actual number of protein molecules (calculated from adsorption amount, Wads) 
that associated on the surface of 1 gram of RSNs/C18-RSNs. NA stands for Avogadro constant, and 
MWprotein shows protein molecular weight. 
     
         
      
         
  (2) 
c
Coverage% represents the actual protein coverage percentages, compared to theoretical number of 
protein molecules where the surface is assumed to be fully covered in a single-layered manner. 
                       ⁄   (3) 
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Table 5.S4 SPR signal intensity. 
Sample ID without IgG-F(RU) with IgG-F(RU) 
RSN-211@13 -1.9 462.3 
RSN-211@28 -3.8 531.2 
RSN-211@54 -4 564 
RSN-211@98 -2.6 527.5 
PBS -0.4 -- 
Note: SRP signal intensity was determined at the peak point 128 seconds after sample injection 
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Chapter 6 
Understanding the Contribution of Surface 
Roughness and Hydrophobic Modification on 
Silica Nanoparticles for Enhanced Therapeutic 
Protein Delivery 
 
 
 
 
 
This chapter quantitatively demonstrates both the individual and combined contributions of surface 
roughness and hydrophobic modification for the improvement of protein therapeutics. Both surface 
roughening and hydrophobic modification enhance protein (RNase A) adsorption capacity, while 
the contribution from surface roughness is more dominant. Hydrophobic modification has a 
stronger effect to retard RNase A release. The contribution difference to enhance cellular uptake is 
cell type-dependent. Importantly, only hydrophobic modification facilitates endo/lysosomal escape. 
Collectively, octadecyl-functionalized rough silica nanoparticles (C18-RSNs) thus show the best 
performance in RNase A delivery, causing significant cell viability inhibition in both human breast 
cancer (MCF-7) and SCC-25 cell lines, compared to unmodified rough silica nanoparticle and 
smooth silica nanoparticles with (C18-SSN) or without (SSN) octadecyl-group modification. This 
work has been submitted for publication in Journal of Materials Chemistry B (2015, full 
paper). 
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6.1 Introduction  
Protein-based therapeutics has attracted increasing attention in the field of cancer therapy.
1
 
Compared to small molecule drugs, therapeutic proteins such as enzymes can manipulate 
key signalling pathways without influencing normal biological functions.
2
 However, cell 
membrane impermeability to protein molecules limits intracellular delivery of therapeutic 
proteins. To address this issue, various synthetic vectors have been developed to compact 
therapeutic proteins, for example, liposomes,
3, 4
 cationic polymers,
5
 micelles,
6
 dendrimers
7
 
and inorganic nanoparticles (e.g., silica nanoparticles
8, 9
 and gold nanoparticles
10
). Among 
these synthetic vectors, silica-based nanomaterials possess excellent biocompatibility, 
tuneable nanostructures and the ease of surface modification, making them attractive 
candidates for therapeutic protein delivery.
11
 Pristine mesoporous silica nanospheres were 
firstly used for intracellular delivery of cytochrome c into cervical cancer cells (HeLa),
12
 but 
the therapeutic efficacy was not demonstrated. 
To achieve successful intracellular delivery of proteins, it is crucial to use nano-carriers with 
high protein loading level, effective cellular uptake and sustained protein release in 
cytosols
13
 without proteolysis and degradation in endosome/lysozymes.
14, 15
 Bale and co-
workers
16
 illustrated that hydrophobically modified solid silica nanospheres can immobilize 
protein molecules on the surface and deliver them into cancer cells without extended 
entrapment in endosomes. However, extremely large amount of nanoparticles was required 
for significant cell growth inhibition, because solid particles have limited surface area for 
protein loading. Recently, Zhang and co-workers
17
 developed silica vesicles with hollow 
cavities to provide sufficient space for enhanced protein loading capacity. After octadecyl-
group (C18) attachment, C18-modified silica vesicles successfully delivered ribonuclease A 
(RNase A) to human squamous carcinoma cells (SCC-25), causing a significant cell growth 
inhibition. Roughening the surface of nanoparticles has been demonstrated as another 
approach to improve biomolecule loading capacity.
18
 More importantly, surface roughness 
was confirmed to enhance cellular uptake efficiency.
18, 19
 As two independent parameters of 
nano-carriers, unfortunately there is no report to compare the individual contribution of 
surface roughness and hydrophobic modification for protein delivery. A comparative study 
to understand their roles is of fundamental importance in the design of advanced nano-
carriers with enhanced delivery efficacy. 
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Herein, we report a systematic study on the contribution of surface roughness and 
hydrophobic modification on silica nanoparticles for therapeutic protein delivery. The 
influence of one individual parameter and their combination on protein loading capacity, 
release behavior, cellular uptake and endosome escape performance of silica nanoparticles 
have been demonstrated. Both surface roughening and hydrophobic modification enhance 
protein adsorption capacity, while the contribution from surface roughness is higher. For 
sustained protein release, hydrophobic modification has a higher impact compared to rough 
surface. Both surface roughness and hydrophobic modification improve cellular uptake 
performance; however the contribution difference is cell type-dependent. It is clear that the 
surface roughness has little contribution to endo/lysosomal escape. Only the surface 
chemistry, i.e., the hydrophobic modification, facilitates the release of nanoparticle/cargo 
molecules from endosome/lysosome entrapment. Collectively, octadecyl-functionalized 
rough silica nanoparticle (C18-RSN) shows the best performance in therapeutic protein 
(RNase A) delivery, causing significant cell viability inhibition in both human breast cancer 
(MCF-7) and SCC-25 cell lines among all groups under study. 
6.2 Experimental 
6.2.1 Materials and reagents 
For nanoparticle synthesis: ammonium hydroxide solution (28%), 3-aminopropyltriethoxy 
silane (APTES, 98%) and L-arginine (98%), octane (98%) were purchased from Sigma-
Aldrich. Tetraethyl orthosilicate (TEOS, 98%) and trimethoxy(octadecyl) silane (OTMS, 
90%) were purchased from Aldrich. Toluene was purchased from Merck. All chemicals 
were used without further purifications.  
For biology experiments: Dulbecco's Modified Eagle Medium (DMEM), Dulbecco's 
modified Eagle's medium and Ham's F12 medium (DMEM/F12), penicillin-streptomycin 
(10,000 U/mL) and trypsin-EDTA (0.25%) were purchased from GIBCO or Invitrogen, Life 
Sciences, Life Technologies. Fetal bovine serum (FBS) and trypan blue solution (0.4%) 
were purchased from Sigma-Aldrich. Ribonuclease A (RNase A) from bovine pancreas was 
purchased from ROCHE (Germany). Adenocarcinoma cell line MCF-7 (HTB-22™)  nd 
human squamous cell carcinoma cell line SCC-25 (ATCC® CRL-1628™) w r  pur   s d 
from ATCC (American Type Culture Collection). MCF-7 cells were maintained as 
monolayer cultures in DMEM, supplemented with 10% FBS, 1% penicillin-streptomycin at 
37 °C and 5% CO2. SCC-25 cells were maintained as monolayer cultures in DMEM/F12, 
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supplemented with 10% FBS, 1% penicillin-streptomycin, 0.5 mM sodium pyruvate and 
400ng/mL hydrocortisone at 37 C and 5% CO2. 
6.2.2 Synthesis of nanoparticles 
Synthesis of smooth silica nanoparticles (SSN): Un  orm sol d s l    p rt  l  w t  t   s z  
o    232 nm w s synt  s z d us n  St   r m t od.20 Typically, 3.8 mL of deionized (DI) 
water and 2 mL of ammonium hydroxide solution were added into 50 mL of absolute 
ethanol, and the reaction was carried out for 6 hours after adding 3 mL of TEOS at room 
temperature under vigorous stirring. Nanoparticles were collected by centrifugation, 
washing and drying. Then calcination treatment at 550 °C was conducted to remove organic 
components.  
Amine-group modification: Uncalcined SSN was functionalized with amine-silane and used 
as positively charged core particle. Dried samples (200 mg) were re-suspended in 30 mL of 
toluene with 1% (v/v) APTES. The mixture was refluxed for 2 h at 110 °C. Then, the amino-
modified nanoparticle was obtained by centrifugation, washing and drying at room 
temperature overnight, and it will be used as core particles. 
Synthesis of shell particle: Shell nanoparticle with the size of 20 nm was also fabricated 
using the Stöber method. The reaction components were the same as that for SSN, but the 
reaction temperature was increased to 70 °C.  
Synthesis of RSN: After reacting for 20 min of the shell particle above, core particle (200 
mg) suspension in 2 mL of ethanol was added into the shell reaction solution at 70 °C. Then, 
RSN was collected 2 h later by washing with ethanol and drying at room temperature 
overnight, followed by calcination treatment at 550 °C for 5 h to remove organic 
components in silica framework.  
Hydrophobic (octadecyl-group) modification: SSN and RSN were functionalized to have 
hydrophobic feature. Nanoparticles (200 mg) were re-suspended in 30 mL of toluene 
containing 0.5% (v/v) OTMS. Then, C18-SSN and C18-RSN were obtained after refluxing 
at 110 C for 20 h, followed by washing and drying at room temperature overnight. 
6.2.3 Characterizations 
Hydrodynamic size and z t  (ζ)-potential (ZP) measurements: Dynamic light scattering 
(DLS) size and ZP values were collected at 25 °C using a Zetasizer Nano-ZS from Malvern 
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Instruments. The nanoparticles were suspended in DI water or phosphate buffered saline 
(PBS, pH 7.4) by ultra-sonication.  
Transmission electron microscopy (TEM) and high resolution scanning electron microscopy 
(HRSEM): TEM images were taken using a JEOL 1010 microscope operated at 100 kV for 
observing nanoparticles, which were dispersed in ethanol and then transferred to a copper 
grid. HRSEM images were obtained on a JEOL JSM 7800 FE-SEM operated at a low 
accelerating voltage of 0.8-1.5 kV with 20% specimen bias.
21
 The microscope was equipped 
with an in-column upper electron detector (UED) and gentle beam technology. SEM 
samples were prepared by dropping nanoparticle suspensions onto the aluminum foil pieces, 
which attach to conductive carbon film on SEM mounts, followed by baking in vacuum at 
70 °C for overnight.  
Surface area test: Brunauer–Emmett–Teller (BET) specific surface area of nanoparticles 
were collected from nitrogen sorption isotherms, carried out at -196 °C using a 
Micromeritics Tristar II system. Before the measurements, the samples were degassed at 180 
°C for at least 6h in vacuum. BET specific surface area was calculated from experimental 
points at a relative pressure of P/P0 = 0.05- 0.25.  
Fourier transform infrared (FTIR) measurements: FTIR spectra of OTMS, RNase A and 
different nanoparticles before and after RNase A adsorption were collected using the 
T  rmo S   nt    ™ N  ol t™ 6700 FT-IR spectrometers.  
C18-modification determination: Elemental analysis was carried out on a CHNS-O Analyzer 
(Flash EA1112 Series, Thermo Electron Corporation) to determine the weight percentages 
of carbon (C) element. Different nanoparticles of 10-20 mg were required for the test. 
Cystine with 29.99% the element of carbon was used as the standard control. 
Atomic force microscopy (AFM) measurements: RSN and C18-RSN were dispersed in DI 
water, and then the suspensions (10 µl) were placed onto silicon wafers, evaporating at room 
temperature. For the preparation of C18-RSN+RNase A, C18-RSN was first mixed with 
RNase A, at nanoparticle concentration of 10mg/ml and RNase A concentration of 1mg/ml. 
After that, the complex was washed with DI water to remove salts by centrifugation and 
pipetting, followed by mounting on silicon wafer. AFM measurements of RSN, C18-RSN 
and C18-RSN+RNase A were processed using the instrument of Cypher S AFM (Asylum 
Research, an Oxford Instruments company). AFM images were obtained at the tapping 
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mode of AFM in air using Al-coated silicon probe with tip radius of 2 nm 
(NANOSENSORS™, Switzerland). 
Stability test of silica nanoparticles: Different nanoparticles were dispersed in PBS pH 7.4 at 
the concentration of 1mg/ml, shaking at room temperature for 72h. The suspension (3ml) 
was picked up every 24 h and then centrifuged at 20000 rpm for 10 minutes. Silica 
concentration of different nanoparticles in supernatant was tested by inductively coupled 
plasma optical emission spectrometry (ICPOES) using a Vista-PRO instrument (Varian Inc, 
Australia). After 72 h, TEM images of different nanoparticles were taken using a JEOL 
1010 microscope operated at 100 kV. 
6.2.4 Biological experiments 
Loading and Release Profile of RNase A by nanoparticles  
Different nanoparticles were mixed with RNase A in PBS for 2 h at room temperature. Final 
nanoparticle concentration is 10 mg/ml and RNase A concentration is 1 mg/ml. After this 
time, the mixtures were centrifuged, and protein adsorption amount was determined using a 
NANODROP 1000 spectrophotometer (Thermo Scientific) at 278 nm, based on the original 
and residual RNase A concentrations and volumes. ANOVA analysis is processed. The 
precipitates (RNase A loaded nanoparticles) were re-suspended in PBS or acetic buffer (pH 
4.5) for protein release, shaking at 1000 rpm at 25 °C using an eppendorf MixMate (Thermo 
Fisher Schentific). Certain volume of the mixtures was picked up at different time points and 
the same volume of solvent was refilled until 72 h. In addition, RNase A release was also 
investigate in DMEM, under static condition at 37 °C for 4h. The released RNase A content 
was stained with BCA reagents (Thermal Scientific, Life Sciences, Life Technologies) and 
the absorbance was collected at 562 nm using a Synergy HT Microplate Reader. 
Detection of cellular uptake performance  
To quantitatively compare the cellular uptake of different nanoparticles, 3×10
5
 MCF-7 and 
SCC-25 cells were seeded in 6-well plates. RNase A was incubated with nanoparticles for 
protein adsorption for 2h, and then the complexes were incubated with cells in serum free 
medium for 4h. RNas  A  on  ntr t on  s 2 μ /mL, and nanoparticle concentration is 50 
μ /mL for each sample. Afterwards, cells were harvested by the digestion of trypsin/EDTA 
mixture, and cell number for each sample was recorded. After centrifugation, cell pellets 
were washed twice followed by supersonic schizolysis in DI water. Supernatants (containing 
cell components) were removed, and aqueous NaOH solution (1 M) was used to allow the 
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dissolution of silica components with ultrasound. The silicon concentrations were detected 
by inductively coupled plasma optical emission spectrometry (ICPOES) using a Vista-PRO 
instrument (Varian Inc, Australia), and the mass of silica per cell was then calculated. 
ANOVA analysis is processed. 
Toxicity assay  
Both MCF-7 and SCC-25 cells were seeded in 24-well plates at a density of 3×10
4
 cells per 
well and incubated for 24 h. To evaluate the cytotoxicity of different pure nanoparticles, 
they were made in a 2-fold serial dilution in culture medium, and incubated for 24 h, 48 h 
and 72 h. For the measurements of cell growth inhibition caused by RNase A, protein was 
first mixed with SSN, C18-SSN and C18-RSN in PBS for 2 h at 4 °C to achieve a saturated 
adsorption. Then the complexes were suspended in serum containing culture medium. The 
final RNase A  on  ntr t on  s 2 μ /mL,  nd n nop rt  l   on  ntr t on  s 50 μ /mL.  After 
24, 48h and 72 h, culture medium from each sample was collected, and cells were harvested 
by incubating with trypsin/EDTA mixture. Detached cells were then re-suspended in the 
medium previously collected from the samples. Dead cells were marked with trypan blue 
reagent in a 1:1 ratio, and cell viability was recorded by counting live and dead cells.  
TEM study on nanoparticle-cell interaction 
MCF-7 cells were seeded in 3-cm petri-dishes at a cell number of 3×10
5
 for 24 h, and they 
were incubated with a suspension of nanoparticle (SSN, RSN, C18-SSN and C18-RSN) at 
t    on  ntr t on o  50 μ /mL for another 24 hours. Then cells were first fixed with 2.5% 
glutaraldehyde at room temperature for 30min, and post-fixed in 1% osmium tetraoxide in 
microwave condition. After that, cells were embedded into 2% agarose gel cube, followed 
by dehydration in acetone of increasing concentration (50%, 70%, 90%, 100% and 100%) in 
microwave condition. The dehydrated cell cubes were embedded in Epon resin, and 
solidified in 60°C for 2 days. Microtome (Leica, EM UC6) was then used to cut the 
embedded cell-resin cube into ultra-thin slices (70–90 nm in thickness). Samples were 
mounted on form-bar coated copper grids and double stained with 2% aqueous uranyl 
acetate and commercial lead citrate aqueous solution. TEM images were taken using a JEOL 
1010 microscope operated at 80 kV. 
6.3 Results and discussion 
Preparation of nanoparticles  
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RSN (ZP -22±0.7 mV) with a core-shell structure was fabricated according to the reported method 
with minor modification.
18
 A typical TEM image of RSN is shown in Figure 6.1a. The average 
particle size is measured to be 296±10.0 nm. C18-modified silica nanospheres have been 
demonstrated to successfully deliver therapeutic proteins into cancer cells.
15
 Therefore, C18-RSN 
(299±14.6 nm, Figure 6.1b, ZP -22±0.6 mV) was synthesized by refluxing RSN and 
trimethoxy(octadecyl) silane (OTMS) in toluene. HRSEM image (Figure 6.1c) clearly shows that 
the core particles are uniformly attached by shell particles. The mean void size between neighboring 
shell particles is 14.9±3.6 nm. For control groups, smooth silica nanoparticles (SSN) without 
surface roughening (240±9.3 nm, Figure 6.1d, ZP -34±0.4 mV) and C18-SSN (240±17.5 nm, Figure 
6.1e, ZP -33±0.5 mV) were also synthesized. FTIR spectra confirm successful C18-modification of 
C18-RSN and C18-SSN (Figure 6.S2a&b). AFM images indicate that the surface topography of 
RSN (Figure 6.S3a) is not influenced after hydrophobic modification (C18-RSN, Figure 6.S3c). 
The void height of C18-RSN (16.7±3.6 nm, Figure 6.S3d) remains similar to that of RSN (16.7±3.3 
nm, Figure 6.S3b). 
 
Figure 6.1 TEM (a, b, d, e) and HRSEM (c) images and particle size distribution curves (f) 
of RSN (a&f-i), C18-RSN (b, c&f-ii), SSN (d&f-iii), C18-SSN (e&f-iv). Scale bar: 100 nm. 
DLS method was further utilized to characterize particle size and dispersity in both DI water 
and biological media. As shown in Figure 6.1f and Table 6.S1, the intensity mean size of 
SSN, RSN, C18-SSN and C18-RSN in DI water is 324 nm (PDI: 0.30), 630 nm (PDI: 0.23), 
277 nm (PDI: 0.03) and 499 nm (PDI: 0.16), respectively, indicating that all nanoparticles 
have good dispersibility, while hydrophobically modified ones are more uniform in size. In 
PBS, the intensity mean sizes of four samples increase (391 nm for SSN, 512 nm for RSN, 
599 nm for C18-SSN, and 683 nm for C18-RSN), and PDI values grow to 0.3-0.4, 
suggesting that silica nanoparticles tend to aggregate in some extent (Table 6.S2, Figure 
Chapter 6 Understanding the Contribution of Surface Roughness and Hydrophobic Modification on 
Silica Nanoparticles for Enhanced Therapeutic Protein Delivery 
122 
 
6.S4), due to the decrease of electrical double layer thickness under the condition of high 
ionic strength.
22
  
Nitrogen sorption analysis was used to measure BET specific surface area (SBET) of SSN, 
RSN, C18-SSN and C18-RSN, which is 13.0, 26.5, 11.6 and 21.8 m
2
/g, respectively (Table 
6.1). The shell particles with a smaller size on the core particle surface provide higher SBET 
to RSN compared to SSN. The slight decrease in surface area after hydrophobic 
modification can be attributed to the grafted layer of silica-octadecyl-groups.
17
 All 
nanoparticles showed excellent stability in physiological solution of PBS after shaking for 
three days (Figure 6.S5). 
RNase A (13.7 kD) with hydrophobic nature and dimensions of 2.2 nm × 2.8 nm × 3.8 nm 
was chosen as a model of therapeutic protein.
23
 The isoelectric point of RNase A is 9.3, so 
that it can be directly immobilized onto negatively charged silica nanoparticles at pH 7.4 in 
PBS.
24
 FTIR data (Figure 6.S2c&d) demonstrate the successful immobilization of RNase A 
molecules on four different silica nanoparticles. As shown in Figure 6.2a, both RSN (16.4 
µg/mg) and C18-SSN (9.4 µg/mg) have higher RNase A adsorption capacity compared to 
SSN (7.3 µg/mg). The increment of RSN over SSN is much higher than that of C18-SSN 
(225% vs 129%), suggesting surface roughness is more effective in the improvement of 
RNase A loading than hydrophobic modification. By the combination of surface roughness 
and hydrophobic modification, C18-RSN shows the highest adsorption capacity of RNase A 
(20.7 µg/mg) among the four samples. A decrease in void height from 16.7±3.6 nm (Figure 
6.S3c&d) to 14.8±5.3 nm (Figure 6.S3e&f) is detected after RNase A loading under AFM 
characterization, suggesting that protein molecules are entrapped and accumulated into the 
voids on C18-RSN. 
Compared to SSN, the surface area of RSN increased to 204% (p<0.05), which is slightly 
lower than the increase of RNase A adsorption (to 225%, see also Table 6.1). RNase A 
adsorption capacity per unit surface area (RNase A adsorption density, mg/m
2
) is calculated 
(Table 6.S3), dividing the adsorption capacity by SBET. It can be seen that the rough surface 
also enhances protein adsorption density (to 109%), which can be explained by regional 
protein aggregation in void spaces of rough surface.
25
 Therefore, the improvement of RNase 
A adsorption caused by surface roughness is resulted from the increase of both surface area 
and in-void protein adsorption. 
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Figure 6.2 (a) RNase A adsorption and (b) release profiles of SSN, RSN, C18-SSN and C18-RSN. 
Data represent mean ± SD. 
Hydrophobic modification improves protein adsorption by the dehydration around C18-
groups, resulting in the reduction of Gibbs energy and the enhancement of spontaneous 
RNase A adsorption.
24, 26
 C18-RSN with 82% surface areas of RSN promotes stronger 
RNase A adsorption to 126% (p<0.05). This enhancement is consistent with that of smooth 
nanoparticles, where C18-SSN having 89% surface areas of SSN enables RNase A 
adsorption to 129% (p<0.05). Therefore, the improvement of RNase A adsorption caused by 
hydrophobic modification is limited compared to the role of surface roughness. 
It should be noted that C18-RSN increases RNase A loading amount to 220% (p<0.05) and 
284% (p<0.05), compared to C18-SSN and SSN, highly beyond their corresponding surface 
area enlargement of 188% and 168%, respectively. This can be explained by the 
significantly increased RNase A adsorption density of 117% and 170%, due to the densified 
C18-groups on C18-RSN surface (2.42 µmol/m
2
), compared to C18-SSN (1.61 µmol/m
2
, 
Table 6.S3), respectively, implying stronger interaction with RNase A molecules. 
Noticeably, although stronger negative charges on C18-SSN and SSN (Table 6.S1) are 
beneficial for RNase A adsorption, C18-SSN and SSN show much lower loading capacity 
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compared to C18-RSN and RSN. It can be concluded that surface roughness and 
hydrophobic modification play dominant roles in the enhancement of RNase A adsorption 
(Table 6.1).  
Both high loading capacity and sustained release are crucial for intracellular delivery of 
therapeutic proteins,
27
 therefore we further investigated the roles of surface roughness and 
C18-modification in the release profile of protein molecules. As shown in Figure 6.2b, SSN 
has a burst release of 82% of the loaded RNase A within 1 hour (h) in PBS at 25 °C. In 
comparison, C18-SSN and RSN shows a relatively slow release with a percentage of 52% & 
64% at 1 h, respectively, suggesting that hydrophobic modification is more effective in 
retarding protein release, because of strong hydrophobic interaction between RNase A and 
C18-SSN (Table 6.1). Nevertheless, up to 90% of the loaded proteins release from both RSN 
and C18-SSN at 6 h, and the protein release reaches to plateau (up to 95% of total loaded 
RNase A) at 24 h. However, C18-RSN only exhibits a release percentage of 71% at 6 h and 
89% at 24 h (Table 6.1). At 48-72 h, it reaches to the release plateau (of 94%). The sustained 
release profile of C18-RSN could be explained by the combination of both surface 
roughness and the hydrophobic surface with densified C18-groups compared to C18-SSN. 
RNase A release profiles from four samples were also evaluated in acidic buffer (pH 4.5), 
mimicking the cancer cell compartments (endosome/lysosome),
14
 and in DMEM at 37 °C 
under static condition for 4 h, imitating cell uptake process in the following experiments. A 
slower release can be seen in both acidic buffer (Figure 6.S6a, 36%, 34%, 22% and 18% for 
SSN, RSN, C18-SSN and C18-RSN at 72 h, respectively) and DMEM medium (Figure 
6.S6b, 50%, 27%, 20% and 10% for SSN, RSN, C18-SSN and C18-RSN, respectively), 
compared to those values in PBS solution with pH 7.4 (Figure 6.2b). The most sustained 
release of RNase A is observed in the sample of C18-RSN (Figure 6.S6a). When solution 
pH value decreases from 7.4 to 4.5, RNase A tends to have more positive charges, enabling 
improved electrostatic interaction with negatively charged silica nanoparticles and 
subsequent retarded release. Static condition in DMEM medium (Figure 6.S6b) is also 
beneficial for retarded release, compared with shaking process in PBS solution. These data 
suggest C18-RSN is effective to deliver protein molecules into cytosols, avoiding premature 
release in cancer cell compartments. 
Efficient cellular uptake is another important property for successful protein delivery. We 
studied the roles of surface roughness and C18-modification on cellular uptake performance 
of the complexes of RNase A and silica nanoparticles in MCF-7 and SCC-25 cells, 
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measured by ICPOES. In both cell lines (Figure 6.3), RSN/ RNase A and C18-SSN/ RNase 
A show a higher cellular uptake performance than SSN/ RNase A, suggesting that both 
surface roughness and hydrophobic modification could enhance cellular uptake, 
independently. Noticeably, in MCF-7 cells, RSN/RNase A (10.8 pg silica/cell) shows better 
performance than C18-SSN/RNase A (8.2 pg silica/cell). However, this difference trend is 
reversed and C18-SSN/ RNase A (9.0 pg silica/cell) is taken up more than RSN/ RNase A 
(7.6 pg silica/cell) in SCC-25 cells. Therefore, the influence of surface roughness and 
hydrophobic modification on cellular uptake performance is cell type-dependent. In 
addition, C18-RSN/RNase A exhibits the best cellular uptake performance of 14.8 pg 
silica/cell in MCF-7 and 10.4 pg silica/cell in SCC-25, which is almost 3 (p<0.05) and 2 
(p<0.05) times of SSN/RNase A (5.5 and 5.6 pg silica/cell), respectively. These significant 
improvements of C18-RSN in cellular uptake are also attributed to the contribution of both 
surface roughness and hydrophobic modification. 
 
Figure 6.3 Cellular uptake performance of RNase A loaded nanoparticles in (a) MCF-7 and 
(b) SCC-25 cells, measured by ICPOES. Cells only were used as a control group. Data 
represent mean ± SD. 
The endocytic pathway is the major cell uptake mechanism of silica nanoparticles with the 
sizes from several nanometers to hundreds of nanometers.
28
 After taken up by cells, the 
internalized protein-nanoparticle complexes tend to be entrapped in endosome/lysosomes, 
followed by protein degradation by enzymes.
14, 29
  Therefore, it is very important to facilitate 
efficient endo/lysosomal escape (EE/LE) to ensure cytosolic delivery of the therapeutics. 
The EE/LE performance of SSN, RSN, C18-SSN and C18-RSN was evaluated by TEM 
(Figure 6.4), which show nanoparticle distributions on outer surface of cell membranes 
(CM, white arrows), in cytoplasm (C), electron-lucent endosomes (E) or electron-dense 
lysosomes (L) of MCF-7 cells after 24 h incubation with nanoparticles. Both SSN (Figure 
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6.4a) and RSN (Figure 6.4b) are generally localized in endosome/lysosomes (black arrow), 
indicating inefficient EE/LE. On the contrary, the majority of C18-SSNs (Figure 6.4c) and 
C18-RSNs (Figure 6.4c) are found distributed in cytoplasm (black dash arrow). The 
disrupted membranes of endosome/lysosomes (Figure 6.4c &d, black arrowhead) indicate 
successful release of the enclosed C18-SSNs and C18-RSNs into cytosols, with the help of 
hydrophobic modification.
16
 Therefore, hydrophobic modification plays the dominant role in 
EE/LE. 
 
Figure 6.4 Typical TEM images of ultra-thin sections of MCF-7 cells incubated with (a) 
SSN, (b) RSN, (c) C18-SSN and (d) C18-RSN for 24 h. White arrow indicates cell 
membrane (CM), black arrow indicates nanoparticles entrapped in endosome (E) or 
lysosome (L), black arrowhead shows locally disrupted membrane of endosomes, black dash 
arrow indicates nanoparticles distributed in cytoplasm (C). "N" refers to nucleus. Scale bar: 
100 nm. 
The contribution of surface roughness, hydrophobic modification and their combination on 
protein loading capacity, sustained release, cellular uptake and endosome escape 
performance is summarized in Table 6.1. Both surface roughness and hydrophobic 
modification can enhance RNase A adsorption compared to the smooth particle, while the 
contribution from surface roughness is more important. The combination of surface 
roughening and hydrophobic modification (C18-RSN) thus significantly increase the RNase 
A loading capacity compared to SSN (20.7 vs 7.3 mg/g). In terms of protein release, the 
hydrophobic modification is more effective compared to rough surface. It is clear only 
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hydrophobic modification can induce effective endo/lysosomal escape, independent of 
smooth or rough silica surface. Moreover, different cell types have varied sensitivity to 
surface roughness and hydrophobic modification for cellular uptake performance. MCF-7 
cells internalized higher amount of the nanoparticles with a rough surface, while more 
hydrophobically modified nanoparticles have been taken up into SCC-25 cells. However, it 
is evident both functionalization increases the cellular uptake of silica nanoparticles 
although their individual contribution is cell type-dependent. Collectively, silica 
nanoparticles with both rough surface and hydrophobic modification are desired nano-
carriers for the cellular delivery of proteins.  
Table 6.1 Summary of the contribution of surface roughness and hydrophobic modification 
 SBET
a 
(m
2
/g) 
Ads
b 
(µg/mg) 
Des
c
(%) CU (pg /cell)
 d
 
e
EE/ 
LE 
 1h 24h MCF-7 SCC-25 
SSN 13.0 7.3 82 97 5.5±0.5 5.6±0.6 - 
RSN 26.5 16.4 64 95 10.8±0.2 7.6±1.9 - 
C18-SSN 11.6 9.4 52 93 8.2±0.7 9.0±0.2 + 
C18-RSN 21.8 20.7 36 89 14.8±2.1 10.4±0.4 + 
Note: a: surface area; b: adsorption capacity of RNase A; c: RNase A desorption percentage; 
d: cellular uptake of silica amount per cell; e: qualitative endo/lysosomal escape (EE/LE) 
performance, where "-" represents inefficient escape, "+" represents efficient escape. 
It has been reported the delivery of RNase A into cytosols will degrade mRNA and tRNA 
and inhibit protein synthesis, thus strongly influence cell functions and cause deleterious 
effects on cell viability.
4
 Therefore, we evaluated the cytotoxicity of RNase A delivered by 
different silica nanoparticles to MCF-7 and SCC-25 cells. C18-SSN and C18-RSN were 
mixed with excessive RNase A to achieve saturated adsorption for intracellular delivery, and 
SSN was used as a control group. The total protein concentration in each well is 2 µg/mL 
and the nanoparticle concentration is 50 µg/mL, which is much lower than that in the 
literature report (800 µg/mL).
16
 The toxicity of SSN, C18-SSN and C18-RSN is mild to 
either MCF-7 or SCC-25 cells at a concentration of 50 µg/mL (Figure 6.S7). As shown in 
Figure 6.5, free RNase A cannot significantly impact cell viability in both cell lines at all-
time points of 24, 48, 72 h, because naked protein cannot enter cells. As expected, C18-
SSN/ RNase A and C18-RSN/ RNase A exhibit evident reduction of cell survival rate in a 
time-dependent manner. C18-RSN/ RNase A inhibits the viability of MCF-7 and SCC-25 
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cells from 76%/69% at 24 h to 44%/50% at 48 h and finally to 25%/24% at 72 h, 
respectively. This effect is stronger than C18-SSN/ RNase A (from 85%/92% at 24 h to 
67%/75% at 48 h and finally to 45%/53% at 72 h). In contrast, SSN/RNase A causes little 
inhibition to cell viability in both MCF-7 (75%) and SCC-25 (79%) cells even after 72 h 
incubation, because pure silica nanospheres (SSN and RSN) cannot achieve effective 
endo/lysosomal escape
30
 as demonstrated in Figure 6.4. 
 
Figure 6.5 Cell viability of (a) MCF-7 and (b) SCC-25 cells treated with RNase A at a dosage of 2 
μ /mL after 24, 48, and 72 h incubation. Data represent mean ± SD. 
6.4 Conclusion 
In summary, we have systematically studied the contribution of surface roughness and 
hydrophobic modification on silica nanoparticles for protein (RNase A) delivery in different 
aspects of protein loading capacity, release behavior, cellular update and endosome escape 
performance. Both surface roughness and hydrophobic modification demonstrate improved 
RNase A adsorption, sustained release and cellular uptake performance. However, surface 
roughness plays more important role in RNase A adsorption enhancement and hydrophobic 
modification has stronger influence on sustained release. The contribution difference of two 
structural parameters in enhanced cell uptake efficiency is cell-type dependent. Only 
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hydrophobic modification demonstrates contribution to endo/lysosomal escape. Therefore, 
the combination of surface roughening and hydrophobic modification demonstrates 
enhanced therapeutic RNase A delivery, leading to significant cell growth inhibition in 
cancer cells of MCF-7 and SCC-25. Our work provides understanding of the importance of 
surface roughness and modification in the design of promising nano-carriers with enhanced 
delivery efficacy.  
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Supplementary Figures and Tables 
 
 
Figure 6.S1 TEM images (a) OH-core particle, (b) NH2-core particle and (c) shell particle. Scale 
bar: 100 nm. (f) Particle size distribution curves measured by DLS.   
 
Figure 6.S2 Fourier transform infrared (FTIR) spectra of (a) pure liquid OTMS, (b) bare 
nanoparticles, (c) RNase A and (d) nanoparticles complexed with RNase A.  
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The nanoparticles with and without modification of octadecyl group was characterized by FTIR 
technique. Figure S2a shows the FTIR spectrum of pure liquid OTMS, in which the characteristic 
peaks at 809, 1085, 1190, 1465, 2856 and 2926 cm
-1
   n     ttr  ut d to ν(S -O), ν(C-O)+ ν(C-C), 
ρ(CH3), δ(C-H) 
1 and symmetric and anti-symmetric -CH2- stretching,
2, 3 respectively. The spectra 
of SSN (Figure S2b i), C18-SSN (Figure S2b ii), RSN (Figure S2b iii) and C18-RSN (Figure S2b 
iv) show the same characteristic bands at 804 cm
-1
 and broad band peaked at 1050 cm
-1
, which 
indicate -Si-O-Si- bonding.4 In the spectra of hydrophobic modified silica nanoparticles (Figure S2b 
ii & iv), besides the characteristic peaks of silica, two extra peaks at 2858 and 2929 cm
-1
 can be 
observed, which are assigned to symmetric and anti-symmetric -CH2- stretching, respectively, 
indicating the successful attachment of octadecyl-groups.5 
Figure S2c exhibits the FTIR spectrum of RNase A. The characteristic amide I band centered at 
1635 cm-1 is mainly attributed to C꞊O str t   n  v  r t on and the amide II band centered at 1515 
cm
-1
 can be assigned to in-plane N-H bending and C-N stretching.
6, 7
 After RNase A adsorption 
onto silica nanoparticles, the two characteristic peaks of RNase A at 1635 and 1515 cm
-1
 can be 
clearly observed (Figure S2d). SSN (Figure S2d i) and RSN (Figure S2d iii) also show 
characteristic peaks of silica, while C18-SSN (Figure S2d ii) and C18-RSN (Figure S2d iv) show 
additional characteristic peaks of silica and octadecyl-groups. These results suggest RNase A 
molecules have been successfully loaded onto the four samples.  
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Figure 6.S3 (a, c, e) AFM images and (b, d, f) void height profiles of (  &  ) RSN, (  & d) C18-
RSN  nd (  &  ) C18-RSN + RN s  A, generated by drawing a typical cross-sectional line on the 
top region, Scale bar: 100 nm. The average height values are measured and calculated by recording 
20 data. Data represent mean ± SD. 
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Figure 6.S4 Particle size distribution curves of (a) SSN, (b) C18-SSN, (c) RSN and (d) C18-RSN.  
 
Figure 6.S5 Silica dissolution of different nanoparticles, tested by (a) ICPOES and TEM images of 
(b) SSN, (c) C18-SSN, (d) RSN and (e) C18-RSN, after shaking in PBS for 3 days. Scale bar: 100 
nm. 
SSN, RSN, C18-SSN and C18-RSN show good stability in PBS with silica dissolution percentages 
less than 10% after 3 days (Figure S5a). Slight increases in the silica dissolution percentage are 
observed in four samples as shaking time increases. After 3 days, RSN and C18-RSN exhibit 
relatively higher silica dissolution percentages (7.6% and 4.1%), compared to SSN and C18-SSN 
(6.4% and 3.1%), respectively. This can be explained by the larger surface area of rough 
nanoparticles, which facilitates quicker interaction with medium and subsequent silica dissolution. 
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In addition, the hydrophobic layer has an obvious protection effect to reduce silica dissolution. The 
stability of nanoparticles was further confirmed by TEM images, where the surface morphologies of 
both smooth (Figure S5b&c) and rough nanoparticles (Figure S5d&e) were not significantly 
affected after shaking in PBS for 3 days.  
 
Figure 6.S6 RNase A release profiles of SSN, RSN, C18-SSN and C18-RSN at (a) acidic condition 
(pH 4.5) and (b) in DMEM under static condition at 37 °C for 4 h. Data represent mean±SD. 
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Figure 6.S7 The evaluation of toxicity from pure nanoparticles (a,c,e) in MCF-7 cells and (b,d,f) in 
SCC-25 cells, at 24 h, 48 h and 72 h, respectively. Data represent mean ± SD. 
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Table 6.S1 S z   nd ζ pot nt  l    r  t r z t ons o  n nop rt  l s. 
Sample ID 
Size 
PDI
c
 ζ-potential 
TEM
a
 DLS
b
 
Shell particle 20±2.4 34±0.6 0.07±0.01 -42±8.3 
OH-core particle 232±9.6 281±10.4 0.13±0.03 -24±1.3 
NH2-core particle 235±10.9 328±11.5 0.24±0.09 +38±0.9 
SSN 240±9.3 324±10.3 0.30±0.07 -34±0.4 
C18-SSN 240±17.5 277±7.0 0.03±0.03 -33±0.5 
RSN 296±10.0 630±44.3 0.23±0.01 -22±0.7 
C18-RSN 299±14.6 499±42.6 0.16±0.01 -22±0.6 
a
Mean size±SD of shell/core particles by recording 50 data from TEM images. 
b
Intensity mean size 
±SD of shell/core particles by DLS method. 
c
Polydispersity index. 
 
Table 6.S2 DLS size measurements in PBS. 
Sample ID Size
a
 PDI
b
 
SSN 391±68.1 0.40±0.05 
C18-SSN 599±111.3 0.31±0.01 
RSN 512±158.2 0.43±0.01 
C18-RSN 683±12.9 0.30±0.01 
a
Intensity mean size ±SD of shell/core particles by DLS method. 
b
Polydispersity index. 
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Table 6.S3 RNase A adsorption density and C18-modification characterization of nanoparticles 
 
 
 
 
 
 
 
a
RNase A adsorption density 
b
Carbon percentage tested by Elemental Analysis. 
c
Octadecyl-group (C18) -group density: C18-group amount per unit surface area. The molecular 
weight of C18 (MWC18) is 236g/mol. SSN  nd RSN w r  us d  s  ontrol  roup. 
C 8 density  
          
          
   (1) 
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S mpl  ID 
DRNase A
a  
(m /m2) 
C r on (%)  
DC18
   
(µmol/m2) 
SSN 0.56 0.011 -- 
C18-SSN 0.81 0.453 1.61 
RSN 0.61 0.025 -- 
C18-RSN 0.95 1.274 2.42 
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Chapter 7  
Conclusions and outlook 
7.1 Conclusions 
The understanding of structure–function relationship of natural particulates provides a useful guide 
for the design of new nanocarriers. Currently, many research attempts have focused on the synthesis 
of new drug delivery systems by mimicking the advantages of natural particulates, for example, 
enveloped viruses, which have evolved sophisticated mechanisms that make use of or shield off 
cellular signalling and transport pathways to traffic within host cells and deliver cargos into the 
appropriate subcellular compartment.
1
 In this thesis, virus-mimicking silica nanoparticles with well-
controlled surface roughness have been synthesized. The understanding of the structure-function 
relationship for the significantly enhanced intracellular cargo delivery, including genetic molecules 
and therapeutic proteins, has been revealed. In addition, the mechanism for the synthesis of stable 
core-shell structure has been investigated, providing guidelines for the design of effective non-viral 
carriers. The following conclusions can be drawn based on the studies in this thesis.   
1. A virus-mimicking silica nanoparticle (VMSN) for enhanced gene delivery has been developed. 
It possesses a core-shell structure, where small shell particles (~13 nm) were studded onto large 
core particles (~211 nm), forming a rough morphology. The increase in nanoscale surface 
roughness can promote adsorption, while reducing the leakage of genetic molecules, including cy3-
oligoDNAs and siRNAs. Cellular uptake of VMSN was also improved, thus cargo delivery 
performance was significantly enhanced. Importantly, the advantages from nanoscale surface 
roughness were confirmed generalizable, regardless of surface functionality (amine-groups or PEI-
modification) and cell types (HeLa or KHOS cells). Moreover, using VMSN as the nanocarrier to 
deliver PLK1-siRNA into KHOS cells, cell growth inhibition by knocking down PLK1 gene was 
significantly enhanced, compared to smooth nanoparticles and a commercial transfection reagent 
(Oligofectamine
TM
). (Relevant content: Chapter 4) 
2. Following the intracellular delivery of genetic molecules, in Chapter 5, therapeutic protein 
delivery performance using rough silica nanoparticles (RSNs) as the nanocarriers, with 
systematically controlled surface morphologies, have been investigated. RSNs with a fixed core 
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particle of ~211 nm and different shell particles, from ~13 nm to ~98 nm, were fabricated by the 
"neck-enhancing" approach, and the surface roughness was correlated to the core-to-shell size ratios 
from 16.2:1 to 2.2:1. In comparison to the method detailed in Chapter 4 and other reported methods, 
rough morphologies of different RSNs can be stably maintained by a bigger "neck" between shell 
and core particles, which extended the synthesis limitation of core-to-shell ratio of larger than 5.6:1. 
The increase of shell particle size from ~13 nm to ~98 nm, enlarged interspacing distance between 
neighbouring shell particles from ~7 to ~38 nm, and protein loading capacity of RSNs was also 
found interspacing distance-dependent. Proteins with a suitable molecule size were favourably 
absorbed onto one of the RSNs. The optimal interspacing distance of RSNs for high protein loading 
capacity was 7, 21 and 38 nm for cytochrome c (~3 nm), IgG-fragment (IgG-F, domain antibody, 
~10 nm) and non-specific rabbit IgG antibody (IgG-A, ~20 nm), respectively. Moreover, the 
hydrophobically modified RSNs (C18-RSNs) were confirmed effective nanocarriers. The C18-RSN 
with an interspacing distance of ~38 nm facilitated the intracellular delivery of therapeutic anti-
pAkt antibody (an IgG type antibody), causing enhanced cell growth inhibition to MCF-7 cells, 
compared to literature reports. 
3. After understanding the influence of surface morphology on protein adsorption behaviour, we 
further quantitatively investigated the individual and combined contribution of surface roughness 
and surface modification (e.g., C18-modification) for the improvement of protein therapeutics. To 
achieve this goal, four samples, smooth silica nanoparticle (SSN), rough silica nanoparticle (RSN), 
C18-SSN and C18-RSN, have been fabricated, where the core size was ~232 nm and shell diameter 
was ~20 nm, suitable for the entrapment of ribonuclease A (RNase A, ~3 nm). Both surface 
roughening and hydrophobic modification enhance RNase A adsorption capacity, while the 
contribution from surface roughness was more dominant. Hydrophobic modification had a stronger 
effect to retard RNase A release. The contribution difference to enhance cellular uptake was cell 
type-dependent. Importantly, only hydrophobic modification facilitated endo/lysosomal escape. 
Collectively, C18-RSN showed the best performance in RNase A delivery, causing significant cell 
viability reduction in both human breast cancer (MCF-7) and SCC-25 cell lines, compared to other 
nanoparticles in this study. (Relevant content: Chapter 6) 
In summary, rough silica nanoparticles bio-inspired by the nanoscale structure of enveloped viruses 
are promising nanocarriers for intracellular delivery of either genetic molecules or therapeutic 
proteins, regardless of surface chemistry and cell types. The surface roughness allows the 
entrapment of biomolecules in the valley or void space between neighbouring shell particles, 
improving adsorption capacity and retarding release r. In addition, cellular uptake performance has 
also been increased. Taking these advantages, the delivery performance of therapeutic agents has 
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been significantly enhanced, compared to silica spheres with smooth surfaces. Our research 
suggests a new parameter for the rational design and synthesis of efficient drug delivery carriers for 
highly improved disease therapy. 
7.2 Recommendations for future work 
The following recommendations are made for the future work. 
1. To extend the advantages of rough nanoparticles, porous structures should be included for 
enhanced drug loading or co-delivery of therapeutic molecules. 
2. To further imitate the features of enveloped viruses with specific infectivity, targeting moieties, 
for example, F3 peptide
2
 or Tat peptide,3 are needed to be conjugated onto the rough surface for 
targeted and enhanced delivery. 
3. Apart from replacing solid shell or core particle by porous ones, the particles can pre-encapsulate 
drug molecules inside for multi-functional applications. For example, the photosensitiser of silicon 
phthalocyanine dichloride (SiPCCl2) can be encapsulated in solid silica nanoparticle of 20-50 nm,
4
 
and they can be used as shell particles for combined chemotherapy and photodynamic therapy. 
4. In addition to silica materials, other materials can be introduced into the system. Calcium 
phosphate nanoparticles (CaP-NPs) are good candidates. For example, the siRNA encapsulated and 
lipid-coated CaP-NPs of ~30 nm can be used as shell particles for multifunctional drug delivery.
5
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